Clinical resistance to platinum chemotherapy in ovarian cancer by Newton, C
Clinical resistance
to platinum
chemotherapy
in ovarian cancer
DECLARATION
I can confirm that all work presented in this thesis is my own.
DEDICATIONS
I would like to dedicate this thesis to my husband James, who has been very supportive
throughout.
ABSTRACT
Platinum drugs are the most active agents in ovarian cancer. Their cytotoxicty results
from DNA crosslinking. High tumour response rates are seen, but 80 % of patients
relapse. Major mechanisms of platinum resistance in patients remain to be established.
We have studied DNA interstrand crosslinking and its repair in response to ex vivo
treatment with cisplatin in forty patients with ovarian cancer using the single cell gel
electrophoresis (comet) assay. Tumour cells from resected tumours or tumour and
mesothelial cells from ascites were obtained from chemonaïve patients and those
relapsing after platinum-based therapy. The average percent decrease in tail moment at
the peak of crosslinking was 61.1%9.25 in 34 pre-chemotherapy patient samples
following treatment with 100M cisplatin. In 14 post-chemotherapy patient samples it
was 58.1%9.94. The average percentage repair at 24 hours was 3.6%18.89 in pre-
chemotherapy patients and 44.6%43.4 for post-chemotherapy patients (p<0.001).
In 6 paired samples, before and after chemotherapy the average percentage repair at 24
hours was 7.2%12.64 increasing to 69.5%23.42 after chemotherapy. Differences in
cell cycling, and cell signalling gene expression levels using microarray analysis was
found, between pre- and post-chemotherapy patients. Real time PCR was also used to
investigate the levels of ERCC1 (excision-related cross complementation group 1) in 3
of these paired patient samples, which was found to be increased by an average of
14.4% +/-0.8% in 3 post-chemotherapy samples.
In ten pre-chemotherapy and seven post-chemotherapy patient tumours incubated ex
vivo with 50M melphalan, the percent decrease in tail moment at the peak of
crosslinking was 41.411.2, and 44.6 7.6, respectively. 24 hours later the percentage
repair was 3.1.25.6 for untreated and 2.826.3 for treated tumours. In conclusion,
repair of DNA interstrand crosslinks appears to be an important mechanism of clinical
platinum resistance in ovarian cancer. Repair of melphalan crosslinks is unaffected.
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1. INTRODUCTION
1.1 Ovarian cancer
Ovarian cancer is the leading cause of death from gynaecological malignancies. It is
the fourth most common cancer among women in the UK (Cancer Research UK,
2004), and the lifetime risk of a woman developing ovarian cancer is 1 in 70 (Ozols
et al., 2001). The cause of ovarian cancer is unknown however there are risk factors,
such as increased age. Half of all ovarian cancers occur in women after the age of 65
(Cancer Research UK, 2004). Women who have been pregnant have a 50%
decreased risk of developing ovarian cancer compared to nuliparous women (Garcia
et al., 2004), and further pregnancies confer additional protective effect, while the
oral contraceptive pill decreases the risk. These risk factors support the theory that
the risk of ovarian cancer is related to ovulation, and that suppressing ovulation
plays a protective role (Garcia et al., 2004). In addition, a prior history of breast
cancer increases a woman’s risk of ovarian cancer (Garcia et al., 2004).
Another important risk factor is family history. The lifetime risk for developing
ovarian cancer is 1.6% in the general population. This risk increases to 5% when one
first-degree relative has had ovarian cancer, rising to 7% when two first-degree
relatives have been affected (Garcia et al., 2004). Less than 5% of all ovarian
cancers are inherited, and so far two syndromes have been identified: breast/ovarian
cancer syndrome, and Lynch II syndrome (also called hereditary nonpolyposis
colorectal cancer) (Garcia et al., 2004). Breast/ovarian cancer syndrome is
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associated with early onset of either or both of the diseases. There are often several
family members affected. The inheritance follows an autosomal dominant
transmission, and can be inherited from either parent. Most cases are associated with
BRCA1 and BRCA2 gene mutations (Garcia et al., 2004). Families that have the
Lynch II syndrome are at high risk of developing colorectal, endometrial, stomach,
small bowel, breast, pancreas, and ovarian cancers, which is caused by mutations in
the mismatch repair genes (Garcia et al., 2004).
About 70% of women diagnosed with ovarian cancer are stage III or IV (Rustin et
al., 2004). They usually present at an advanced stage due to the vagueness of the
symptoms, the difficulty of diagnosis, and the lack of a screening test. Symptoms
include malaise, weight loss, pressure symptoms (e.g from ascites or an enlarging
tumour), pelvic pain, vaginal bleeding, abdominal distension, and change in bowel
habit. Physical findings are uncommon in patients with early disease, while patients
with advanced disease may have an ovarian pelvic mass, ascites, pleural effusion,
abdominal mass or bowel obstruction, or a combination of these. Investigations
include an ultrasound scan of the pelvis, a blood test for a tumour marker called
Cancer antigen –125 (Ca-125), an MRI scan of the abdomen and pelvis, and a Chest
X-ray, as well as routine blood tests, such as a full blood count, and urea and
electrolytes. Other investigations may be appropriate depending on the patients’
symptoms e.g a colonoscopy if they have bleeding from the rectum.
The standard care for ovarian cancer includes a primary staging and cytoreductive or
debulking laparotomy (Baird et al., 2001). Peritoneal washings are usually taken
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immediately on entering for cytology. A thorough exploration of the abdomen and
pelvis is performed to assess the extent of spread. The surface of the liver,
diaphragm, and spleen are examined, as well as the small and large bowel,
omentum, para-aortic and pelvic lymph nodes. A total abdominal hysterectomy,
bilateral salpingo-oophorectomy, omentectomy, para-aortic and pelvic lymph node
sampling, peritoneal biopsies, and peritoneal cytology (peritoneal washings) are
usually performed if ovarian cancer is confirmed. In advanced disease cytoreduction
or debulking surgery (where as much tumour tissue as possible is removed) is
performed, which will then offer the best response to subsequent chemotherapy. It is
recommended to achieve a residual disease of less than 1cm (Stuart et al., 2001).
When doubt exists about the diagnosis of ovarian cancer, a frozen section can be
performed. The ovaries are removed and placed in a dry container for a pathologist
to look at them immediately. They convey their findings whilst the patient is still on
the operating table, which helps the surgeon to decide what other tissues need to be
taken (if any).
1.1.1 Staging of Ovarian Cancer
The FIGO (Federation International of Gynaecology and Obstetrics) staging for
ovarian cancer is as follows:
1. Stage I – Growth limited to the ovaries
 Stage 1a – Growth limited to one ovary, no ascites, no tumour on
external surface, capsule intact
 Stage 1b – Growth limited to both ovaries, no ascties, no tumour on
external surface, capsule intact
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 Stage 1c – Tumour either stage 1a or 1b but with tumour on surface
of one or both ovaries, ruptured capsule, ascites with malignant cells
or positive peritoneal washings
2. Stage II – Growth involving one or both ovaries, with pelvic extension
 Stage IIa – Extension and/or metastases to the uterus or tubes
 Stage IIb – Extension to other pelvic tissues
 Stage IIc – Stage IIa or IIb but with tumour on surface of one or both
ovaries, ruptured capsule, ascites with malignant cells or positive
peritoneal washings.
3. Stage III – Tumour involving one or both ovaries, with peritoneal implants
outside the pelvis and/or positive retroperitoneal or inguinal nodes;
superficial liver metastases equals stage III.
 Stage IIIa – Tumour grossly limited to pelvis, negative lymph nodes
but histological proof of microscopic disease on abdominal peritoneal
surfaces
 Stage IIIb – Confirmed implants outside of pelvis in the abdominal
peritoneal surface; no implant exceeds 2cm in diameter and lymph
nodes are negative
 Stage IIIc – Abdominal implants larger than 2cm in diameter and/or
positive lymph nodes.
4. Stage IV – Distant metastases; pleural effusion must have a positive cytology
to be classed as stage IV; parenchymal liver metastases equals stage IV.
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The survival rates for ovarian cancer depend on the stage at diagnosis:
 Stage 1 – 90% 5 year survival
 Stage 2 – 70% 5 year survival
 Stage 3 – 21% 5 year survival
 Stage 4 – 6% 5 year survival (Cancer Research UK, 2004)
1.1.2 Histopathology of Ovarian Tumours
All tissues removed are sent to the hisopathologist who examines the material and
helps in assessing the stage (see above), grade and type of cancer. The grade of the
ovarian cancer refers to the cells themselves. The most important features in
assessment of grade are mitotic activity, nuclear size and pleomorphism, and
differentiation from the original cells (Underwood, 2000). Grading is not entirely
objective, and different pathologists may disagree on the grade of a particular
ovarian cancer, as there are different systems for grading ovarian cancers (Dolson,
2004). Pathologists usually use a combination of the pattern system and Broder’s
grading system.
There are three different grades; grade 1 (well differentiated), grade 2 (moderately
differentiated), and grade 3 (poorly differentiated) (Dolson, 2004). Tumours are
often heterogenous, and the grading should be performed on what appears to be the
least differentiated area (Dolson, 2004). Overall low-grade (grade 1) tumours grow
more slowly, and have a better prognosis than high-grade (grade 3) tumours
(Underwood, 2000). However, determining prognosis is multi-factorial (Dolson,
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2004). Ovarian tumours may be divided into five broad categories (Underwood,
2000) according to the World Health Organisation :
 Epithelial
 Germ-cell
 Sex-cord stromal
 Metastatic
 Miscellaneous
1.2 Chemotherapy
1.2.1 Chemotherapy agents used in ovarian cancer
There are many chemotherapeutic agents used to treat ovarian cancer, depending on
the type, grade, stage of the disease, and the health of the patient. Metaanalyses of
randomized clinical trials have shown that platinum compounds
(cisplatin/carboplatin), anthracyclines (doxorubicin/epirubicin), alkylating agents
(cyclophosphamide/melphalan), spindle poisons (paclitaxel/docetaxel),
antimetabolites such as gemcitabine, and the topoisomerase I inhibitor topotecan are
the most active agents in ovarian cancer (Berkenblit et al., 2005).
1.2.1.1 Spindle Poisons
Spindle poisons include taxanes such as paclitaxel and docetaxel, and promote the
assembly of microtubules by binding to -tubulin, which inhibits depolymerisation
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(Yoshida et al., 2001). This action disturbs mitosis in normal and malignant cells
(Schiff et al., 1979). The taxanes were originally derived from the bark of the
Pacific Yew tree, Taxus brevifolia, and paclitaxel was identified as the active
constituent in 1971 (McGuire et al., 2003). Docetaxel is a semi-synthetic taxoid
derived from the needles of T. baccata (Lister-Sharp et al., 2000) and has been
shown to be less neurotoxic than paclitaxel (Vasey et al., 2002). The introduction of
paclitaxel in the 1990’s to treat ovarian cancer increased the survival rates of women
with the disease (Rustin et al., 2004).
1.2.1.2 Anthracyclines
Anthracyclines such as doxorubicin and epirubicin, have several cytotoxic actions.
Their main mechanism of action appears to be mediated by their effect on
topoisomerase II, whose activity is markedly increased in dividing cells (Rang et al.,
2005). Topoisomerase II binds to the double stranded DNA, cleaves both strands of
duplex DNA and passes a second duplex through this transient cleavage, involving
hydrolysis of ATP, and enzyme recycling (Swift et al., 2006). The intermediate form
is termed the ‘cleavable complex’ (Swift et al., 2006). As a result of its double-
stranded DNA passage mechanism, topoisomerase II is able to remove negative or
positive superhelical twists (i.e., under- or overwinds) from the genetic material and
resolve intramolecular DNA knots as well as intermolecular tangles (Wang et al.,
1996)
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Doxorubicin poisons the cleavable complex, inhibiting religation of the cleaved
complex, resulting in double strand breaks of the DNA. Doxorubicin intercalates
into the DNA and becomes trapped (Epstein et al., 1998). Apoptosis results if the
cell is unable to repair these DNA double-strand breaks. However, these drugs have
additional modes of action such as production of oxygen free radicals, and formation
of covalent adducts which may contribute to its toxicity (Minotti et al., 2004).
1.2.1.3 Topoisomerase inhibitors
Topoisomerase I inserts a nick into one strand of the DNA to relax supercoiled DNA
that occurs when DNA replicates itself. It also re-ligates the cleaved DNA.
Irinotecan and topotecan (9-dimethylaminoethyl-10-hydroxycamtothecin) are potent
inhibitors of topoisomerase I (Xu et al., 2002).
In patients with platinum-resistant ovarian cancer, there was a low probability of
responding to single agent Topotecan (Main et al., 2006). Unfortunately Topotecan
in combination with gemcitabine in the treatment of platinum refractory ovarian
cancer in a phase I/II trial and has shown disappointing results (Goff et al., 2008).
1.2.1.4 Antimetabolites
Antimetabolites such as gemcitabine, interfere with nucleic acid production, either
by mimicking nucleotide structure, enabling them to be incorporated into nucleic
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acids, thus terminating their production, or by preventing synthesis of nucleotides
directly.
Gemcitabine (2’, 2’-difluorodeoxycytidine dFdC) is a fluorinated deoxycytidine
derivative, which can be used in a variety of solid tumours including ovarian cancer
(usually in combination with carboplatin), non-small cell lung cancer, head and neck
cancer, and genitourinary cancer (Fruscella et al., 2003). Gemcitabine enters the cell
through a membrane nucleoside transporter (Mackey et al., 1998), and it is activated
by phosphorylation to gemcitabine monophosphate, which is subsequently
phosphorylated to the 5’-diphosphate (dFdCDP) and triphosphate (dFdCTP), which
represent the active forms of gemcitabine (Fruscella et al., 2003). dFdCTP is
incorporated into DNA instead of cytosine, followed by one or more
deoxynucleotides, thus blocking DNA synthesis and preventing repair by 3’-5’-
exonuclease activity (Fruscella et al., 2003). Gemcitabinetriphosphate is also
incorporated into RNA, thus terminating RNA synthesis (Fruscella et al., 2003).
Only a proportion of gemcitabine is converted into the di- or triphosphate forms.
The majority of gemcitabine is rapidly inactivated in the blood, liver and kidneys by
deamination into 2’, 2’-diflourodeoxyuridine in a reaction catalysed by
deoxycytidine deaminase (CDD) (Fruscella et al., 2003).
1.2.1.5 Platinum compounds cisplatin and carboplatin
Cisplatin (cis-dichlorodiammine platinum(II)) was discovered serendipitously by
Rosenberg in the 1950’s while investigating inhibition of bacterial growth by
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electric currents (Rosenberg 1985). The resulting inhibitory complexes were
produced by the reaction of platinum electrodes with growth media. Cisplatin (a
neutral complex) was the most active of these, and was tested in clinical trials
(Higby et al., 1973).
Cisplatin and Carboplatin
It is thought that cisplatin enters the cell by both passive diffusion and facilitated
transport, possibly by a gated channel (Gateley et al., 1993). Some of the uptake is
dependent on energy because pharmacological agents such as ouabain (a Na+, K+-
ATPase inhibitor) reduce it (Judson I et al., 2002).
Cisplatin is a water-soluble complex, which has a central platinum atom surrounded
by two chlorine atoms and two ammonia groups (Rang et al., 1995) (figure 1).
When cisplatin enters the cell, the chloride ions dissociate (due to the low
concentration of intracellular chloride ions) leaving a reactive diamine-platinum
complex, which reacts with water and then, can interact with DNA (Rang et al.,
1995). Cisplatin binds preferentially to the N7 atom of guanine and adenine residues
(Eastman et al., 1987), although there are numerous potential reaction sites in all
four bases (Singer et al., 1977).
Cisplatin is widely used not only for the treatment of ovarian cancer, but also for
many other solid tumours such as those arising from the testes, bladder, lung, and
head and neck. Cisplatin was first introduced in 1973 for treatment of ovarian
cancer, which improved disease-free survival and response rates when compared to
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the then-standard treatments (Rustin et al., 2004). Cisplatin was either used alone or
in combination with cyclophosphamide (Rustin et al., 2004). Cisplatin causes very
severe nausea and vomiting, and is highly nephrotoxic (Rang et al., 1995).
(a)
(b)
(c)
Figure 1: Structure of (a) cisplatin (b) carboplatin (c) oxaliplatin
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In the early 1980’s carboplatin, which is a derivative of cisplatin, was introduced
(figure 1). Carboplatin causes less nephrotoxicity, neurotoxicity, and ototoxicity,
and less severe nausea and vomiting than cisplatin, but it is more myelotoxic (Rang
et al., 1995). Tinnitus and hearing loss in the high frequency ranges may occur, as
may peripheral neuropathies, hyperuricaemia, myelotoxicity and nephrotoxicity.
The cytotoxicity of cisplatin and carboplatin are believed to result from the
formation of platinum-DNA adducts. These include mononadducts, intrastrand
crosslinks, interstrand crosslinks (ICLs), and DNA-protein crosslinks (Fichtinger-
Schepman et al., 1995) (figure 2). There has been much debate about which adduct
is responsible for the cytotoxicity of cisplatin. Fischtinger-Schepman et al concluded
that 1,2 intrastrand crosslinks produced by cisplatin were responsible for its
cytotoxicity because the peak of formation of these lesions co-incided with the peak
of cytotoxicity in Chinese hamster ovary cells (CHO) (Fischtinger-Schepman et al.,
1995). Zamble et al., demonstrated that the 1,2-cisplatin adducts are poorly
recognised, adding support to the argument that they are a critical cytotoxic lesion
(Zamble et al., 1996). In contrast Zwelling L.A et al found a correlation between
cytotoxicity and ICLs in L1210 cells in vitro using alkaline elution (Zwelling et al.,
1979). Meyn et al demonstrated that an ERCC1 mutant CHO cell line, UV20, was
extremely sensitive to cisplatin and defective in the uncoupling of ICLs, which was
taken to demonstrate a direct relationship between sensitivity and ICL repair (Meyn
et al., 1982). In the nitrogen mustard class, there is a clear correlation between the
extent of interstrand crosslinks (ICL) and cytotoxicity (O’Connor et al., 1990).
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However, the platinum drugs produce a high proportion of intrastrand crosslinks that
clearly contribute to their activity (McHugh et al., 2000).
Figure 2: The different types of DNA adducts produced by cisplatin, and frequencies
of occurrence.
Carboplatin has a much slower rate of aquation and ICL formation compared to
cisplatin (Knox et al., 1986), and therefore the time to reach the peak of ICL
formation is much longer with carboplatin.
95%
Intrastrand
crosslinks
2%
Interstrand
crosslinks
2%
Monoadducts
1% DNA-
protein
crosslinks
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Oxaliplatin
Oxaliplatin is an analogue of cisplatin that was developed to try and overcome drug
resistance (figure 1). It has a different spectrum of anti-tumour activity and has
shown activity in treatment of advanced colorectal cancer either as a single agent or
in combination with 5-fluorouracil (Becouarn et al., 1998). Side effects of
Oxaliplatin include neurotoxicity, including facial dyaesthesia, which may be
provoked by cold weather, and peripheral sensory neuropathy (Judson et al., 2002).
1.2.1.6 Alkylating agents - Melphalan
There are a large number of alkylating agents used in cancer chemotherapy
including nitrogen mustards (e.g cyclophosphamide, melphalan, and chlorambucil),
chloroethylnitrosoureas (carmustine and lomustine), the alkylalkanesuphonate
busulphan, and the natural product mitomycin C. Uptake of alkylating agents into
the cell is usually by passive diffusion, although melphalan is transported into the
cell by a specific amino acid transport protein (Hartley, 2002).
Alkylating agents have the ability to form covalent bonds with suitable nucleophilic
substances within the cell (Rang et al., 1995). The main step is formation of a
carbonium ion – a carbon atom with only 6 electrons in its’ outer shell (Rang et al.,
1995). These ions are very reactive, and react immediately with an electron donor
group such as –SH, -OH, or an amine group. The 7 nitrogen (N7) of guanine, is
strongly nucleophilic, and is the main molecular target for simple alkylating agents,
although N1 and N3 of adenosine, O6 of guanine and N3 of cytosine may also be
affected (Rang et al., 1995). However, it is not just single bases that attract
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alkylating agents, but groups of bases, so guanine-rich sequences will attract these
agents more than a guanine base flanked by cytosines (Mattes et al., 1988). Most
chemotherapeutic alkylating agents have two alkylating groups (called bi-
functional), and can therefore react with two groups, causing intra- and inter-strand
crosslinking (Rang et al., 1995). Intra-strand crosslinking occurs if the two groups
are on the same strand of DNA, and ICL formation occurs if these two groups are on
the two opposite strands of the DNA.
Initially in the formation of crosslinks, monoadducts are formed in which only one
of the alkylating groups of the drug reacts with the DNA. For many drugs (e.g
melphalan) where only a fraction of monoadducts go on to form crosslinks, the
second reaction is slow (Spanswick et al., 2000). The ICLs distort the structure of
the DNA and prevent the two strands of the DNA from separating during replication
and transcription. ICLs also block DNA and RNA polymerases. If not repaired, the
cell undergoes apoptosis.
Melphalan
Melphalan (figure 3) was first synthesized in 1953, and is a phenylalanine derivative
of nitrogen mustard (also called L-phenylalanine mustard (L-PAM)) (Rothbarth et
al., 2002). It has been used to treat patients with breast cancer, melanoma, and
colorectal cancer, but is primarily used in multiple myeloma patients (Dollery et al.,
1991). The most commom side effect of melphalan is bone marrow suppression,
including leukopenia and thrombocytopenia (Rothbarth et al., 2002). However
melphalan has the potential to be carcinogenic itself, causing secondary
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malignancies such as acute nonlymphocytic leukaemia, and myeloproliferative
syndrome (Dollery et al., 1991). Twenty years ago alkylating agents such as
melphalan, cyclophosphamide, and chlorambucil were used as monotherapy to treat
ovarian cancer (Mcguire et al., 2003). These drugs were associated with overall
objective response rates ranging between 33% and 65%, with complete clinical
responses seen in 20% of patients (Young et al., 1979).
Melphalan can be given intravenously as well as orally, and enters the cell by
diffusion and by active transport via two distinct amino acid transport systems (Pu et
al., 2000). Melphalan is completely hydrolysed after 8 hours in water at 37ºC to
monohydroxymelphalan and dihydroxymelphalan – the chlorine atoms are replaced
in a nucleophilic attack by hydroxyl groups. The hydrolysis rate is dependent on pH,
temperature, protein concentration, and chloride ion concentration. Hydrolysis
decreases with increasing concentration of plasma proteins and in an acidic
environment (Bolton et al., 1993).
Melphalan exerts its cytotoxic effect by formation of interstrand and intrastrand
crosslinks as well as DNA-protein crosslinks by alkylation via the two chloroethyl
groups of the molecule (Kohn et al., 1981). Common sites of alkylation in DNA
include the N-7 position of guanine, the N-1, N-3, and N-7 positions of adenine, the
N-3 position of cytosine and the O-4 position of thymidine (Rothbarth et al., 2002).
As cell killing is observed throughout the cell cycle (although there are variations
within it), melphalan is a cell cycle phase non-specific agent (Tannock et al., 1986),
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and although rapidly dividing cells are killed preferentially, slower dividing cells are
also killed.
Figure 3: Structure of melphalan
1.2.2 Chemotherapy protocols in Ovarian Cancer
The usual first-line treatment for ovarian cancer is cytoreductive surgery, followed
by paclitaxel-carboplatin chemotherapy for stage III –IV disease which has been
tested (Baird et al., 2001) by the Gynaecologic Oncology Group (GOG) 111 trial
(McGuire et al., 1996) and the National Cancer Institute of Canada (NCIC) OV10
trial (Piccart et al., 2000). The GOG trial was a phase III randomised trial comparing
cisplatin and cyclophosphamide, with cisplatin and paclitaxel in patients with
suboptimal stage III/IV disease. Three hundred eighty-six patients with advanced
ovarian cancer entered the trial. Progression-free survival was significantly longer (P
<0.001) with cisplatin/paclitaxel (median, 12.9 v 17.9 months). Overall survival was
also significantly longer (P <0.001) with cisplatin/paclitaxel (median, 24.4 v 37.5
months) (McGuire et al., 2003). However, there has been some doubt about the
clinical value of platinum/taxane combinations after the publication of the large
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International Collaberative Ovarian Neoplasm Group 3 (ICON3), which looked at
2074 patients with ovarian cancer. The data from this trial suggest that there was no
benefit, in terms of either progression-free or overall survival, from the use of
paclitaxel/carboplatin compared with carboplatin alone or of
cyclophosphamide/doxorubicin/cisplatin (ICON 2002). Furthermore, the incidences
of alopecia, fever, and sensory neuropathy were significantly higher in the taxane
treatment arm compared with carboplatin alone (ICON 2002) This has lead to many
European women being offered single-agent carboplatin.
A recent randomised phase III study by Arbeitsgemeinschaft Gynaekologische
Onkologie-Group d’Investigateurs Nationaux pour L’Etude des Cancers Ovariens
(GINECO), involving 1200 patients with advanced ovarian cancer looked at the
addition of epirubicin to standard carboplatin-paclitaxel 1st line regimens. The
results showed no statisticall significant difference in overall survival between the
standard carboplatin-paclitaxel arm versus the carboplatin-epirubicin-paclitaxel arm.
Furthermore, the addition of epirubicin increased the number of side effects such as
nausea and vomiting, and grade 3 or 4 haematological toxicities (Du Bois et al.,
2006). As a result epirubicin cannot be recommended for clinical use in this
population of patients.
Another recent randomised controlled phase III study by the AGO-GINECO group
examined whether sequential administration of topotecan could improve the efficacy
of carboplatin and paclitaxel in first-line treatment of advanced epithelial ovarian
cancer. 1300 previously untreated patients with advanced ovarian cancer (FIGO
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stages III-IV) were randomized to receive the standard carboplatin-paclitaxel
regimen followed by four cycles of topotecan, or surveillance. The sequential
addition of topotecan to carboplatin-paclitaxel did not result in superior overall
response or progression-free or overall survival. Therefore, this regimen cannot be
recommended as standard of care treatment for ovarian cancer (Pfisterer et al.,
2006).
The Gynaecologic Oncology Group (GOG), have shown that intraperitoneal
chemotherapy regimen represents a new standard of care for patients with optimally
resected stage III ovarian cancer, but should be offered on an individualized basis
(Runowiscz et al., 2006) (Armstrong et al., 2006). In this study, 400 patients with
stage III ovarian cancer with residual disease of less than 1cm after debulking
laparotomy were included. Participants were randomly assigned to receive six cycles
of treatment with intravenous paclitaxel (135 mg/m2) on day 1 followed by
intravenous cisplatin (75 mg/m2) on day 2 (intravenous therapy), or six cycles of
intravenous paclitaxel (135 mg/m2) on day 1 followed by intraperitoneal cisplatin
(100 mg/m2) on day 2 and intraperitoneal paclitaxel (60 mg/m2) on day 8
(intraperitoneal therapy). The patients in the intraperitoneal chemotherapy arm had
statistically significant increased survival compared to the intravenous arm
(Armstrong et al., 2006). However, the quality of life up to 6 weeks after treatment
was much worse in the intraperitoneal chemotherapy arm due to side effects such as
haematological, gastrointestinal, neurologic toxicities, and catheter complications.
However, 1 year after treatment, there was no difference in quality of life between
the two groups (Armstrong et al., 2006). As a result of this trial, The National
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Cancer Institute (NCI) issued a bulletin suggesting that, in women with stage III
epithelial ovarian cancer, consideration should be given to the administration of
intraperitoneal cisplatin and a taxane (National Institute of Health, 2006).
Pegylated liposomal doxorubicin (PLD) has been used as consolidation
chemotherapy in patients with advanced ovarian cancer who have had a complete
response to standard carboplatin-paclitaxel regimens. In two studies, a total of 41
patients were given PLD at a dose of 40 mg/m2 every 28 days for four cycles
(Rocconi et al., 2006) (Disilvestro et al., 2006). These studies concluded that PLD
was well tolerated, and the main side effect was palmar-plantar erythrodysesthesia.
Overall survival results were promising, but more work needs to be done on optimal
dosage and schedule for these patients (Rocconi et al., 2006) (Disilvestro et al.,
2006).
In the recurrent disease setting, there are a number of second-line single
chemotherapeutic regimens. In a phase II Gynaecologic Oncology Group study Rose
et al (1998) reported a 27% response rate in platinum-resistant and 34% in platinum
sensitive patients given oral etoposide at 50 mg/m2/day for 21 days out of a 28-day
cycle. Bookman et al used topotecan 1.5 mg/m2 for 5 days on a 21 day schedule in a
phase II trial, and reported response rates of 12.4% in platinum-resistant patients,
and 19.2% response rate in platinum-sensitive patients (Bookman et al., 1998).
There are also combination chemotherapeutic regimens for treating relapsed disease.
Gemcitabine combined with either carboplatin or cisplatin has demonstrated an
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increase in progression-free survival in patients with clinically resistant ovarian
cancer compared to platinum chemotherapy alone (Villella et al., 2004).
Carboplatin is much less toxic than cisplatin, and has been used instead of cisplatin
since publication of a meta-analysis of 37 trials in over 5000 patients that showed
equivalent efficacy of cisplatin and carboplatin (Aabo et al., 1998). It also showed
the superiority of platinum- over non-platinum-based treatment (Aabo et al., 1998).
There have been very few clinical trials to assess the effectiveness and tolerability of
melphalan in patients with ovarian cancer which is resistant to platinum
chemotherapy. One small study investigated double intermediate-dose melphalan
(100mg/m2) supported by autologous stem cells in 14 patients with refractory
ovarian cancer and poor performance status (Magagnoli et al., 2004). This regimen
was well tolerated, and converted one patient from partial remission (PR) to
complete remission (CR). Another four patients had disease stabilisation with this
melphalan regimen. Nine patients with progressive disease (PD) showed a partial
response. Interestingly all patients had a marked improvement in their performance
status (Magagnoli et al., 2004).
In another study the effectiveness of 10mg of oral melphalan given once a day for 5
days every 6 weeks for 6 cycles was assessed in patients with platinum-resistant
relapsed ovarian cancer (Hasan et al., 2003). Melphalan was well tolerated, but there
were no responses in these 22 patients. Melphalan had no impact on progression-
free survival or overall survival (Hasan et al., 2003). Given these two small trials it
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is still unclear whether melphalan has a place in the clinical setting in patients with
platinum-resistant relapsed ovarian cancer.
Aggressive treatment that involves debulking surgery followed by carboplatin and
paclitaxel chemotherapy results in complete response rates of 70-80% (Ferry et al.,
2000). Unfortunately, 80% of complete responders eventually relapse at a median of
18-28 months (Ozols et al., 1999) with disease that is resistant not only to platinum
compounds, but also to a wide range of other chemotherapeutic agents (Rustin et al.,
2004). The prognosis for these patients remains poor, with a 5-year survival of 20%
(National Institues of Health, 2006). It is therefore important to overcome resistance
to chemotherapy to improve patient survival.
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1.3 Cellular pathways
When DNA damage occurs, the cell activates a complex series of pathways, which
are incompletely understood that involve DNA repair, cell cycle arrest and/or cell
death. There is a critical balance between cell cycle arrest (promoting DNA repair
and survival), and cell death following chemotherapy (Longley et al., 2005). If the
cell is unable to repair its damaged DNA following cell cycle arrest, then apoptosis
occurs.
BRCA 1 is involved in many of these cellular pathways. The gene encodes a
220kDa nuclear protein (Kennedy et al., 2004) and was discovered in 1994 by
genetic linkage studies, which localised it to chromosome 17q (Miki et al., 1994).
Patients with loss-of-function mutations in BRCA1 gene have an 82% risk of
developing breast cancer and up to 54% risk of developing ovarian cancer by 80
years of age (King et al., 2003). However, these mutations only account for about
5% of all ovarian cancers (Garcia, 2004). Approximately 70% of ovarian cancers
and 30% of breast cancers have reduced BRCA1 expression that is partly caused by
methylation of the BRCA1 promoter (Wang et al., 2004).
1.3.1 The Cell cycle
Cellular proliferation needs to be tightly controlled as loss of this control can lead to
cell death or deregulated proliferation characteristic of cancers. Dividing cells enter
the cell cycle in order to grow, replicate their DNA and divide in an organised and
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controlled manner. There are 4 distinct phases in a well defined order, each of which
should be completed successfully before the next begins. Between each step of the
cell cycle there are regulatory checkpoints.
The cell cycle controls cellular proliferation through the integration of negative
signals called cell cycle checkpoints, and positive signals (Lowndes et al., 2000).
Serine-threonine protein kinases called cyclin-dependent kinases (CDK1, 2, 4, 6)
and their essential activating coenzymes (cyclins A, B, D, E), as well as CDK-
inhibitory proteins (CDKIs) control cell cycle transitions (Funk et al., 1999).
The cell cycle starts with G1 in which the cells grow. The next step is S phase where
initiation of DNA synthesis takes place. Promotion of the transition from G1 to S
phase is regulated by cyclin D-cdk4, cyclin D-cdk6, cyclin E–cdk2 and cyclin A-
cdk2 (Lee et al., 2002). G2 is the next phase of the cell cycle followed by M phase
(mitosis). Cyclin A and B are involved in G2/M transition (Viallard et al., 2001).
1.3.1.1 The effect of DNA damage on the cell cycle
When DNA damage such as double-strand breaks (DSBs) occur in G1 or S phases
of the cell cycle, entry into S phase or progression through S phase is prevented or
slowed, respectively. When DSBs arise in G2, entry into mitosis is prevented
(Jackson et al., 2002)
It has been proposed that ICLs do not activate the G1 or G2 cell cycle checkpoint,
suggesting that they are tolerated by the cell until a DNA replication fork is
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encountered (Akkari et al., 2000). The S-phase checkpoint could have a major role
as co-ordinator of the cellular response to ICLs (Akkari et al., 2000).
The combined mechanisms of BRCA1 promote DNA repair and prevent replication
of damaged DNA by activating cell cycle checkpoints, although these processes
have different mechanisms. This is illustrated by mutation of the serine 988 residue
of BRCA1, (this residue is phosphorylated by CHK2 in order to activate BRCA1)
which results in defective DNA repair, but not activation of cell cycle checkpoints
(Zhang et al., 2004). Once BRCA1 is phosphorylated, it is thought that it stimulates
the transcription of p21 (cyclin-independent kinase inhibitor 1A), and p27 (cyclin-
dependent kinase inhibitor 1B) (Williamson et al., 2002), which arrests cells at the
G1/S boundary and S phase, respectively, by inhibiting cyclin-dependent kinase
(Williamson et al., 2002). BRCA1 also arrests cells at the G2/M–phase checkpoint,
through the reduction in cyclin B-cdc2 levels (Mullan et al., 2001), by a number of
mechanisms. These include, inhibiting its expression (Mullan et al., 2001), and
inducing other proteins such as GADD45 (Growth Arrest and DNA Damage-
inducible protein 45) (Mullan et al., 2001), Wee 1 kinase and 14-3-3. 14-3-3
binds to cdc25C, which is then prevented from activating the cyclin B-cdc2 complex
(Yarden et al., 2002). Wee1 kinase inhibits cdc2 by phosphorylation, which means it
cannot bind to cyclin B (Yarden et al., 2002). GADD45 binds to cyclin B-cdc2
preventing its localisation in the nucleus (Mullan et al., 2001).
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1.3.2 DNA Repair Pathways
There are many different DNA repair pathways that occur in the cell. The type of
lesion present in the DNA determines activation of a particular pathway.
1.3.2.1 Mismatch repair (MMR)
MMR plays a critical role in the maintenance of genomic stability in prokarytes,
simple eukaryotes and humans (Kolodner et al., 1999). DNA MMR deficiency
produces the microsatellite instability phenotype, which is detected as variations in
lengths of DNA repeat sequences present in the genome (Fischel et al., 1995). MMR
is an evolutionary conserved process that corrects mismatches generated during
DNA replication which escape proofreading (Kunkel et al., 2005). MMR is also
responsible for correcting base substitution mismatches and insertion-deletion
mismatches (IDLs) generated during DNA replication in organisms from bacteria to
mammals (Kunkel et al., 2005) Studies have indicated that excision is mismatch
dependent, is initiated at a nick or a gap, and has bidirectional capacity (Genschel et
al., 2002). MMR also preferentially proceeds along the shortest path to the
mismatch, and terminates about 150 nucleotides beyond the mismatch (Genschel et
al., 2002).
MMR starts with recognition of the lesion. The mammalian E.coli MutS homologs
(MSH proteins) are thought to directly contact double-stranded DNA, and slide
along it like a ‘sliding clamp’ until they encounter a base pair containing a mismatch
(Acharya et al., 2003). The MSH proteins then interact with a host of other proteins
including the mammalian E.coli MutL homologs (MLH), and yeast post-meiotic
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segregation (PMS) homolog proteins, as well as RPS, EXO1, and RFC (Kunkel et
al., 2005). Specific MSH proteins identify and repair different sizes of lesions, for
example, MSH2-MSH6 (MutSα) heterodimer is thought to primarily repair single
base substitutions and 1 base pair insertion-deletion mutations, while MSH2-MSH3
(MutSβ) heterodimer is thought to primarily repair larger 1-4 base pair insertion-
deletion mutations (Kunkel et al., 2005). MLH-PMS2 is the primary MutL complex
that interacts with both MSH2/6 and MSH2/3 complexes to help catalyse their
different functions (Kunkel et al., 2005).
There is evidence that PCNA (proliferating cell nuclear antigen) interacts with both
replication and MMR proteins (Gu et al., 1998), and is required at both early and
late stages of MMR (Gu et al., 1998), suggesting that it could be involved with the
initiation of MMR. RFC (replication factor C) is the factor required to load PCNA
onto the DNA, and may also be involved in MMR (Xie Y et al., 1999). PCNA is
also a processivity factor for replicative polymerases, and it interacts with and
stimulates the activity of proteins involved in processing Okazaki fragments. Early
evidence suggests that PCNA is required for MMR prior to DNA repair synthesis
and that PCNA interacts with MSH2 and MLH1 (Umar et al., 1996), leading to the
suggestion that replication and MMR may be physically coupled and that primers at
the replication fork may provide the strand discrimination signal.
In addition to undamaged mismatches, the MMR machinery also recognizes certain
DNA lesions generated by normal intracellular metabolism (e.g oxidative stress)
(Russo et al., 2004), and by physical and chemical insults from the external
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environment. MMR proteins activate cell cycle checkpoints and signal apoptosis
(Stojic et al., 2004). Loss of these functions decreases apoptosis, increases cell
survival, and results in resistance to chemotherapy (Stojic et al., 2004).
1.3.2.2 Base excision repair
Base excision repair corrects small alterations to bases, including oxidation and
alkylation, and is distinct from nucleotide excision repair which repairs bulky
adducts and helix distorting lesions. In base excision repair a lesion-specific
glycosylase removes the base and the resulting apurinic/apyrimidinic site is
converted to a break. A small gap, one or two nucleotides long is filled in by DNA
polymerase plus ligase (Evans et al., 2000). BER is also a key pathway in the repair
of DNA single-strand breaks (Wooster et al., 2003), and involves the enzyme poly
(ADP-ribose) polymerase (PARP) (Wooster et al., 2003). PARP inhibition leads to
persistent single-strand breaks in the DNA (Boulton et al., 1999). When single-
strand breaks are encountered by a replication fork, they become double-strand
breaks, and arrest of DNA replication occurs (Haber et al., 1999).
Tumours in carriers of BRCA1 and BRCA2 mutations lack wild-type BRCA1 and
BRCA2, but normal tissues retain a single copy of the relevant wild-type gene
(Bryant et al., 2005). This difference could be exploited to treat these patients using
PARP inhibitors, as the tumours would be unable to repair the persistent single-
strand breaks in the DNA effectively, leading to apoptosis (Bryant et al., 2005). This
principle could also be applied to other sporadic cancers that have impairments in
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the homologous recombination pathways, and thus has wider implications (Bryant et
al., 2005).
It is interesting that no diseases that are defective in BER have been reported. This is
probably because defects in this repair process include defective repair of oxidation
DNA damage caused by oxygen free radicals. Due to the abundance of oxygen free
radicals, many mutations would occur and thus would be lethal in embryo (Collins
et al., 2002).
1.3.2.3 Nucleotide excision repair (NER)
This is the main pathway used to repair bulky, helix-distorting DNA adducts
including those produced by platinum-based chemotherapy (McHugh et al., 2000),
such as intrastrand crosslinks, and ICLs. NER removes oligonucleotides of
approximately 28 bases long, and repairs the correspondingly long repair patch
(Collins et al., 2002). The importance of NER is highlighted, by the finding that
defects in this pathway result in hypersensitivity to cisplatin, and restoration of NER
activity reduces sensitivity to more normal levels (Furuta et al., 2002).
NER can be further subdivided according to how the lesion is initially recognised
into transcription-coupled repair, and global genomic repair pathways (Le Page et
al., 2000). Once recognition of the lesion is completed, both transcription-coupled
NER and global genomic NER have a common pathway involving TFIIH complex,
XPA, XPG, ERCC1 and XPF (Mitchell et al., 2003).
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Transcription-coupled nucleotide excision repair is initiated by the arrest of RNA
polymerase II at a lesion on the transcribed strand during transcription. TFIIH, XPG,
CSA and CSB are then recruited to the site of blocked transcription (Mitchell et al.,
2003), where they all participate in the removal of the stalled RNA polymerase
(Mitchell et al., 2003). Therefore DNA that is transcriptionally active is repaired
preferentially. MSH2 (mutS homolog 2) and MSH6 (mutS homolog 6) are also
involved. BRCA1 forms a complex with both MSH2 and MSH6 (Wang et al.,
2000), and is therefore indirectly linked to this pathway, which may explain the
increased cisplatin sensitivity shown in BRCA1-deficient cells (Quinn et al., 2003).
The first step of global genomic repair is recognition of the lesion. There is
supporting evidence for the involvement of the XPC (xeroderma pigmentosum
group C) and hHR23B (the human homologue of yeast RAD23) proteins in humans
(Batty et al., 2000). It is thought that XPC is one of the first proteins to be localised
to sites of helical distortions within the DNA (Sugasawa et al., 2000). Breast-Cancer
susceptibility gene 1 (BRCA1) can modulate the transcription of XPC, DDB2
(damaged DNA binding protein), and GADD45 (growth arrest and DNA damage
response protein 45), and has been implicated in global genomic repair (Hartmann et
al., 2002).
The zinc-finger protein XPA (xeroderma pigmentosum group A) and the
heterotrimeric replication protein RPA (replication protein A) are also involved in
recognising the damaged DNA (Ferry et al., 2000). The XPA-RPA complex is
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believed to recruit a large complex called TFIIH (transcription factor IIH), (Ferry et
al., 2000) which contains helicases (XPB and XPD) (McHugh et al., 2000). The
helicases unwind the DNA in the vicinity of the DNA lesion in an ATP-dependent
manner (Evans et al., 1997). The unwinding of the DNA produces a ‘bubble’
surrounding the lesion, which acts as a structural landmark for asymmetric dual
incisions that release the damage in the form of a lesion-containing nucleotide
(McHugh et al., 2000) (figure 4).
ERCC1 (excision repair cross-complementation group 1) is a single stranded DNA
endonuclease (Park et al., 1995) that forms a tight complex with its heterodimeric
partner XPF (xeroderma pigmentosum group F), and this complex is believed to
interact with both XPA (xeroderma pigmentosum group A) and RPA (replication
protein A) (Saijo et al., 1996). This suggests that ERCC1-XPF plays a role in DNA
damage recognition. The XPF-ERCC1 complex makes the initial cut in the DNA
strand 5’ (Sancar et al., 1996) (where XPF is thought to act as the nuclease
(McHugh et al., 2000) and the XPG (xeroderma pigmentosum group G) protein
makes the incision in the 3’to the DNA lesion. The oligonucleotide 24-32
nucleotides long, containing the damage is released (Sancar et al., 1996). DNA
synthesis occurs across the gap, followed by ligation, and the DNA is restored.The
rate-limiting step within this process is DNA damage recognition and excision (Mu
et al., 1995), particularly involving ERCC1.
The inherent sensitivity of testicular cancer to platinum has led to its curability,
which may be due to a defect in the NER pathway. They are defective in NER
Page 32
because they have very low amounts of XPA and XPF-ERCC1 proteins (Koberle et
al., 1999). In confirmation of this, the absence of ERCC1 is associated with the most
severe DNA repair defect yet discovered (Weeda et al., 1997).
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Figure 4: Pictorial representation of the key steps involved in mammalian nucleotide
excision repair (McHugh et al., 2001).
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The organisation of chromatin is crucial for the regulation of gene expression. The
nucleosome core within the cell contains DNA wrapped around a central histone
octamer comprising two molecules of each of the core histones. The four core
histones (H2A, H2B, H3, and H4) are subject to a wide variety of enzyme-catalysed
post-translational modifications, thereby modulating the function of the chromatin
such as acetylation (Yoshida et al., 2001). The primary sites of histone acetylation
are specific lysine residues in the positively charged N-termini tails that protrude
from the octamer, resulting in neutralisation of these residues (Yoshida et al., 2001).
Histone acetylation by histone acetyltransferases (HAT’s) loosens histone-DNA
contacts, and as such is an important step in transcription, and allows access by
DNA repair proteins to DNA (Kouzarides et al., 1999).
The architecture of the nucleosme, with the helical DNA strands wrapped almost
twice around a tight octameric histone core, presents an obvious physical barrier to
any repair proteins that need to interact with damaged DNA. The histones H2A and
H2B are known to be reversibly post-translationally modified by ubiquitination. The
globular ubiquitin molecule is added to specific lysine residues located on the
flexible histone C-termini, which is capable of relaxing chromatin (Wolffe et al.,
1999). This would be expected to make sites of DNA damage more accessible to
proteins of the NER pathway. Lending support to this hypothesis is the transient
unfolding of nucleosomes during NER in both normal and XPC human cells (Baxter
et al., 1998). It is also intriguing that the carboxy termini of the human hHR23A and
hHR23B RAD23 homologs contain a 50-amino-acid domain highly homologous to
E2 ubiquitin-conjugating enzymes (Masutani et al., 1997). The hHR23A and
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HHR23B enzymes form complexes with the XPC DNA damage recognition protein
(Masutani et al., 1997).
Proteasome inhibition stabilizes polyubiquitinated proteins, depletes cytosolic
unconjugated ubiquitin, and thereby promotes the deubiquitination of nucleosomal
histones in chromatin, resulting in the condensation of chromatin. The balance of
histone ubiquitination/deubiquitination is rapidly tilted in favour of the enzymatic
cleavage of ubiquitin from the histones because the nuclear pool of unconjugated
ubiquitin is normally low (Mimnaugh et al., 1997, Chen et al., 1998).
1.3.2.4 Homologous Recombination
Homologous recombination is a template-dependent DNA repair pathway that is
most efficient in late S and G2 phases of the cell cycle found in all organisms
studied (Heyer et al., 2006). It is critical for the repair of DNA damage, and the
recovery of stalled and broken replication forks which preserves genomic stability
(Heyer et al., 2006). Homologous recombination involves the exchange of DNA
between sequences of perfect or near perfect homology over several hundreds of
base pairs. In contrast, nonhomologous recombination occurs between sequences
with little or no sequence homology (Symington et al., 2002).
Homologous recombination can be divided into three stages, pre-synapsis, synapsis,
post-synapsis. In pre-synapsis formation of a protein complex consisting of BRCA1,
and RAD50-MRE11-Xrs2/ Nbs1 (neijman breakage syndrome) (Zhong et al., 1999),
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nicks the DNA using its 5’-3’ exonuclease activity to expose the 3’ ends on either
side of the DSB (Hoeijmakers et al., 2001). Exo1 is also involved in this process
(Heyer et al., 2006). Phosphorylation of the serine 1423 residue of BRCA1 activates
it, which is important for its function in DNA repair (Cortez et al., 1999). RPA then
binds to the ssDNA produced at the break site, and is able to recruit and activate
ATR (Zou et al., 2003).
The mediator proteins Rad52, Rad54, Brca2 (Chen et al., 1998), and the Rad 51
paralogs (Rad51B, Rad51C, Xrcc2, Xrcc3), orchestrate the formation of the pre-
synaptic Rad51 filament on RPA-coated ssDNA. In support of this, BRCA2-
deficient cells have increased sensitivity to ionising radiation, which indicates a
defect in DSB repair (Moynahan et al., 2001). BRCA2 regulates the intracellular
location and function of RAD51 (Davies et al., 2001). RAD51 directly binds 6 of
the 8 BRC repeats on the BRCA2 protein (Davies et al., 2001).
The homology driven pathway then enters synapsis in which single strand
annealing, or strand invasion pathways occur. During synapsis a physical connection
(d-loop) is generated between the recombinogenic substrate and an intact
homologous duplex DNA template leading to the formation of a heteroduplex (or
hybrid) DNA (Heyer et al., 2006).
The third and final part of homologous recombination is post-synapsis in which a
double-holiday junction intermediate is formed. This is resolved by crossover or
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non-crossover outcomes involving Rad51 and Rad54, in which the DNA strands are
restored (Heyer et al., 2006).
In strand invasion RAD51 coated single stranded DNA nucleoprotein filament
invades and pairs with a homologous region in the sister chromatid, (Baumann et
al., 2006) leading to crossing over of genetic material. This usually happens in G2
and S phases of the cell cycle (Kennedy et al., 2004).
Single strand annealing (SSA) forms part of homologous recombination, and occurs
when a DSB is flanked either side by homologous regions. This is likely to occur
frequently in the mammalian genome because there is a high proportion of repetitive
DNA (e.g Alu repeats) (McHugh et al., 2000). The DSB is resected as above, and
the complimentary 3’ ends anneal in the regions of homology, while the
overhanging ends are clipped off. Ligation completes the repair (McHugh et al.,
2000). Again a member of the RAD52 family is involved. The 3’ ends of the DNA
are removed by the XPF-ERCC1 heterodimer (Sargent et al., 2000). SSA is non-
conservative and an error prone mechanism of DSB repair.
1.3.2.5 Non-homolgous end-joining (NHEJ)
NHEJ is active throughout the cell cycle (Chu et al., 1997), but it is especially
important in G1. It appears to be the predominant pathway for repairing DSBs in
mammalian cells such as those caused by ionising radiation (McHugh et al., 2000).
In NHEJ the two ends of the DSB are directly joined together, requiring very little
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homology (McHugh et al., 2000) and because no template is used, it is less accurate,
and therefore is error prone.
NHEJ requires the removal of 1-10 nucleotides to uncover microhomology
sequences to allow proper base pairing and ligation of the broken ends (Ting et al.,
2004). It has been proposed that the MRN complex (Mre/Rad50/Nbs1) is involved
in processing the ends. In vitro Mre11 has 3’-5’ endonucleolytic activity which is
enhanced by the presence of Rad50 and Nbs1 (Paull et al., 1999). Brca1 inhibits the
nucleolytic activity of Mre11, suggesting that Brca1 regulates the function of the
MRN complex to prevent extensive DNA end processing (and hence loss of genetic
material) (Paull et al., 2001).
Once the ends have been processed, a heterodimeric complex of the Ku70 and Ku80
proteins stabilise the ends, by recruiting DNA protein kinase, and facilitates
rejoining by DNA ligase IV and ERCC4 proteins (McHugh et al., 2001) (figure 5).
Under electron microscopy a region of Brca1 (452-1079) is seen to form protein-
DNA complexes cooperatively between multiple DNA strands suggesting that Brca1
may act like DNA-PKcs to bridge adjacent DNA molecules (Paull et al., 2001).
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Figure 5: The main pathways for the repair of DSBs in eukaryotic cells. (a) classic
model for DSB repair based on experimental data from Saccharomyces cerevisiae.
(b) single-strand annealing (c) Non-homologous end-joining (McHugh et al., 2001).
In BRCA1- and BRCA2- deficient cells, RAD51-dependent homologous
recombination cannot occur, and the DSB is repaired by other error-prone
mechanisms such as non-homologous end-joining (NHEJ) (Lomonosov et al.,
2003). This results in large numbers of aberrations and chromatid breaks, leading to
loss of viability (Lomonosov et al., 2003).
1.3.3 Repair of different DNA lesions
1.3.3.1 Repair of single strand breaks
Single strand breaks can occur during DNA replication or repair, after UV
irradiation, or from intermediates of type 1 topoisomerases (Pacques et al., 1999).
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PARP-1 (poly(ADP-ribose)) binds to single-strand DNA breaks, and initiates the
recruitment of the DNA repair machinery (Leppard et al., 2003). There is evidence
that the DNA ligase IIIa-XRCC1 complex is recruited to DNA single-strand breaks
by virtue of the preferential binding of both subunits of the complex to automodified
PARP-1 (Leppard et al., 2003).
1.3.3.2 Repair of double-strand breaks
There are many ways in which Double strand breaks (DSB) may occur. They can
occur naturally, for example in meiosis where rearrangement of gene segments (VDJ
joining) during immune-cell development, are important developmentally regulated
processes involving DSB intermediates. They can also result from normal metabolic
processes that generate reactive oxygen species within the cell that attack DNA
(Sankaranarayanan et al., 2005). Ionising radiation (McHugh et al., 2000)
mechanical stress, endonucleases, or replication of a single-stranded nicked
chromosome can also produce DSBs (Pacques et al., 1999). DSBs can also arise
indirectly when a DNA replication fork collides with an un-repaired single-strand
break (SSB), giving rise to a collapsed replication fork (Haber et al., 1999).
DSBs are the sole instigators of recombination in meiotic cells and are a major
factor in recombination in mitotic cells (Pacques et al., 1999). DSB are lethal if left
unrepaired, and if mis-repaired can lead to translocations and other potentially
carcinogenic-causing chromosomal abnormalities (McHugh et al., 2000).
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DSBs are repaired by mechanisms such as, homologous recombination, and non-
homologous end joining (NHEJ), but there is co-operation between them
(Richardson et al., 2000). Single strand annealing, which is a variant of HR, is also
involved in the repair of DSBs. This takes place when direct repeat sequences flank
the two DNA ends (Jackson et al., 2002). Brca 1 is linked to HR and NHEJ, and is
likely to participate in establishing the mechanism of repair of the DSB (Ting et al.,
2004). In support of this notion, cells display either Rad50 or Rad51 IRIF (ionising
radiation-induced foci), and Brca1 co-localises with either Rad50 or Rad51, but not
with both at the same time (Zhong et al., 1999). Since the MRN complex may be
involved in both HR and NHEJ, Brca1 likely executes this decision through
coordinating the activities of the MRN complex (Ting et al., 2004).
BRCA1 is activated by ataxia telangiectasia mutated protein (ATM) and checkpoint
kinase 2 (CHK2) in the response to double strand breaks of the DNA (Tutt et al.,
2002). ATM and/or ATR become activated in response to DSB, and then
phosphorylate histone H2AX (Burma et al., 2001) at serine 139, which enables it to
recruit a number of proteins: Brca1, MRN (Mre11/Rad50/Nbs1) complex, DNA-
PKcs, Chk2 kinases, Mdc1/Nfbd1, 53BP1, and Rad51 all co-localise to histone
H2AX following ionising radiation and DSB production (Paull et al., 2000). The
phosphorylation of histone H2AX produces a type of nuclear foci (or ionising
radiation induced foci (IRIF)), and is rapidly detected within 3 minutes of ionising
radiation (Rogako et al., 1998). There is evidence that Mdc1/Nfbd1 and 53BP1 may
play redundant roles in initially associating with histone H2AX, which in turn
recruit Brca1 and MRN to histone H2AX (Goldberg et al., 2003) (Wang et al.,
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2002). In response to ICL formation, Fancd2 (one of the proteins involved in the
cancer susceptibility syndrome Fanconi anaemia (FA)) becomes mono-ubiquinated
and colocalises with Brca1 at IRIF (Garcia-Higuera et al., 2001).
1.3.3.3 Repair of DNA interstrand crosslinks (ICLs)
As the ICLs involve both strands, they are critical lesions since they block
transcription and replication (McHugh et al., 2001). The repair of ICLs in
mammalian cells involves components of different repair pathways such as NER,
and homologous recombination (McHugh et al., 2001). However, the full
mechanistic details of mammalian ICL repair have not been fully elucidated
(McHugh et al., 2001). It has been established that NER and homologous
recombination are important for the removal of cisplatin DNA adducts in
Eschierichia coli (Zdraveski et al., 2000) and yeast (McHugh et al., 2000). De Silva
et al demonstrated that the high cisplatin sensitivity of ERCC1- and XPF-mutant
cells likely results from a defect other than in excision repair (De Silva et al., 2002).
It has also been shown in human tissues from patients with ovarian cancer, a
possible molecular basis for co-ordinate mRNA expression of genes involved in
NER, suggesting that NER is important in human cancers (Zhong et al., 2000).
Defects in the homologous recombination repair pathways for DSBs result in
increased sensitivity to ICLs in human cells, suggesting that these pathways are
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involved in ICL repair (Moynahan et al., 2001). In support of this Brca1 (which is
involved in HR), deficient cells are sensitive to mitomycin C, which induces ICLs
(Dronkert et al., 2001). The observation that XRCC2 and XRCC3 mutants are
extremely sensitive to cisplatin suggests that homology-driven recombination plays
a major role in the repair of cisplatin DNA damage (Caldecott et al., 1991). XRCC2
and XRCC3 mutants are also unable to uncouple cisplatin ICLs, which raises the
possibility that homologous recombination is initiated prior to the incisions which
uncouple the cisplatin cross-link, and that the incision reaction depend upon an early
recombination intermediate being formed (De Silva et al., 2002)
1.3.4 Apoptosis
Apoptosis plays a major role in chemotherapy-induced tumour cell killing. There is
a careful balance between cell cycle arrest to enable DNA repair to occur, and
apoptosis. Apoptosis is carried out by the activation of caspases. There are two main
pathways to activate caspases: the intrinsic pathway regulated by Bcl-2 proteins, and
the extrinsic pathway regulated by tumour necrosis factor (TNF) receptor
superfamily (Reviewed in Hengartner et al., 2000).
In the intrinsic pathway, the pro-apoptotic Bcl-2 family proteins (such as bax, bad,
bak) promote the release of cytochrome c from mitochondria, which forms a
complex called the apoptosome with caspase 9 and APAF-1 in the cytosol
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(Reviewed in Hengartner et al., 2000). Caspase 9 is activated by the apoptosome,
leading to cleavage and activation of effector caspases such as caspase 3 and 7.
These executioner caspases bring about the morphological and biochemical changes
that characterise apoptosis, including, chromatin condensation and nuclear
fragmentation, membrane blebbing, and cell shrinkage (Reviewed in Hengartner et
al., 2000). The cell then breaks into membrane bound fragments called apoptotic
bodies that are cleared by phagocytosis without causing an inflammatory response
(Longley et al., 2005). Other Bcl-2 family members are anti-apoptotic such as Bcl-2
itself, Bcl-XL and Mcl-1. They bind to the pro-apoptotic members of the Bcl-2
family, and prevent them from becoming activated.
The extrinsic apoptotic pathway is regulated by cell surface ‘death’ receptors of the
TNF-receptor family, such as Fas (CD95/APO-1), DR4 (TNF-related apoptosis-
inducing ligand recptor 1, TRAIL-R1), and DR5 (TRAIL-R2). When Fas ligand
(FasL), binds to Fas, caspase 8 is recruited via an adaptor molecule FADD (Fas-
associated death domain) to form a death-inducing signalling complex (DISC)
(Nagata et al., 1999), which in turn activates the effector caspases 3 and 7 (Nagata et
al., 1999). FLIPP (FADD-like interleukin-1-converting enzyme-inhibitory protein)
binds to the DISC and inhibits capase 8 activation (Krueger et al., 2001).
Apoptosis is also inhibited by members of the IAP (inhibitors of apotosis) family,
which include c-IAP1, c-IAP2, X-IAP, and surviving (Salvesen et al., 2002). IAPs
can bind directly to caspases, such as caspase 3, 7, and 9, which inhibit their activity
(Salvesen et al., 2002). IAPs themselves are inhibited by Smac/DIABLO, which is
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released from mitochondria along with cytochrome c in response to pro-apoptotic
stimuli (Salvesen et al., 2002).
MEK is a MAP kinase kinase apoptosis inhibitor that plays a role in signal
transduction from growth factors in a receptor tyrosine kinase –RAS-RAF-MEK-
ERK cascade (Garrett et al.,1999). It has been shown that MEK may stimulate
antiapoptotic Bcl-2, Bcl-XL, and MCL-1 proteins (Boucher et al., 2000), as well as
inactivate proapoptotic protein BAD (Scheid et al., 1998). The role of MEK kinase
in response of cancer cell lines to cisplatin-based chemotherapy is unclear: some
report MEK inhibition of TP53-dependent apoptosis after cisplatin administration
(Hong et al., 1999), and others report an activation (Wang et al., 2000), although in
the latter case apoptosis was blocked by MEK inhibitors (Wang et al., 2000). In a
study by Kupryja et al, 2003, high MEK expression was associated with the highly
aggressive endometriod and clear cell carcinomas (p=0.049).
P53 is a tumour suppressor protein encoded by the TP53 gene, and has a central role
in the regulation of the cell cycle, apoptosis, survival, DNA repair, transcription,
differentiation, senescence as well as glucose metabolism oxidative stress and
angiogenesis (Vogelstein et al., 2000). Normal cells have low levels of P53 as it has
a short half life. Mutations in P53 often encode proteins that are resistant to
degradation, and mutant P53 often accumulates in the nucleus of cancer cells.
P53 protein downregulates Bcl-2 (an apoptosis inhibitor), and upregulates BAX
expression (an apoptosis promoter), thus promoting apoptosis (Miyashita et al.,
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1994). It has also been shown that cisplatin-induced apoptosis is associated with
wild-type TP53/BAX complex formation (Raffo et al., 2000). Cell line studies show
that TP53-regulated protein levels may differ before or after cisplatin administration
depending on the TP53 status (Jones et al, 1998), therefore evaluating functional and
dysfunctional TP53 protein, may possibly mask the biological significance of
proteins regulated or interacting with wild-type TP53, but not with mutant TP53.
BAX expression was a strong prognostic indicator of disease free survival in TP53
(+) ovarian carcinomas, but high levels of BAX expression negatively influenced
complete remission in all patient groups, which is in contrast to its pro-apoptotic
function (Kupryja et al., 2003)
Cisplatin induces apoptosis, which in the majority of ovarian carcinoma cell lines is
TP53-dependent (Jones et al., 1998). Impaired TP53 protein function resulting from
TP53 gene mutation contributes to cisplatin resistance in ovarian cancer cell lines
(Jones et al., 1998). TP53 is the most frequently mutated gene in human cancers,
with up to 50% of tumours carrying a mutation (Levine et al., 1997) and has a
central role in determining the response of tumour cells to chemotherapy following
DNA damage. This lack of functional p53 may contribute to drug resistance through
the inability of cells to undergo apoptosis in response to DNA damage (Ferreira et
al., 1999).
DNA damage results in the activation of upstream kinases such as ATM (ataxia-
telangiectasia-mutated), ATR (ATM and Rad-3 related), and DNA-PK (DNA-
dependent protein kinase), which directly or indirectly activate p53 (Ljungman et
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al., 2000). ATR (ATM-related kinase) also phosphorylates and activates BRCA1
(Zou et al., 2003).
Once activated, p53 acts as a transcription factor by up-regulating genes such as
GADD45 and p21, which induce cell cycle arrest in response to DNA damage
(Dotto et al., 2000). However, p53 can also trigger apoptosis by up-regulating pro-
apoptotic genes such as Bax, NOXA, TRAIL-R2 (DR5), and Fas (Schuler et al.,
2001). These processes act to maintain genomic integrity and prevent damaged
DNA from being passed on to daughter cells.
In breast cancer cell lines, BRCA1 induces apoptosis, mediated by caspases 9 and 3,
in response to spindle damage through activation of the c-jun N-terminal kinase
pathway (JNK) (Harkin et al., 1999). This pathway also involves activation of the
kinases H-Ras, MEKK4, Fas ligand and its receptor (Thangaraju et al., 2000), and is
specifically activated after treatment with spindle poisons such as paclitaxel (Mingo-
Sion et al., 2004).
However, there have been conflicting results in ovarian cancer cell lines. BRCA1
expression decreased paclitaxel sensitivity in BRCA1-mutant SNU human ovarian
cancer cell lines (Zhou et al., 2003), and expression of a dominant negative BRCA
in the ID-8 murine ovarian cancer cell line increased the sensitivity of the cells to
paclitaxel (Sylvain et al., 2002).
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1.4 Drug Resistance in Ovarian Cancer
Chemotherapy resistance is clinically defined as the progression of disease during
therapy, absence of regression during therapy, or recurrence within 6 months after
completed treatment. Progression of disease during therapy is defined by the
RECIST (response evaluation criteria in solid tumours) guidelines as a 20% increase
in the sum of the longest diameter of the target (i.e ovary) or non-target lesions
(Therasse et al., 2000). Absence of regression during therapy is defined by the
RECIST guidelines as neither disappearance of all target lesions (complete
response), >30% decrease in the sum of the longest diameter of target lesions
(partial response), or progressive disease (defined above) (Therasse et al., 2000).
Recurrence of disease is confirmed as a rise of serum Ca-125 levels to more than
twice the upper limit of normal (Rustin et al., 1996), and in patients with persistently
elevated Ca 125 serum levels, recurrence of disease is a doubling of Ca 125 above
the nadir (Rustin et al., 2001). Recurrence of disease can also be confirmed by CT
scans.
Tumours are considered to be sensitive if they exhibit complete clinical response to
therapy, or if relapse occurs after remission and treatment has not been administered
for more than 6 months (Ringborg et al., 1998). Resistance to cisplatin can be
intrinsic or acquired. Intrinsic is present at the time of diagnosis, and patients fail to
respond to first line chemotherapy. Laboratory studies have shown that cisplatin
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resistance is multifactorial, consisting of mechanisms such as: (1) decreased drug
accumulation (2) increased drug inactivation (3) evasion of apoptosis (4) enhanced
ability to repair DNA damage. However, because cancer cells are heterogenous,
more than one mechanism of drug resistance may be present at one time.
1.4.1 Decreased drug accumulation
This can be due to an insufficient dose, low bioavailiblity, poor drug distribution,
increased metabolism (e.g extensive first-pass metabolism) and excretion, impaired
diffusion of drug to tumour cells, high plasma protein binding, low tissue binding
and increased drug efflux. In some human ovarian cancer cell lines, decreased
cellular accumulation of platinum compounds has been found to be partly
responsible for the resistant phenotype (Jekunen et al., 1994). The adenosine
binding cassette (ABC) superfamily can confer drug resistance in vitro (Taniguchi et
al., 1996) , and are an important part of enhancing drug efflux. In other non-ovarian
cancer cell lines, two cell membrane proteins that may be involved in platinum
compound uptake and efflux have been indentified that may account for the cisplatin
phenotype (Bernal et al., 2005). However due to practical limitations, the
importance of decreased drug accumulation as a mechanism of platinum resistance
in the clinical setting remains to be established.
A major problem in the treatment of cancer patients with chemotherapy is the
development of multi-drug resistance (MDR). This is the resistance of tumour cells
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to structurally and functionally unrelated drugs such as the anthracyclines, Vinca
Alkaloids, and the epipodophyllotoxins. The multidrug resistance-associated protein
gene (MRP1) encodes a protein that is part of the ABC transporters, and is very
important in the development of chemotherapy resistance. cMOAT(MRP2), MRP3,
MRP4, and MRP5, are all homologues of MRP1. Two proteins, MDR1 gene
encoded-P-glcoprotein (P-gp), and MRP1 (MDR associated protein), are involved in
drug transport and are well known for causing MDR, usually by drug efflux. They
are both members of the ATP binding cassette transporter superfamily, that transport
diverse compounds such as metal ions, phospholipids, and nucleosides (de Jong et
al., 2001). Despite their common involvement in MDR, there are clear differences in
their function and substrate specificity of P-gp, and MRP1. Pgp binds and transports
neutral or positively charged, hydrophobic compounds, whereas MRP1 transports
conjugated organic anions such as the leukotriene C4 and GSH S-conjugates of
prostaglandin A2 and aflatoxin B1 (de Jong et al., 2001). GSH is required for the
transportation of anthracyclines by MRP1, but GSH is not necessarily conjugated to
the drug, instead GSH may be co-transported (Loe et al., 1998).
Increased drug efflux can be due to enhanced expression of drug transporter proteins
such as P-glycoprotein, and MRP (Gottesman et al., 1993). The reduction of
expression of MDR1 by RNAi has been found to sensitise cells to paclitaxel (Duan
et al., 2004), and the reduction of expression of MRP2 with ribozymes confers
sensitivity to cisplatin (Materna et al., 2005). This suggests that the ABC family of
transporters are involved with transporting cisplatin and paclitaxel out of the cancer
cells, which confers resistance. Other inhibitors of these drug efflux pumps include
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verapamil and cyclosporin A, and have been developed to reverse multidrug
resistance (Kool et al., 1999). However, P-gp and MRP have also been expressed in
normal tissues, so the inhibition of these pumps has distinct adverse effects and is
difficult to use these inhibitors in clinical therapy (Kool et al., 1999).
Furthermore, in ovarian cancer up to two thirds of tumour specimens have been
found to overexpress P-glycoprotein on immunohistochemistry. This overexpression
has been shown in some cases to correlate with poor overall survival, (Baekelandt et
al., 2000) and poor response to standard chemotherapy (Yokoyama et al., 1999). As
a result of this, inhibitors of P-glycoprotein (P-gp) have been studied in trials. One
such phase III trial compared carboplatin and paclitaxel with or without PSC-833
(Valspodar, which is an inhibitor of P-gp) for the treatment of 762 patients with
advanced ovarian cancer. The results showed that the addition of PSC-833 led to a
reduction in response rates and no difference in overall survival (Baird et al., 2001).
However it has since been shown that valspodar has unpredictable pharmacokinetic
interactions and in addition targets other transport proteins (Thomas et al., 2003),
which may contribute to the disappointing clinical results. There are other novel p-
gylcoprotein inhibitors such as tariquidar and zosuquidar that are highly specific for
p-glycoprotein (Starling et al., 1997). They are currently being tested in phase III
clinical trials to determine if they can reduce drug resistance (Starling et al., 1997).
ABCC2 is a human ABC transporter also called multidrug resistance-associated
protein (MRP2), or canalicular multiple organic anion transporter (cMOAT), and is
expressed in the apical membranes of canalicular cells in the liver (Kool et al., 1997)
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where it functions as the major exporter of organic anions from the liver into the bile
(Wada et al., 1998). In vitro experiments showed that overexpression of ABCC2
could confer resistance to platinum-based chemotherapy in ovarian cancer cell lines
by increasing cisplatin efflux (Taniguchi et al., 1996). Although xpression of
ABCC2 could be detected in clinical specimens of ovarian carcinoma, an
immunohistochemical study using frozen tissue sections of tumours could not show
any prognostic value of ABCC2 assessment for response to chemotherapy or
progression-free survival (Arts et al., 1999).
1.4.2 Increased drug inactivation
Gluthathione is a powerful antioxidant, which inhibits oxidative stress that can
damage DNA and RNA (Rothbarth et al., 2002). It is a tripeptide thiol which has an
important role in cellular detoxification of various toxins (Van der Zee et al., 1995).
Binding of drugs such as cisplatin and carboplatin by glutathione, catalysed by
glutathione-S-transferase (GST-) (Gottesman et al., 1993), inactivates them. The
resulting complex is a substrate for ABC transporter proteins in leukaemia cells,
which transport it out of the cell (Ishikawa et al., 1993), contributing to drug
resistance further.
High levels of glutathione have been found in tumour cell lines resistant to platinum
chemotherapy (Kelland et al., 1993) and melphalan (Schroder et al., 1996). In a
study by Bratasz et al. 2008, it was shown that NCX-4040, a nitric oxide-releasing
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derivative of aspirin, could resensitize drug-resistant ovarian cancer cells (ovarian
cell lines and xenograft tumours) to cisplatin, possibly by depletion of cellular thiols
(Bratasz et al., 2008)
A relationship has also been reported between high levels of GST-, worse
prognosis, and resistance to platinum chemotherapy in ovarian cancer (Green et al.,
1993). Another study has also shown high levels of GST- in platinum resistant
ovarian cancer cells (Sakamoto et al., 2001) and tumours (Green et al., 1993).
However, other studies did not support these findings and could not find any
relationship between GST- expression and survival or response to chemotherapy in
ovarian cancer (Van der Zee et al., 1995). In a large recent study by Nagle et al,
2007, the common glutathione-S-tansferase polymorphisms (GSTM1, GSTP2,
GSTT1) of 239 Australian women with primary epithelial ovarian cancer were
analysed to see if there was a relationship to survival. Reduced GST function was
associated with better survival outcomes (Nagle et al., 2007).
A platinum analogue called ZD0473 avoids binding to cytoplasmic thiols, thereby
overcoming thiol-mediated detoxification. This was tested in phase II clinical trials
in 94 patients with ovarian cancer that had been previously treated with carboplatin.
The results were disappointing and showed that ZD0473 had much poorer response
rates, median survival, and median time to progression than carboplatin (Gore et al.,
2002). This pathway therefore does not appear to be a major factor in the clinical
resistance to platinum compounds.
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1.4.3 Evasion of apoptosis
P53 is a tumour suppressor protein encoded by the TP53 gene, and has a central role
in the regulation of the cell cycle and apoptosis (Vogelstein et al., 2000). The TP53
gene is often mutated in ovarian cancer, and a number of studies have shown that
these patients have worse clinical outcomes following platinum-based
chemotherapy, (Marx et al., 1998). However, it is difficult to know if the p53 status
predicts poor response to chemotherapy, or an inherently aggressive tumour type.
The Gynecologic Oncology Group (GOG) performed a detailed analysis of p53
overexpression in previously-untreated women with early invasive or advanced
stage epithelial ovarian cancer (EOC). Women included had participated in either
the GOG-157, a randomized phae III trial of three vs six cycles of paclitaxel +
carboplatin in high risk, early stage EOC, or GOG-111, a randomized phase III trial
of cyclophosphomide + cisplatin, vs paclitaxel + cisplatin in sub-optimally resected,
advanced stage EOC (Darcy et al., 2008). P53 overexpression was assessed by DO-
7 immunostaining, and was found to be overexpressed in 51% (73/143) and 66%
(90/136) of cases on the GOG-157 and GOG-111 cohorts, respectively. P53
overexpression was not associated with any clinical characteristics or overall
survival (OS) but was associated with worse progression free survival (PFS)
(logrank test: p=0.013; unadjusted Cox modelling: p=0.015). In the GOG-111
cohort, p53 overexpression was associated with GOG performance status (p=0.018)
and grade (p=0.003), but not with age, stage, cell type, or tumour response and
disease status after primary chemotherapy, PFS, or OS. Adjusted Cox regression
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modelling demonstrated that P53 overexpression was not an independent prognostic
factor in either cohort (Darcy et al., 2008).
Experimental and clinical data seem to show that paclitaxel enhances apoptosis
through a p53 –independent pathway that probably involves the BAX gene. Whereas
patients with wild type p53 tumours have a good chance to respond to platinum,
patients with mutant p53 tumours may have a clinical need to add paclitaxel to
platinum-based chemotherapy (Gadducci et al., 2002). Therefore determining p53
status can be useful in predicting therapeutic response to specific drugs. Other
studies are being performed to assess whether wild-type p53 can be reintroduced
into tumour cells using adenovirus ADP53 to restore chemosensitivity in these cells
(Wolf et al., 2000). A large scale randomised trial is underway to assess
intraperitoneal ADP53 in combination with platinum-based chemotherapy (Vasey et
al., 2003).
Lactacystin (LC) and N-acetyl-leucyl-leucyl-norleucinal (ALLnL), which are both
proteasome inhibitors potently increase p53 levels in cell lysates and stimulated the
binding of p53 to chromatin (Mimnaugh et al., 2000). Bcl-2 and Bcl-xL inhibit
apoptosis by regulating the release of cytochrome c from the mitochondrial
membrane. Expression of Bcl-xL is associated with a shorter disease-free survival
period in patients receiving platinum-based chemotherapy for ovarian cancer
(Williams et al., 2005). In confirmation of this, ectopic expression of Bcl-xL renders
the A2780 ovarian cancer cell line more resistant to cytotoxic agents both in vitro
and in tumour models in vivo (Williams et al., 2005). Conversely, down–regulation
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of Bcl-2 (in this case in combination with antisense directed to MDR1) leads to a
significant sensitisation to doxorubicin (Pakunlu et al., 2003).
Several cytotoxic agents have been shown to induce the ligand for Fas, which
contributes to drug-induced apoptosis, since the Fas receptor is part of a death-
induced signalling complex (Pakunlu et al., 2003). FLIP (FLICE-like inhibitory
protein) inhibits apoptosis by preventing the assembly of the Fas receptor with its
signalling complex. Ectopic expression of FLIP inhibits cisplatin-induced apoptosis
and RNAi directed to FLIP sensitises cells to cisplatin (Abedini et al., 2004).
Similarly TRAIL, another ligand, which induces apoptosis, is able, in some cells to
potentiate apoptosis induced by cytotoxic agents, including carboplatin and
paclitaxel (Cuello et al., 2001). Decoy receptor 3 (DcR3) is a soluble tumour
necrosis factor receptor found in ascites of patients with ovarian cancer. Ascites
from 44 patients inhibited fas-ligand mediated apoptosis, and higher levels of DcR3
were associated with stage 4 disease, and higher incidence of platinum resistance
(Connor et al., 2008).
Another molecule that has been implicated in drug resistance through its anti-
apoptotic mechanism is the caspase inhibitor XIAP. In cell lines that are sensitive to
cisplatin, XIAP is down regulated by the drug, which leads to a corresponding
activation of the pro-apoptotic caspase 3. In contrast, drug-resistant cell lines have
shown no decrease in XIAP after exposure to an equimolar concentration of
cisplatin (Yang et al., 2004). Ectopic expression of XIAP can render cells more
resistant to cisplatin (Asselin et al., 2003) and this appears to depend on activation
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of the PI 3-kinase/Akt signalling pathway (Asselin et al., 2003). Conversely anti-
sense oligonucleotides directed to XIAP can sensitise resistant cells to cisplatin
(Yang et al., 2004). These studies suggest that by preventing apoptotis, XIAP can
potentially contribute to drug resistance.
The phosphatidylinositol 3-kinases (PI3Ks) are widely expressed lipid kinases that
phosphorylate phosphoinositides at the D-3 position of the inositol ring. These
enzymes function as signal transducers downstream of cell-surface receptors
(Reviewed in Garcia-Echeverria et al., 2008). The products of PI3K-catalzed
reactions are second messengers and have central roles in a number of cellular
processes including cell growth, differentiation and survival. In the PI3K/Akt
pathway, PI3K recruitment to tyrosine kinase receptors leads to a transient rise in
phosphatdylinositol 2,4,5-triphosphate (PIP3), which recruits PH-domain containing
proteins such as Akt (Bellacosa et al.,1998). After translocation to the plasma
membrane, Akt is activated by phosphorylation, which then activates downstream
cytosolic and nuclear effectors. In tumour cells, Akt is constitutively activated which
leads to dysregulated proliferation, increased angiogenesis, cell growth and survival
(Bellacosa et al., 1998).
PIK3CA gene encodes a catalytic subunit of PI3K. In a study by Kolasa et al,
molecular analysis on 117 ovarian carcinomas revealed PIK3CA mutations occurred
in 5/117 (4.3%) carcinomas, exclusively in the endometrioid and clear cell sub-types
(p=0.0002). PIK3CA amplification occurred in 28/117 (24%) of ovarian tumours
and strongly diminished odds of complete remission (OR=0.25, p=0.033), and
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platinum sensitive response (PS, OR=0.12, p=0.004) in the taxane-platinum patients,
suggesting that PIK3CA amplification may be a marker predicting ovarian cancer
response (Kolasa et al., 2009).
The PI 3-kinase-Akt pathway has been identified as a potential contributor to drug
resistance by preventing chemotherapeutic drugs from inducing apoptosis (Pommier
et al., 2004). The tumour suppressor PTEN catalyses the degradation of the 3-
phosphoinositides that are generated by the PI 3-kinase pathway, and thus
antagonising this pathway. Although the gene encoding Akt is amplified in only
12% of ovarian cancers (Bellacosa et al., 1995) it is reported to be
hyperphosphorylated and activated inbetween 36 and 68% of clinical samples
(Altomare et al., 2000). Activation of this survival pathway by ectopic expression of
PI 3-kinase (Lee et al., 2005), constitutively active Akt (Yuan et al., 2003) or by
RNAi directed to PTEN (Lee et al., 2002) appears to increase resistance of ovarian
cancer cells. Similarly, inhibiting this pathway by inhibition of PI 3-kinase (Hu et
al., 2002) or expression of a dominant-negative interfering variant of Akt (Yuan et
al., 2003) can increase sensitivity to cytotoxic drugs.
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1.4.4 Enhanced ability to repair DNA damage
Increased platinum-DNA adduct removal has been shown by several DNA repair
assays to be associated with cisplatin resistance in an A2780 cisplatin resistant
human ovarian cancer cell line (A2780cisR) (Ferry et al., 2000). Up-regulation of
ERCC1 mRNA in response to cisplatin exposure correlates with the development by
tumour cells of an acquired resistance to this chemotherapeutic agent (Parker et al.,
1991). The importance of this enzyme is demonstrated by the fact that cisplatin-
DNA adducts cannot be repaired without functional ERCC1 enzyme (Lee et al.,
1993), and expression of antisense ERCC1 leads to sensitisation of cells to cisplatin
both in vitro and in xenograft tumour models (Selvakumaran et al., 2003).
Proteasome inhibitors (such as LC and ALLnL) prevent the increase in ERCC1
mRNA expression that occurs in cells exposed to cisplatin (Mimnaugh et al., 2000).
Clinically in ovarian cancer, there is a direct association between mRNA levels of
ERCC1 gene and clinical resistance to platinum-based chemotherapy (Dabholkar et
al., 1994). Activator protein 1 (AP-1) is an important transcription factor for ERCC1
(Li et al., 1998), and pharmacological modulation of AP1 levels appear to impact
strongly on ERCC1 mRNA and protein expression (Li et al., 1998). AP1
transcription factor consists of either, heterodimers formed between Jun and Fos
family members of proto-oncoproteins, or homodimers of Jun proteins (Gottlicher et
al., 1997).
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There is evidence that cisplatin induces expression of proto-oncogenes c-fos/c-jun
and activates c-Jun NH2 –terminal Kinase / stress-activated protein kinase
(JNK/SAPK) in ovarian cancer cells and other tumour cells (Liu et al., 1996).
JNK/SAPK is a subfamily of MAP kinases in the Ras pathway, which is responsible
for the phosphorylation of Jun protein (Li et al., 1998). Phosphorylation of the
transcription factor c-Jun at serine residues 63 and 73 in its NH2-terminal domain
greatly enhances the transcriptional activity of the AP1 binding sites (Pulverer et al.,
1991) and AP1 regulated genes (Derijard et al., 1994). In addition, cell lines
resistant to cisplatin exhibited higher levels of c-jun and c-Fos, and down-regulation
of c-jun and c-Fos expression sensitizes the cells to cisplatin (Moorehead et al.,
2000). In support of this, a dominant-negative c-jun reduces the repair of cisplatin
adducts (Gjerset et al., 1997). Therefore it is possible that the effect of cisplatin on
ERCC1 could be through AP1 induction or c-Jun phosphorylation.
The JNK/SAPK pathway has been reported to protect against cisplatin-induced
DNA damage and that this response is required for DNA repair and survival
following cisplatin treatment (Potapova et al., 1997). This suggests that the Ras/JNK
pathway may mediate a physiological response to DNA damage such as the
induction of one or more DNA repair enzymes. Youn et al have shown in NIH3T3
mouse embryo cell lines that activation of oncogenic H-Ras increases ERCC1
promoter activity through Ap1-binding sites. This is an essential role for oncogenic
H-Ras mediated cell survival against platinum-based agents, and is important in the
development of resistance to chemotherapy and ionising radiation in tumour cells
(Youn et al., 2004).
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To try and inhibit the increase in DNA repair, ways of creating a physical barrier to
the components of the NER pathway have been tried. Proteasome inhibitors promote
deubiquitination of nucleosomal histones in chromatin, resulting in the condensation
of chromatin. When cells were pretreated with proteasome inhibitors (such as
lactacystin) and then treated with cisplatin, chromatin condensation, increased
amounts of cisplatin-DNA adducts, diminished NER-dependent repair of cisplatin-
DNA lesions were all observed, compared to control cells which were just treated
with cisplatin alone (Mimnaugh et al., 2000). Another component of the NER
pathway, XPA, is overexpressed in cells that are cisplatin resistant (Dabholkar et al.,
1994).
Ovarian cancer cell lines over-expressing BRCA1 have been shown to be cisplatin
resistant, which has been attributed to BRCA1-dependent DNA repair (Husain et al.,
1998). Also, in support of this, inhibition of BRCA1 by antisense RNAs increased
cisplatin sensitivity, and overexpression of BRCA1 in murine ovarian cancer cells
increased resistant to cisplatin (Sylvain et al., 2002). Experiments in mouse
embryonic stem cells with a mutant BRCA1 showed increased sensitivity to
alkylating agents such as mitomycin C, and cisplatin, compared with cells
expressing wild type BRCA1 (Moynahan et al., 2001). This is probably because
BRCA1 mediated DNA repair does not happen and the cell undergoes apoptosis. In
the clinical setting, it has been shown in a retrospective trial that patients with
mutations in BRCA1 or BRCA2 respond better to platinum-based chemotherapy,
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and have an overall better prognosis than those patients with sporadic disease (Cass
et al., 2003).
Cell lines deficient in the mismatch repair genes hMLH1 or hMSH2 are resistant to
cisplatin in vitro (Brown et al., 1997). A common reason for their deficiency in
these genes is hypermethylation of the hMLh1 promoter (Plumb et al., 2000). In
support of this, a clinical study found that residual ovarian tumours exhibited
microsatelite instability after platinum-based chemotherapy, which was linked to a
loss of expression of hMLH1 (Watanabe et al., 2001). In response to this 2’-deoxy-
5-azacytidine (DAC), which inhibits DNA methyltransferase activity, can be used to
re-sensitize cells to chemotherapy drugs including cisplatin (Plumb et al., 2000) by
reducing the hypermethylation of the hMLH1 promoter. DAC is now in clinical
trials in combination with carboplatin in ovarian cancer (Longley et al., 2005).
However, newer platinum-based drugs such as oxaloplatin, do not show the same
resistance caused by loss of expression of hMLH1 (Raymond et al., 2002). This is
because the MMR machinery does not recognise the DNA adducts introduced by
oxaloplatin (Raymond et al., 2002).
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1.5 Aims
The comet assay has made it possible to study levels of ICLs in individual cells. It
can also be used in the clinical setting as the number of cells it requires can easily be
obtained from patients.
The human paired A2780 and A2780cisR ovarian cancer cell line will be used as an
in vitro model to establish peak of ICL formation and repair, after treatment with
cisplatin. These time points will then be used in clinical samples. Little is known
about clinical resistance, especially ICL formation and repair and their contribution
to platinum chemotherapy resistance. Ovarian cancer cells obtained from patients
with ovarian cancer that are clinically resistant and sensitive to platinum
chemotherapy will be compared to determine the importance of ICL formation and
repair in clinical platinum resistance. It is unclear if upstream mechanisms such as
drug efflux, drug detoxification mechanisms, or decreased drug influx play an
important role in platinum resistance in the clinical setting. By measuring ICL
formation it will become apparent if upstream mechanisms significantly contribute
to platinum resistance.
Melphalan used to be used in the treatment of ovarian cancer, and also causes
interstrand crosslinking. Results from our laboratory suggest that multiple myeloma
patients resistant to melphalan may be sensitive to cisplatin, and it was hypothesised
that ovarian cancer patients resistant to platinum chemotherapy, may be sensitive to
melphalan. Again, the human paired A2780 and A2780cisR ovarian cancer cell line
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will be used as an in vitro model to establish peak of ICL formation and repair, after
treatment with melphalan. These time points will be used in clinical samples.
Microarrays have enabled as many as 30,000 genes to be analysed in a single
sample. This has enabled great advances in the understanding of gene expressions in
different cell populations. Gene expression will be investigated in platinum-resistant
and platinum-sensitive patients with ovarian cancer to look for any possible
differences in ICL formation and repair found in patient samples.
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2. MATERIALS AND METHODS
2.1 Patient Recruitment
Ethics Approval for this study was granted by the joint UCL/UCLH committees on
the ethics of Human research. Ethics reference number 04/Q0505/77 (Appendix 1 –
study protocol).
All patients being treated at University College Hospital between October 2004 and
January 2006 with known epithelial ovarian cancer were included in the study.
Patients with suspected or known epithelial ovarian cancer were approached in
clinics, and on the wards. They were given the patient information leaflet to read
(Appendix 2 – Patient information sheet), and the study was explained to them. If
patients wanted to enter the study, written consent was obtained using the patient
consent form (Appendix 3 – Patient consent form). There were two parts of the
consent form, the first signature was required for the patient to take part in the study,
and the second signature was required to store samples received from the patient for
future research. All patients needed to sign the first part to be included in the study,
but not all patients signed the second part so their samples could not be used for
future research. Only patients with proven epithelial ovarian cancer by cytology
and/or histopathology were included. There were no other exclusion criteria.
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2.2 Measurement of cisplatin cytotoxicity on human ovarian cancer cell lines
First the cells were prepared, counted, and plated up for the experiment. The SRB
(sulphorodamine Blue) assay was used.
2.2.1 Preparation of A2780 and A2780cisR human ovarian cancer cell lines
A2780 and A2780 cisplatin resistant cell lines were used. All cell lines tested
negative for mycoplasma. An aliquot of each cell line containing 1x106 cells was
taken from a stock in liquid nitrogen. The vials were quickly thawed at room
temperature, and 9mls of RPMI media containg 10% FCS and 1% glutamine was
added to each sample and pipetted into a 20ml conical tube. The tubes were spun in
a Jouan CT422 centrifuge (Thermoelectron, Basingstoke, UK) at 270g for 5
minutes. The supernatant was poured off and the pellet was re-suspended in 12mls
of RPMI media containg 10% FCS and 1% glutamine and the whole sample was
pipetted into an 80cm2 flask. The flasks were put into an incubator (37C, 5% CO2)
overnight for the cells to attach.
The cells were looked at under the microscope to assess confluency, which is seen
as cells touching each other with very little space between them. Once the cells were
reaching confluency, they were split to enable their growth and multiplication to
continue. The RPMI media containing 10% FCS and 1% glutamine was poured off,
and 3mls of trypsin (Autogen Bioclear Uk ltd. Wiltshire, UK) was pipetted into the
flask to wash the cells, and then poured off. A further 5mls of trypsin was pipetted
into the flask and left in the incubator for 5 minutes, at 37˚C and 5%CO2. After 5
minutes the trypsin was pipetted off and added to 10mls of RPMI media containing
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10% FCS and 1% glutamine in a 20ml conical tube, and spun in a centrifuge at 270g
for 5 minutes. The supernatant was poured off and the cell pellet was re-suspended
in 12mls of RPMI media containing 10%FCS and 1% glutamine. A variable amount
of the suspension, according to the size of the cell pellet, was pipetted into sterile
80cm2 flasks. If the cell pellet was approx 0.2mls then 10mls of the RPMI media
containg 10% FCS and 1% glutamine with the cells suspended in it was used. If the
cell pellet was approx 1.0mls, then only 2mls of the RPMI media containg 10% FCS
and 1% glutamine containing the cells was used.
Once the cells were reaching confluency, as viewed down an inverted microscope,
they were then split again. This was repeated, until the cells were ready to use for
the experiments below. Cells were only used if they were at the point of reaching
confluency, as this meant they were in the exponential phase of growth.
2.2.2 Determining the concentration and amount of cells present in media
1ml of RPMI media (containing 10% FCS and 1% glutamine) containing the single
cell suspension of tumour cells, was pipetted onto a haemocytometer which already
had a cover slip pushed on the slide to create a vacuum. The haemocytometer had a
grid of 9 large squares printed on it which was clearly seen under the microscope.
The cells in each large corner square were counted (4 in total) and the number
averaged to give the number of cells present. This was the number of cells present
x104 in 1ml of sample (i.e the concentration of the sample). The solution was diluted
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as appropriate to obtain the right concentration of cells to be used in each
experiment.
2.2.3 Measurement of cisplatin cytotoxicity using the SRB assay
Four 96 well plates were plated up with 100l of 0.5x104/ml of cells in each well.
Two plates had A2780 and the other two had A2780cisR cells. They were left to
adhere overnight. They were all treated with a range of cisplatin concentration:
0M, 0.03M, 0.1M, 0.3M, 1M, 3M, 10M, 30M, 100M. The cisplatin was
added to RPMI media containing only 1% glutamine and no FCS, to obtain these
concentrations, and 100l was pipetted into each well. The cisplatin was left on for
1 hour and then carefully pipetted off. 100μl of RPMI media with 1% glutamine
and 10% FCS was pipetted into each well. The plates were then left for 4 days in the
incubator (37º C, 5%CO2).
After this time, the media was removed by inverting and flicking the plates. 100l of
30% acetic acid was added to each well to fix the cells for 20 minutes at 4C in the
fridge. The acetic acid was removed by flicking the plates. The plates were then
washed with tap water 4 times. 100l of a protein stain called sulphorodamine blue
(SRB) (sigma, Poole, Dorset, UK) was then pipetted into each well, and left at room
temperature for 20 minutes. The SRB was removed by flicking the plates. Excess
SRB was removed by washing with 1% acetic acid 5 times. The plates were left to
dry overnight. 100l of 10mM trizma base (Sigma, Poole, Dorset, UK) was added to
each well to solubilise, and left for 20 minutes at room temperature. The plates were
read at 540nm.
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2.3 Measurement of ICL formation and repair in human ovarian cancer cell
lines
2.3.1 Preparation of A2780 and A2780cisR human ovarian cancer cell lines
These cell lines were prepared as above (see section 2.2.1)
2.3.2 Determining the concentration and amount of cells present in media
The cells were counted to ensure the correct concentrations of cells to be used in the
experiments (see section 2.2.2).
2.3.3 Drug Treatment
Cells were treated in vitro with varying concentrations of cisplatin to measure the
level of ICL formation in the cells at the peak of crosslinking (9 hours for cisplatin).
Other cells were treated in vitro with either 100μM cisplatin or 50μM melphalan,
and the level of ICL formation and repair measured over time using the comet assay.
2.3.3.1 Treatment in vitro with different concentrations of cisplatin
Two 6 well plates were plated up with 2mls of 5x104/ml of cells in each well. One
plate had A2780 cells and the other A2780cisR. They were left to adhere overnight.
Each well was treated with a different concentration of cisplatin: 0M, 25M,
50M, 100M, 150M, 200M. The cisplatin was added to RPMI media containing
only 1% glutamine and no FCS, to obtain these concentrations, and 1ml was added
to each well. It was then incubated with the cells for 1 hour in an incubator (37ºC,
5% CO2).
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The cisplatin was pipetted off and discarded. This was done by adding sodium
hydroxide to neutralise the drug, before pouring down the sink with plenty of water.
2mls of RPMI media containing 10% FCS and 1% glutamine was pipetted into each
well. After a further 8 hours, the cells were harvested using trypsin: The RPMI
media containing 10% FCS and 1% glutamine was pipettd off, and 1ml of trypsin
was pipetted into the appropriate well and left in the incubator at 37ºC, 5% CO2 for
5 minutes. After 5 minutes the trypsin was pipetted off and added to 5mls of RPMI
media containing 10% FCS and 1% glutamine in a 10ml conical tube, and spun in a
centrifuge at 270g for 5 minutes. The supernatant was poured off. Into each tube 1ml
of DMSO (VWR International, Leicester, UK) with 10% FCS was pipetted, and the
sample stored at -80ºC ready for the comet assay (see section 2.3). This was
repeated 4 times.
2.3.3.2 Treatment in vitro with 100μM cisplatin
Ten wells of two 6 well plates were plated up by pipetting 2mls of 5x104/ml of
A2780 cells into each well, and another ten wells of two 6 well plates were plated up
with 2mls of 5x104/ml of A2780cisR cells. They were left to adhere overnight.
Cisplatin was added to RPMI media containing only 1% glutamine and no FCS, to
obtain a concentration of 100M, and 1ml was pipetted into each well. Cisplatin was
incubated with the cells in an incubator at 37ºC, and 5%CO2 for 1 hour. After 1 hour
the cisplatin was pipetted off and replaced with 2mls of RPMI media containing
10% FCS and 1% glutamine (except the ‘0 hour’ and ‘0 hour control’ wells).
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The “0 hour” well and “0 hour control” on each plate were harvested using trypsin:
The RPMI media containing 10% FCS and 1% glutamine was pipetted off. 1ml of
trypsin was pipetted into the appropriate well incubated at 37ºC, 5% CO2 for 5
minutes. After 5 minutes the trypsin was pipetted off and added to 5mls of RPMI
media containing 10% FCS and 1% glutamine in a 10ml conical tube. It was spun in
a centrifuge at 270g for 5 minutes and the supernatant was poured off. The cell
pellet was resuspended with 1ml of DMSO (VWR International, Leicester, UK)
with 10% FCS, and the sample stored at -80ºC ready for the comet assay (see
section 2.3). After a further 3, 6, 9, 24, 24 control, 32, 48 control and 48 hours the
appropriate well on each plate was harvested, and frozen as above. The comet assay
was performed on the samples, and the results plotted. The experiment was repeated
4 times.
2.3.3.3 Treatment in vitro with 50μM Melphalan
Seventeen wells of three 6 well plates were plated up with 2mls of 5x104/ml of
A2780 cells in each well, and another seventeen wells of three 6 well plates were
plated up with 2mls of 5x104/ml of A2780cisR cells in each well. They were left to
adhere overnight. The melphalan was added to RPMI media containing only 1%
glutamine and no FCS to obtain 50M, and 1ml was added to each well. It was then
incubated with the cells for 1 hour in an incubator at 37ºC, and 5%CO2.
The melphalan was then pipetted off, and replaced with 2mls of RPMI media
containing 10% FCS and 1% glutamine. The “0 hour” well and “0 hour control” on
each plate were harvested using trypsin: The RPMI media containing 10% FCS and
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1% glutamine was pipettd off, and 1ml of trypsin was pipetted into the appropriate
well and incubated at 37ºC, 5% CO2 for 5 minutes. Then, the trypsin was pipetted
off and added to 5mls of RPMI media containing 10% FCS and 1% glutamine in a
10ml conical tube. It was spun in a centrifuge at 270g for 5 minutes. The supernatant
was poured off. Into each tube 1ml of DMSO (VWR International, Leicester, UK)
with 10% FCS was pipetted and the cell pellet was resuspended. The sample was
stored at -80ºC ready for the comet assay (see section 2.3). After a further 3, 6, 8,
11, 16, 18, 20, 24, 30, 40 and 48 hours the appropriate well on each plate was
harvested, and frozen as above. The comet assay was performed on the samples, and
the results plotted.
2.3.4 Comet assay
2.3.4.1 Background
Techniques such as flurometric alkaline elution, which measure ICL formation and
repair (Rudd et al., 1995), have been hindered in clinical practice due to the high
levels of cells required. The single cell gel electrophoresis (comet) assay uses small
numbers of cells, and is therefore a very useful tool in the clinical setting, where it is
often difficult to obtain large samples. The comet assay has been modified to
sensitively detect and quantify the levels of ICLs in patient lymphocytes and other
cells (Hartley et al., 1999). It can also measure unhooking of the ICLs, which is part
of the DNA repair pathway.
The comet assay was used to process samples received from patients, and on human
paired ovarian cancer cell lines, to detect levels of ICL formation and repair.
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2.3.4.2 Preparation of slides
Single-frosted glass microscope slides 25 x 75mm, 1mm thick (VWR International
Ltd, Leicester, UK) were pre-coated by pipetting 0.8ml of molten 1% type 1A
agarose in water, onto the centre of the slide. They were allowed to dry overnight at
room temperature.
2.3.4.3 Preparation of samples with 10x104 cells present
All procedures were carried out on ice. Samples were thawed on ice and the cell
suspension diluted with RPMI (with 10% FCS and 1% glutamine) to
2.5x104cells/ml. There was at least 4 ml in each sample. Each sample was divided
into two appropriately labelled tubes. Duplicate agarose precoated slides were
labelled and placed in a tray on ice. One of the duplicate samples was irradiated with
12Gy using an X-ray source running at 212.5Kv and 12.5mA (2.35Gy/min).
Into a 24 well multidish, 0.5ml of the appropriate sample was pipetted. 1ml of 1%
LGT agarose (sigma, Poole, Dorset, UK) was also added and mixed with the sample
by pipetting up and down. 1ml of this mixture was then pipetted onto the centre of
the appropriate slide and a coverslip was placed on top of each gel. After the gel had
set, the coverslip was removed. This was repeated for all the slides.
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2.3.4.4 Preparation of samples with 1x104 cells present
For the samples that only had 1x104 cells/ml in each well of the 6 well plates, the
comet assay was adjusted to make the gels smaller. Samples were thawed on ice and
the cell suspension diluted with RPMI (with 10%FCS and 1% glutamine), to wash
the cells, and spun in a centrifuge at 270g for 5 minutes. The supernatant was
discarded, and the cell pellet was diluted with 500μl of RPMI media containing 10%
FCS and 1% glutamine to give a concentration of 2x104cells/ml. Each sample was
divided into two appropriately labelled tubes. Duplicate agarose precoated slides
were labelled and placed in a tray on ice. One of the duplicate samples was
irradiated with 12Gy using an X-ray source running at 212.5Kv and 12.5mA
(2.35Gy/min).
A 96 well plate was used, into which 100l of the appropriate sample was pippetted.
200l of 1% LGT agarose was also added and mixed with the sample by pipetting
up and down. 300l of this mixture was then pipetted onto the centre of the
appropriate slide and a small round coverslip was placed on top of each gel. After
the gel had set, the coverslip was removed. This was repeated for all the slides.
These slides resulted in fewer cells present in the gel overall, and the gel was a lot
smaller. However, the concentration enabled adequate reading of the required 25
cells per slide.
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2.3.4.5 Lysis treatment
After all the gels had been prepared, they were then treated exactly the same,
regardless of the method used. Lysis buffer (100mM disodium EDTA, 2.5M sodium
chloride, 10mMtris-Hcl, pH to 10.5 with sodium hydroxide) containing 1% triton X-
100 (Sigma, Poole, Dorset, UK) was added, ensuring all the slides were sufficiently
covered. They were left for 1 hour on ice in the dark.
The lysis buffer (containing 1% triton X-100) was carefully removed using a
vacuum pump, and ice-cold double distilled water was added which completely
covered the slides. The gels were left for 15 minutes on ice in the dark, and then the
water was carefully removed using the vacuum pump. Ice-cold double distilled
water was added a further three times, and each time left on for 15 minutes on ice in
the dark.
2.3.4.6 Alkali treatment and electrophoresis
After the four washes, the slides were transferred to an electrophoresis tank so that
all the slides were laid lengthways in the same direction. Two litres of ice-cold alkali
buffer (50mM sodium hydroxide (Sigma, Poole, Dorset, UK), 1mM disodium
EDTA, pH 12.5) were poured into the tank completely immersing the slides, and left
for 45 minutes in the dark. The slides were then electrophoresed in the dark for 25
minutes at 18V (0.6V/cm), 250mA.
The slides were then removed from the tank and placed on a horizontal slide rack.
Each slide was flooded with 1ml neutralisation buffer (0.5M Tris-HCl, pH 7.5) and
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left for 10 minutes. The slides were then rinsed twice with 1ml phosphate buffered
saline for 10 minutes each rinse. The slides were then allowed to dry at room
temperature overnight.
2.3.4.7 Preparation of slides for analysis
The slides were rehydrated with double distilled water and left for 30 minutes. Each
slide was flooded with 1ml of 2.5g/ml propidium iodide solution which stains
DNA, and incubated for 15-20 minutes at room temperature in the dark. Propidium
iodide is toxic, and so precautions should be used when handling it. Gloves and
laboratory coats were worn at all times, hair was tied back, and eye protection worn.
The propidium iodide was rinsed off with double distilled water into the tray and
then left for 20-30 minutes. The water containing propidium iodide was disposed of
into plastic containers specific for this toxin. Once these containers were full, they
were disposed of in the correct manner. Under no circumstances was propidium
iodide flushed down the sink. The slides were then dried in the oven at 37C for 1-2
hours and stored in a slide box until image analysis.
2.3.4.8 Analysis of comets
Visualisation and analysis of comets could be done at any time after preparation of
the slides because they keep indefinitely.
A few drops of distilled water was placed onto each slide and covered with a
coverslip. A NIKON inverted epifluorescent microscope (consisting of a high power
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mercury vapour light source, a 580nm dichromic mirror, 510 to 560nm excitation
filter and 590nm barrier filter) at X20 magnification was used to visualise the
comets, which was relayed to a computer screen. The entire slide was visualied to
determine 25 representative cells on the slide. These cells were analysed using
Komet analysis software (Kinetic imaging, Liverpool, UK), by activating the
computer software programme to read each cell selected.
The tail moment for each cell was defined as the product of the percentage in the
comet tail, and the distance between the means of the head and the tail distributions.
This was described by Olive et al (1990) and recently summarized by Spanswick et
al (1999). Crosslinking was calculated as the percentage decrease in tail moment
and compares the drug treated and irradiated control to the non-drug treated
irradiated control. From both samples the comet tails from the non drug-treated
unirradiated control sample is subtracted as this represents background damage to
these cells. The background damage was always negligible in these experiments.
Percent decrease in tail moment is calculated using the formula:
% decrease in tail moment = 1- TMdi – TMpreu x100
TMprei- TMpreu
Where;
TMdi = tail moment of drug treated irradiated sample
TMpreu = tail moment of predose unirradiated control
TMprei = tail moment of predose irradiated control
Page 78
2.4 Measurement of ICL formation and repair in ovarian cancer cells obtained
from patient ascites treated ex vivo with 100μM cisplatin or 50μM melphalan
2.4.1 Preparation of ascites
Ascites was obtained from patients consented for the study. Samples were collected
from theatre and hospital wards. Ascitic fluid was collected from patients in theatre
via suction into a sterile bag once the abdominal cavity had been opened. Ascitic
fluid was also collected from patients on the ward who had had ascitic drains placed
under aseptic conditions. Ascitic fluid was collected from the sterile bags into which
the fluid was drained on the wards. A minimum of 50mls of ascitic fluid was needed
to enable enough ovarian cancer cells to be extracted for experiments. As much
ascites as possible was collected from the patients, up to 3 litres in some cases. Any
ovarian cancer cells that were not needed for experiments, were stored (see below
for protocol) for future research if the patient gave permission by signing part 2 of
the patient consent form (Appendix 3 – Patient consent form).
The ascites obtained was aliquoted into 50ml sterile tubes and spun in a centrifuge
(Megafuge 1.0, Heraeus Instruments, Thermoelectron, Basingstoke,UK) at 249g for
5 minutes. The supernatant was poured off, the cell pellet was examined, and the
cells re-suspended in 25mls RPMI media containing 10% FCS and 1% glutamine.
The cell suspension was then pipetted into one or a varying number of 175cm2
flasks according to the size of the cell pellet. The smallest cell pellet was 0.2mls, and
in this case all of the 25mls was pipetted into one flask. The largest cell pellet was
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approximately 1ml, and in this case 5mls was pipetted into 5 flasks. This was to
ensure a good concentration of cells present in each flask.
The flasks were left for 1 hour in the incubator (37C, 5%CO2) for the mesothelial
cells to attach. After 1 hour, the RPMI media containing the remaining cells (mostly
tumour cells) was pipetted off and added to another sterile 175cm2 flask and left
overnight for the tumour cells to attach. 25 mls of RPMI media containing 10% FCS
and 1% glutamine was then added to the first flask containing predominantly
mesothelial cells and left in the incubator (37C, 5%CO2) to grow. This resulted in
one flask containing predominantly tumour cells, and the other one containing
predominantly mesothelial cells. However, further separation was often necessary
(see section 2.4.2 below).
2.4.2 Separation of cell types from ascites
The morphology of mesothelial and tumour cells are different. Mesothelial cells
look like spindles and are much thinner than tumour cells. They spread out and have
thin projections from the cell. Tumour cells are much rounder than mesothelial cells
and cluster together. The morphology of the two cell types was observed down the
microscope and the levels of contamination by each type of cell, was estimated.
Mesothelial cells and tumour cells both come from ascites. Mesothelial cells become
detached quicker than tumour cells, when exposed to trypsin. Mesothelial cells also
attach to the flasks quicker than ovarian tumour cells when re-suspended in media
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and left in an incubator at 37C, and 5%CO2. These differences were utilised to
enable the separation of mesothelial cells from ovarian cancer cells.
2.4.2.1 Method to obtain mesothelial cells from ascites
The RPMI media containing 10% FCS and 1% glutamine was poured off, and 5mls
of trypsin was added to wash the cells, and then poured off. A further 7mls of
trypsin was added to the 175cm3 flask, and left in the incubator for 5 minutes. After
5 minutes the trypsin was pipetted off, and added to 10mls of RPMI media
containing 10% FCS and 1% glutamine and spun in a centrifuge at 249g for 5
minutes. The supernatant was poured off and the cell pellet was examined, and then
re-suspended in 25mls of RPMI media containing 10% FCS and 1% glutamine. The
smallest cell pellet was 0.2mls, and in this case all of the 25mls was pipetted into
one flask. The largest cell pellet was approximately 1ml, and in this case 5mls was
pipetted into 5 flasks. This was to ensure a good concentration of cells present in
each flask. The flasks were then left for 1 hour in an incubator (37C, 5%CO2) for
the mesothelial cells to attach.
After 1 hour the media containing mostly tumour cells was pipetted off and
discarded. This results in a higher percentage of mesothelial cells in the first flask.
This was repeated if necessary.
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2.4.2.2 Method to obtain ovarian cancer cells from ascites
The RPMI media containing 10% FCS and 1% glutamine was poured off, and 5mls
of trypsin was pipetted to cover the cells, and then poured off. A further 7mls of
trypsin was added and left in the incubator at 37C, and 5%CO2, for 12 minutes.
After 12 minutes the trypsin was poured off and added to 20mls of RPMI media
containing 10% FCS and 1% glutamine and spun in a centrifuge at 249g for 5
minutes. The supernatant was poured off and the cell pellet was re-suspended in 25
mls of RPMI media containing 10% FCS and 1% glutamine. Cell pellets ranged in
size from 0.2-1ml. If the cell pellet was 0.2mls, then all of the 25mls was pipetted
into one flask. If the cell pellet was approximately 1ml, then 5mls was pipetted into
5 flasks. This was to ensure a good concentration of cells present in each flask. The
flasks were then left for 1 hour in an incubator (37C, 5%CO2) for the mesothelial
cells to attach.
After 1 hour the media containing mostly tumour cells was pipetted off and pipetted
into another sterile 175cm2 flask. This resulted in a higher percentage of tumour
cells in the second flask. This was repeated if necessary.
2.4.3 Confirming presence of ovarian cancer cells using immunohistochemistry
In order to be sure of the cell type before experiments were commenced, the cells
were stained using antibody markers.
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2.4.3.1 Preparation of samples
First the cells were harvested using trypsin. The RPMI media containing 10% FCS
and 1% glutamine was poured off, and 5mls of trypsin was pipetted into the flask to
coat the cells, and then poured off. A further 7mls of trypsin was added and left in
the incubator at 37C, and 5%CO2, for 10 minutes. After 10 minutes the trypsin was
poured off and added to 20mls of RPMI media containing 10% FCS and 1%
glutamine and spun in a centrifuge at 249g for 5 minutes. The supernatant was
poured off, and the cell pellet was resuspended in 10mls of RPMI media containing
10% FCS and 1% glutamine.
The cells were counted to determine their concentration (see section 2.2b), and
diluted to obtain a concentration of 1x 104 cells/ml. Four drops were placed into a
cytofunnel (Shandon, Cheshire, UK) mounted onto filter paper with a hole in it,
which was on a slide (Vision Biosystems, Newcastle-upon-Tyne, UK). This was
then put into a Shandon Cytospin II (Shandon, Cheshire, UK) and spun at 650 rpm
for 5 minutes. The centrifugal force pushes the cells onto the slide in the gap in the
filter paper. The filter paper absorbs the remaining media. The slides were then
removed from the funnel and filter paper and left to air dry for 1 hour. They were
then placed in 100% ethanol to fix the cells.
For each sample two slides were made. One was stained with CK5 antibody (stains
mesothelial, but not epithelial cells) and the other was stained with CK7 antibody
(stains epithelial i.e ovarian cancer cells). This was done to estimate the percentage
of each cell type in the sample. Calretinin antibody (stains mesothelial, but not
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epithelial cells) was sometimes used to stain for mesothelial cells instead of CK5.
The slides were stained by the Immunocytochemistry Department at University
College London, using the staining protocol below (see section 2.4.3.2)
2.4.3.2 Immunohistochemistry protocol
The slides were transferred to an incubation tray and rinsed in 0.05% Tween® 20
(Polyoxyethylene sorbitan mono-laurate) in tris-buffered saline (TBS). The circular
area on the slide that contained cells was marked with a hydrophobic pen. The
primary antibodies (CK5, or CK7) were applied at optimal dilution for 60 minutes.
The primary antibody was rinsed off with 0.05% Tween® 20 in tris- buffered saline
(TBS) for 2-3 minutes, and Dako ChemMate peroxidase block was applied for 10
minutes. The peroxidase block was rinsed off with 0.05% Tween® 20 in tris-
buffered saline (TBS) for 2-3 minutes, and the biotinylated secondary antibody
(AB2) was applied for 30 minutes. This was rinsed off with 0.05% Tween® 20 in
tris-buffered saline (TBS) for 2-3 minutes, and peroxidase- labelled streptavidin
(HRP) was applied for 30 minutes. This was rinsed off with 0.05% Tween® 20 in
tris-buffered saline (TBS) for 2-3 minutes, and DAB solution (100l DAB + 5mls
substrate buffer) was applied for 7 minutes. The DAB was rinsed off with 0.05%
Tween® 20 in tris-buffered saline (TBS) for 2-3 minutes, and washed in running tap
water. The slide was stained with Dako ChemMate Haematoxylin for 10 seconds,
and blued in running water. It was differentiated in 1% acid alcohol and blued again
in running water. The slide was dehydrated, and mounted.
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The slides were looked at under an inverted microscope and the percentage of each
cell type was estimated. This was done by counting the total number of cells stained
with each antibody in a particular field. Four different fields were counted, and the
result averaged.
2.4.4 Determining the concentration and amount of cells present in media
See section 2.2.2. The cells were diluted to obtain a concentration of 5x104cells/ml,
and a minimum volume of 28mls (14mls each for the cisplatin and melphalan
experiments). If this was not possible the cells were diluted to obtain a concentration
of 1x104cells/ml with a minimum volume of 14mls (7mls each for the cisplatin and
melphalan experiments). If this was not possible, the drug treatment experiments
were not performed.
2.4.5 Drug Treatment
Cells were either treated with 100M cisplatin or 50M melphalan. If there were
limited numbers of cells, and only one drug treatment experiment was possible, then
100M cisplatin was used.
2.4.5.1 Treatment ex vivo with 100μM Cisplatin
Seven wells in two 6 well plates were plated up with 2mls of 5x104/ml of cells in
each well. They were left to adhere overnight.
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For some samples, there were not enough cells to use. Only 1 ml of 1x104/ml of
cells was plated into seven wells in two 6 well plates (same number of wells as
above). They were left to adhere overnight also, and then treated the same as the
higher concentration of cells (see below).
The plates were treated with 100M cisplatin. The cisplatin was added to RPMI
media containing only 1% glutamine and no FCS to obtain a concentration of
100µM, and 1ml was added to each well. It was then incubated with the cells for 1
hour. After 1 hour the cisplatin was then removed and replaced with 2mls of RPMI
media containing 10% FCS and 1% glutamine, and left for the appropriate amount
of time.
The “0 hour” well and “0 hour control” on each plate were harvested using trypsin
(see section 2.2.2), and frozen at -80C in 1ml of DMSO with 10% FCS. After a
further 9, 24, 24 control, 48 control and 48 hours the appropriate well on each plate
was harvested, and frozen as above. The comet assay was performed on the samples,
and the results plotted.
2.4.5.2 Treatment ex vivo with 50μM Melphalan
2mls of 5x104/ml of cells was pipetted into each of 4 wells in a 6 well plate. The
cells were left to adhere overnight.
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For some samples, there were not enough cells to use. Only 1 ml of 1x104/ml of
cells was pipetted into each well. They were left to adhere overnight also, and then
treated the same as the higher concentration of cells (see below).
The plates were treated with 50M melphalan. The melphalan was added to RPMI
media containing only 1% glutamine and no FCS to obtain this concentration, and
1ml was added to each well. It was then incubated with the cells for 1 hour at 37C,
and 5%CO2. After 1 hour the melphalan was removed and replaced with 2mls of
RPMI media containing 10% FCS and 1% glutamine and left for a further 16 hours.
The “16 hour” well and “16 hour control” on each plate were harvested using trypsin
(see section 2.2.2), and frozen at -80C in 1ml of DMSO with 10% FCS. After 40
hours following drug removal, the remaining wells (40 hours, 40 control) on the
plate were harvested, and frozen as above. The comet assay was performed on the
samples, and the results plotted.
2.4.6 Comet Assay
This was performed as previously described (see section 2.3.4).
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2.5 Measurement of ICL formation and repair in ovarian cancer cells obtained
from patient solid tissue
2.5.1 Preparation of tumour cells from ovarian solid tumour
Solid tumour was obtained from patients consented for the study. Samples were
collected from theatre. Solid ovarian tumour tissue was removed from the patient by
the surgeon. At this point the tissue was cut under asceptic conditions into 3mm
cubes, using a scalpel. Areas of obvious cancer were chosen. At least two pieces
were needed for experiments. As much tissue as possible, was obtained -up to 6
pieces in some cases. Any pieces of solid tumour tissue that were not needed for
experiments were stored for future research if the patient gave permission by signing
part 2 of the patient consent form (Appendix 3 – Patient Consent form). Some
pieces were put into cryotube vials (Nunc, Kamstupvej, Denmark), which
immediately went into enough liquid nitrogen to cover the tubes (within 5-10
minutes). Others were put into tubes containing 10mls of RPMI media (Autogen
Bioclear Uk ltd. Wiltshire, UK), which contained 10% FCS (Autogen Bioclear Uk
ltd. Wiltshire, UK) and 1% glutamine (Autogen Bioclear Uk ltd. Wiltshire, UK).
The samples put into media were immediately processed.
The solid ovarian tumour tissue was removed from the tubes containing 10mls of
RPMI media, and chopped repeatedly (approximately 100 times) in the same 10mls
of RPMI media (containing 10% FCS and 1% glutamine) on a sterile petri dish
using sterile scalpels to create a ‘slurry’ of material. The petri dish was carefully
tilted to 45 degrees, and the media was carefully pipetted off into a sterile 20ml
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conical tube. By tilting the petri dish, the large particulate tumour material was
avoided, whilst still obtaining a single cell suspension of tumour cells. 10mls of
RPMI media (containing 10% FCS and 1% glutamine) was added to the tumour
‘slurry’ and the process was repeated. The resulting 20mls of media containing the
cells was slowly (to ensure cells were not fragmented) pipetted approximately 20
times through a sterile 1ml sized pipette to ensure the cells were in single cell
suspension. 1ml of this 20ml sample was pipetted onto a glass slide, a cover slip
placed on top of the slide, and the slide looked at under the microscope. This was
done to ensure the sample was a single cell suspension. If not, the sample was
repeatedly pipetted approximately 20 times through a sterile 1ml sized pipette, and
rechecked by looking under the microscope. Only samples with a single cell
suspension were used in the comet assay experiments.
2.5.2 Confirming presence of ovarian cancer cells using immunohistochemistry
2.5.2.1 Preparation of samples
The cells were counted to determine their concentration (see section 2.2b), and
diluted to obtain a concentration of 1x 104/ml. Four drops of each sample were
placed into a cytofunnel (Shandon, Cheshire, UK) mounted onto filter paper with a
hole in it, which was on a slide (Vision Biosystems, Newcastle-upon-Tyne, UK).
This was then put into a Shandon Cytospin II (Shandon, Cheshire, UK) and spun at
650 rpm for 5 minutes. The slides were removed and left to air dry for 1 hour. They
were then placed in 100% ethanol to fix the cells for 30 minutes.
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2.5.2.2 Immunocytochemistry protocol
See section 2.4.3.2
2.5.3 Determining the concentration and amount of cells present in media
See section 2.2.2
2.5.4 Drug Treatment
As for the cells obtained from ascites, tumour cells from solid tissue were either
treated with 100M cisplatin or 50M melphalan. If there were limited numbers of
cells, and only one drug treatment experiment was possible, then 100M cisplatin
was used.
2.5.4.1 Treatment ex vivo with 100μM Cisplatin
The solid ovarian tumour tissue was non-adherent, so a suspension cell protocol was
used. The single cell suspension of solid ovarian tumour tissue was counted (see
section 2.2), and 2mls of a concentration of 5x104/ml was added to each of 7 conical
shaped tubes. If there were some extra cells, the experiment was run in duplicate (14
tubes in total) or even triplicate (21 tubes in total).
The tubes were spun in a centrifuge at 249g for 5 minutes, and the supernatant was
carefully discarded. Cisplatin was added to RPMI media containing only 1%
glutamine and no FCS to obtain a concentration of 100M. 1ml was added to each
tube, and pipetted up and down to mix with the cell pellet. All of the conical tubes
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were placed in the incubator for 1 hour at 37C, and 5%CO2. After 1 hour the
cisplatin was removed by spinning the tubes in the centrifuge at 249g for 5 minutes
and carefully pouring off the supernatant. 2mls of RPMI containing 10% FCS and
1% glutamine was added to each tube (except the ‘0 hour’ and ‘0 hour control’
tubes), and pipetted up and down to mix with the cell pellet.
The ‘0 hour’ and ‘0 hour control’ tubes were frozen at -80C in 1ml of DMSO with
10% FCS, which was pipetted up and down to resuspend the cell pellet. After a
further 9, 24, 24 control, 48 control and 48 hours the appropriate tube was
centrifuged at 249g for 5 minutes. The supernatant was poured off and 1ml of
DMSO with 10% FCS was added, and pipetted up and down to mix with the cell
pellet, and then frozen at -80C. The comet assay was performed on the samples,
and the results plotted.
2.5.4.2 Treatment ex vivo with 50μM Melphalan
The solid ovarian tumour tissue was not adherent, so a suspension cell protocol was
used (the same as for treatment ex vivo with 100μM cisplatin – see section 2.5b(i)).
The single cell suspension of solid ovarian tumour tissue was counted (see section
2.2b), and 2mls of a concentration of 5x104/ml was added to each of 4 conical
shaped tubes.
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The tubes were spun in a centrifuge at 249g for 5 minutes, and the supernatant was
carefully discarded. Melphalan was added to RPMI media containing only 1%
glutamine and no FCS to obtain a concentration of 50M. 1ml was added to each
tube, and pippetted up and down to mix with the cell pellet. It was then incubated
with the cells for 1 hour. After 1 hour the melphalan was then removed by spinning
the tubes in the centrifuge at 249g for 5 minutes and carefully pouring off the
supernatant. The cells were then resuspended with 2mls of RPMI media containing
10% FCS and 1% glutamine and left for 16 hours.
After 16 hours the “16 hour” and “16 hour control” tubes were centrifuged at 249g
for 5 minutes. The supernatant was poured off and 1ml of DMSO with 10% FCS
was added and frozen at -80C.
After a further 24 hours, the remaining tubes (40 control and 40hours) were
harvested as above. The comet assay was performed on the samples, and the results
plotted.
2.5.5 Comet Assay
This was performed as previously described (see section 2.3.4).
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2.6 Comparison of gene expression between A2780 and A2780cisR human
ovarian cancer cell lines using microarrays
2.6.1 Preparation of RNA
2.6.1.1 Isolation of total RNA from A2780 and A2780cisR human ovarian
cancer cell lines
The cells were grown as previously described (see section 2.2.1), and the sample
was harvested using trypsin just before the cells reached confluency. The RPMI
media containing 10% FCS and 1% glutamine was poured off, and 3mls of trypsin
was pipetted into the flask to cover the cells. The trypsin was then poured off, and a
further 5mls of trypsin was added to the flask, and left in the incubator at 37ºC, 5%
CO2 for 5 minutes. After 5 minutes the trypsin was pipetted off and added to 5mls of
RPMI media containing 10% FCS and 1% glutamine in a 10ml conical tube, and
spun in a centrifuge at 270g for 5 minutes. The supernatant was poured off. 10mls of
RPMI media containing 10% FCS and 1% glutmaine was added to the sample, and
pipetted up and down to resuspend the cell pellet.
The cells were counted (see section 2.2.2). 4x106 cells were used for total RNA
extraction, and so the correct volume of media containing this number of cells was
pipetted into a 20ml conical tube. The QIAGEN RNeasy mini kit was used and the
instructions followed in the manufacturers’ handbook:
The sample was centrifuged at 249g at 20C for 5 minutes and the supernatant
poured off. The pellet was loosened by flicking the tube, and 600l of RLT buffer
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(from the RNeasy mini kit QIAGEN) was added, and vortexed to mix. The lysate
was passed at least 5 times through a 20-gauge needle (0.9mm diameter) fitted to a
1ml RNase-free syringe, to homogenise the sample. 600l of 70% ethanol (VWR
International, Leicester, UK) was added to the homogenised lysate and mixed well
by pipetting.
Up to 700l of the sample was added to an RNeasy mini column, which was placed
in a 2 ml collection tube. The tube was closed gently and centrifuged in an
Eppendorf 5145D centrifuge for 15 seconds at 9,300g. The flow through was
discarded. Aliquots of the sample were successively loaded onto the RNeasy mini
column and centrifuged as above. The flow-through was discarded each time.
700l of Buffer RW1 was added to the RNeasy mini column, the tube closed gently,
and centrifuged for 15 seconds at 9,300g to wash the column. The flow-through and
collection tube was discarded.
The RNeasy column was transferred to a new 2ml collection tube, and 500l of RPE
buffer was pipetted into the column. The tube was centrifuged again for 15 seconds
at 9,300g to wash the column. The flow-through was discarded. Another 500l of
RPE buffer was pipetted into the RNeasy column and centrifuged, this time for 2
minutes at 9,300g, to dry the RNeasy silica-gel membrane.
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To elute, the RNeasy column was transferred to a new 1.5ml collection tube, and 30-
50l of RNase-free water was pipetted directly onto the RNeasy silica-gel
membrane. The tube was centrifuged for 1 minute at 9,300g to elute.
2.6.1.2 Determining quantity of RNA in sample
To determine the quantity of RNA extracted, the absorbance at 260nm (A260) was
measured in a spectrophotometer. Sometimes it was necessary to dilute the RNA
sample, and this was done using water, and in an RNase-free cuvette. The following
equation was used to calculate the concentration of RNA (where an absorbance of 1
unit at 260nm corresponds to 40g of RNA per ml):
Concentration of RNA sample = 40 x A260 x dilution factor
Another method for determining the quantity and purity of total RNA in the sample,
involved a nanodrop machine. Only 1.2l of sample was loaded onto the machine,
which then calculated the concentration, and purity (see below- section 2.6a(iii)) of
the sample using the formula already described.
2.6.1.3 Determining purity of RNA in sample
To determine the purity of the RNA, the ratio of the readings at 260nm and 280nm
(A260/A280) were calculated. The absorbance of the RNA was measured in dH2O.
Pure RNA has an A260/A280 ratio of 1.9-2.1 in dH2O, and samples in this range only
were used. Others not in this range were discarded.
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2.6.1.4 Determining quality of RNA in sample
To determine the quality of the total RNA, the sample was checked by gel
electrophoresis.
Tris-acetic ethylenediaminetetraacetic acid (TAE) stock buffer (x50) was initially
made, by dissolving 18.6g of ethylenediaminetetraacetic acid disodium salt
dihydrate in 500ml of distilled water. 121g of Trizma base was then added, followed
by 28.55ml of acetic acid (VWR international, Leicester, UK). 20ml of 50x TAE
buffer was added to 980ml of distilled water, to make 1xTAE buffer, and from this
100ml was taken to make the gel.
A 1% gel was made by adding 1g of electrophoresis agarose to 100ml of the 1x TAE
buffer, and heating it until the agarose had dissolved completely. Once the solution
was cooled to be touch hot, 5l of ethidium bromide was added, mixed well, and
poured into a gel holder with combe in place. The gel was allowed to solidify,
before the combe was removed and the gel placed into the gel electrophoresis tank.
The remaining 1x TAE buffer was poured into the tank, up to the fill line.
The required amount of the sample (usually 2g) was added to 3l of formamide
dye and mixed in a 50µl Eppendorf tube. The whole mixture was then pipetted into
the wells in the gel. 5L of the RNA ladder (Invitrogen life technologies, Paisley,
UK) was added to 3l of the dye and also loaded into the gel. The tank was then
turned on to a voltage of 130mV and left for one hour. The gel was read under UV
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light (to see the bands of RNA) by a computer program called Scion Pro, and the
results analysed.
2.6.2 Preparation of microarray sample
2.6.2.1 Synthesis of double-stranded cDNA from total RNA
Invitrogen Life Technologies’ protocol using the SuperScript choice system was
used. It was supplemented with instructions from Affymetrix gene chip systems:
The minimum amount of total RNA per reaction was 10g, which was the amount
used in each experiment. Each experiment produced different amounts and
concentrations of total RNA, and so the amounts of the other reagents altered also
(figure 6).
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Step Reagents in reaction Volume Final
concentration/amount
in reaction
1 DEPC-H20 (variable)
T7-(dT)24 primer (100pmol/l)
RNA
For final reaction volume of 20l
1l
variable amount (l)
100pmol
10g
2 5X First strand cDNA buffer
0.1M DTT
10mM dNTP mix
4l
2l
1l
1X
10mM DTT
500M each
3 SuperScript II RT
(variable)(200U/l)
2l 200 U to 1000U
Total
volume
20 l
Figure 6: Shows the steps, and amounts of reagents used to make cDNA
Step 1 was primer hybridisation. All the reagents listed (DEPC-H20, T7-(dT)24
primer (MWG biotech, London, UK) and RNA) were added together and incubated
at 70C for 10 minutes. They were then quickly spun and put on ice. Step 2 was
temperature adjustment. The reagents (Invitrogen life technologies, Paisley, UK)
were added to the reagents from step 1, vortexed and incubated at 42C for 2
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minutes. Step 3 was first strand synthesis. The Superscript II RT was added to the
tube, vortexed, incubated at 42C for 1 hour, and then put on ice.
The first strand reaction tube was briefly centrifuged to bring down condensation on
the sides of the tube, and the following reagents for the second strand reaction were
added (figure 7).
Component Volume Final concentration
/amount in reaction
DEPC- treated water 91l
5X second strand reaction
buffer
30l 1X
10mM dNTP mix 3l 200M each
10U/l E.coli DNA ligase 1l 10U
10U/l E.coli DNA Polymerase 4l 40U
2U/l E.coli Rnase H 1l 2U
Final volume 150l
Figure 7: Volumes of the components of the reaction
The tube was gently tapped to mix, and then briefly spun in a centrifuge to remove
condensation, and incubated at 16C for 2 hours in a cooling water bath. 2l (10U)
T4 DNA polymerase (Invitrogen life technologies, Paisley, UK) was added and
returned to 16C for 5 minutes. 10l of 0.5M EDTA (93g EDTA, and 10g sodium
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hydroxide in 500mls dH2O, pH 8) was then added and the sample stored at -20C or
the cleanup procedure for cDNA was immediately done.
2.6.2.2 Cleanup of Double-Stranded cDNA
Phase Lock Gels (PLG) (Eppendorf AG, Hamburg, Germany), were used in the
cleanup of cDNA. They form an inert, sealed barrier between the aqueous and
organic phases of phenol-chloroform extractions. The solid barrier allows more
complete recovery of the sample (aqueous phase) and minimizes interface
contamination of the sample.
The PLG was pelleted in a microcentrifuge at 16,100g for 20-30 seconds. 162l of
(25:24:1) phenol:chloroform:isoamylalcohol (saturated with 10mM Tris-Hcl pH 8.0,
1mM EDTA) was added to the final cDNA synthesis preparation (final volume
324l) and vortexed briefly. The entire cDNA-phenol/chloroform mixture was
added to the PLG tube (it was NOT vortexed), and was centrifuged at 16,100g for 2
minutes. The aqueous upper phase was added to a fresh 1.5ml tube.
0.5 volumes (of the sample) of 7.5M Ammonium acetate (Sigma, Poole, Dorset,
UK), and 2.5 volumes of absolute ethanol (VWR international, Leicester, UK), were
added, vortexed and immediately microcentrifuged at 16,100g at room temperature
for 20 minutes. The supernatant was removed, the pellet washed with 0.5ml of 80%
ethanol, and centrifuged again at 16,100g at room temperature for 5 minutes. The
80% ethanol was removed carefully, and the 80% ethanol wash was repeated once
more. The pellet was air dried and re-suspended in a 12l of RNase-free water.
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2.6.2.3 Synthesis of in vitro transcription products
Starting Material (total RNA) Volume of cDNA to use in IVT
10 to 100ng All (12l)
1.0 to 8.0g All (12l)
8.1 to 15.0g 6l
Figure 8: Relationship between starting material and volume of cDNA to use In
Vitro Transcription (IVT)
The correct amount of template cDNA was transferred to RNase-free
microcentrifuge tubes and the following reagents were added:
RNase-free water (to give final reaction volume of 40l), 10X IVT labelling buffer
(4l) (Affymetrix, Bucks, UK), IVT labelling NTP mix (12l) (Affymetrix, Bucks,
UK), IVT labelling enzyme mix (4l) (Affymetrix, Bucks, UK).
All the reagents were carefully mixed together and the mixture collected at the
bottom of the tube by brief (5 seconds) microcentrifugation. The tube was incubated
at 37C (in an oven incubator) for 16 hours. The labelled cRNA was stored at -20C,
or -70C if not quantifying and cleaning up cRNA immediately.
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2.6.2.4 Cleaning up and quantifying in vitro transcription products
This protocol comes from the Affymetrix technical manual (manufacturers’
manual). The sample was aliquoted into two halves. One half was purified first,
using the manufacturers instructions (see QIAGEN RNeasy mini handbook –
protocol for RNA cleanup):
The sample was adjusted to a volume of 100l with RNase-free water, 350l of
RLT buffer was added, and mixed thoroughly. 250l of 96-100% ethanol was added
and mixed thoroughly by pipetting. 700l of the sample was added to an RNeasy
mini column placed in a 2 ml collection tube, and centrifuged for 15 seconds at
10,000rpm. The flow-through was discarded.
The RNeasy column was transferred to a new 2ml collection tube and 500l of RPE
buffer was pipetted onto the column. The column and tube were centrifuged at
10,000rpm for 15 seconds, to wash it. The flow-through was discarded again.
Another 500l of RPE buffer was added to the RNeasy mini column and centrifuged
for 2 minutes at 10,000rpm to dry the silica-gel membrane.
The RNeasy mini column was transferred to a new 1.5ml collection tube and 30-
50l RNase-free water was pipetted onto the column. The column was centrifuged
for 1 minute at 10,000rpm to elute.
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Another method for cleaning up in vitro transcription products was used instead of
the protocol above, once it became available. This protocol is also from Affymetrix
and has been updated from the previous protocol above. It uses the Affymetrix
genechip sample cleanup module:
600l of cDNA binding buffer was added to the double-stranded cDNA (volume
162l) and mixed by vortexing for 3 seconds. The colour of the mixture was
checked to ensure that it was yellow.
500l of the sample was applied to the cDNA cleanup spin column, which sits in a
2ml collection tube. It was centrifuged at 8,000g for 1 minute, and the flow-through
was discarded. The spin column was reloaded with the remaining sample (262l),
and centrifuged at 8,000g for 1 minute. The flow-through and collection tube were
discarded and the spin column was transferred to a new 2ml collection tube. 750l
of cDNA wash buffer was pipetted onto the spin column, and centrifuged at 8,000g
for 5 minutes, and the flow-through was discarded again.The cap of the spin columN
was opened and centrifuged at 16,100g for 5 minutes to allow complete drying of
the membrane.
The spin column was transferred to a new 1.5ml collection tube, and 14l of cDNA
elution buffer was pippetted directly onto the membrane of the spin column. It was
incubated for 1 minute at room temperature, and then centrifuged at 16,100g for 1
minute to elute.
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Sometimes, the cRNA was concentrated by ethanol precipitation if it was too dilute
(minimum concentration 0.6g/l). The method for ethanol precipitation is as
follows:
0.5 volumes of 7.5M ammonium acetate and 2.5 volumes of absolute ethanol was
added to the sample and vortexed. The sample was left to precipitate at -20C for 1
hour to overnight. The sample was then centrifuged at 15,000rpm at 4C for 30
minutes. The pellet was washed twice with 0.5ml of 80% ethanol and air dried. The
pellet was resuspended in 10 to 20l of RNase-free water.
2.6.2.5 Quantifying cRNA
To quantify the cRNA (IVT product) a spectrophotometer or a nanodrop was used.
The absorbance of the sample was measured at 260nm and the equation below used:
1 absorbance unit (at 260nm) = 40g/ml RNA
However, an adjustment needed to be made to reflect carryover of unlabeled total
RNA as this was used as the starting material. The following equation was used:
Adjusted cRNA yield = RNAm – (total RNAi)(y)
RNAm = amount of cRNA measured after IVT (g)
Total RNAi = starting amount of total RNA (g)
(y) = fraction of cDNA reaction used in IVT
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The absorbance of the sample was measured at 260nm and 280nm and the ratio
calculated to determine the concentration and purity. A ratio of between 1.9 and 2.1
are acceptable.
2.6.2.6 Fragmenting the cRNA for target preparation
The cRNA was at a minimum concentration of 0.6g/l. If it was not, it was
precipitated with ethanol (see section 2.6.2.4).
2l of 5X fragmentation buffer for every 8l of RNA plus H2O was added. The
fragmentation buffer has been optimised to break down full length cRNA to 35-200
bases fragments by metal-induced hydrolysis.
The reaction mixture was incubated at 94C for 35 minutes, and then put on ice. An
aliquot of at least 1 g was saved for gel analysis. The undiluted, fragmented sample
of RNA was stored at -20C until ready to perform hybridisation.
2.6.2.7 Checking the cRNA
The unfragmented, and fragmented samples were checked by gel electrophoresis to
estimate the yield and size distribution of labelled transcripts. 1% of each sample
was analysed by gel electrophoresis on a 1% agarose gel (see previous protocol for
gel electrophoresis). The century marker and RNA ladder were used as the ladder
for the fragmanted cRNA and unfragmanted cRNA respectively.
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2.6.3 Processing the Microarray sample
2.6.3.1 Hybrdisation of the probe array
The genechip arrays used were the Human genome U133 plus 2.0 from Affymetrix.
The protocols for these procedures can be found online at www.affymetrix.com
under expression analysis technical manual, and were used by the Wolfson Institue
of Biomedical Sciences at University College London to process the samples.
A summary of the protocol is as follows: The genechip eukaryotic hybridisation
control cocktail (see figure 9 for components) was heated to 65C for 5 minutes to
completely re-suspend the cRNA before aliquotting.
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Component Hybridisation cocktail Final Concentration
Fragmented cRNA (adjusted
amount)
15g 0,05g/l
Control Oligonucleotide B2
(3nM)
5l 50pM
20X Eukaryotic Hybridisation
controls (bioB, bioC, bioD, cre)
15l 1.5, 5, 25 and
100pM respectively
Herring Sperm DNA
(10mg/ml)
3l 0.1mg/ml
Acetylated BSA
(50mg/ml)
3l 0.5mg/ml
2x Hybridisation buffer 150l 1x
dH2O To final volume 300l
Final Volume 300l
Figure 9: contents of the hybridisation cocktail
The human U133 plus 2.0 probe array was equilibrated at room temperature before
use, while the hybridisation cocktail was heated to 99C for 5 minutes in a heat
block.
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The probe array was made wet by filling it through one of the septa, with the
appropriate volume of 1x hybridisation buffer. To make 100mls of 1x hybridisation
buffer the following was added; 8.3ml of 12X MES stock, 17.7ml of 5M NaCl, 4.0
ml of 0.5M EDTA, 0.1ml of 10% Tween20, 69.9ml of water. The probe array filled
with 1x hybridisation buffer was incubated at 45C for 10 minutes.
The hybridisation cocktail was transferred to a 45C heat block for 5 minutes after it
had been heated to 99C. It was then spun in a microcentrifuge for 5 minutes to
remove any insoluble material.
The buffer solution was removed from the probe array, and replaced with 200l of
the hybridisation cocktail. It was then placed in a rotisserie box in a 45C oven,
rotating at 60rpm for 16 hours, to hybridise.
2.6.3.2 Washing, staining and scanning the probe array
After 16 hours, the probe array was washed and stained (see figure 10 below for the
steps involved).
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Post hybridisation wash 1 10 cycles of 2 mixes/cycle with non-stringent wash
Buffer (see below) at 25C
Post hybridisation wash 2 4 cycles of 15 mixes/cycle with stringent wash
Buffer (see below) at 50C
Stain Stain the probe array for 10 minutes in SAPE
solution (see below) at 25C
Post wash stain 10 cycles of 4 mixes/cycle with wash buffer A at
25C
2nd stain Stain the probe array for 10 minutes in antibody
solution (see below) at 25C
3rd stain Stain the probe array for 10 minutes in SAPE
solution at 25C
Final wash 15 cycles of 4 mixes/cycle with non-stringent wash
buffer at 30C. The holding temperature is 25C
Figure 10: Steps involved in the washing and staining of the microarray chip
See figure 11 below for the composition of the different buffers and stains involved
in the process above:
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Solution Composition
12x MES stock buffer 70.4g MES free acid monohydrate
193.3g MES sodium salt
800ml of Molecular biology grade water
pH 6.5-6.7
filter through 0.2m filter
2x MES stain buffer 41.7ml of 12x MES stock buffer
92.5ml of 5M sodium chloride
2.5ml of 10% Tween 20
112.8ml of water
filter through 0.2m filter
store at 2-8C and shield from light
Non-stringent wash buffer 300ml of 20x SSPE
1.0ml of 10% Tween 20
698ml water
filter through 0.2m filter
Stringent wash buffer 83.3ml 12x MES stock buffer
5.2ml of 5M sodium chloride
1.0ml of 10% Tween 20
910.5ml water
filter through 0.2m filter
store at 2-8C and shield from light
SAPE solution 600l of 2x MES stain buffer
48l of 50mg/ml acetylated BSA
12l of 1mg/ml Streptavidin-
Phycoerythrin (SAPE)
540l dH2O
Antibody solution mix 300l of 2x MES stain buffer
24l of 50mg/ml acetylated BSA
6.0l of 10mg/ml of normal Goat IgG
3.6l of 0.5ml/ml of biotinylated
antibody
266.4l of dH2O
Figure 11: Shows the components of each of the buffers
The probe array was scanned using Affymetrix microarray suite computer software.
The pixel value was 3m and the wavelength was 570nm.
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2.6.3.3 Analysis of microarray results
The results were analysed by Dr Stephen Henderson, of the department of Viral
Oncology, Wolfson Institute for Biomedical Research. University College London,
UK using the following protocol:
All microarrays were quantile-quantile normalised to the array with the median
average signal (see mean variance pairs (MVA-pairs). Differential expression was
analysed using the limma package, part of the Bioconductor suite of bioinformatic
packages (http://www.bioconductor.org/), for the R statistical programming
language (http://cran.r-project.org/). Briefly the limma package is a variant of simple
linear models but using a moderated empirical Bayesian estimate of the standard
deviation to calculate p-values. The empirical estimate comes from the strong mean
variance relationship of microarrays, each observed variance being adjusted towards
the population variance of genes with a similar mean expression. This is appropriate
for studies with relatively few replicates in which the standard deviation of a
population of similar genes may be a better estimate than the observed standard
deviation of a single gene (Smyth et al., 2004).
The significance of contrasts is further moderated by the use of a "false discovery
rate" (FDR) algorithm that compensates for the massive multiple testing error
inherent in microarray experiments, adjusting p-values upwards (Benjamini et al.,
1995).
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2.7 Comparison of gene expression between newly diagnosed and treated
patients using microarrays
2.7.1 Preparation of RNA
2.7.1.1 Isolation of total RNA from ovarian tumour cells obtained from patient
ascites
For the isolation of total RNA from patient ascites tumour cells the TRIzol
(Invitrogen Life technology, Paisley, UK) protocol was used. This reagent is a
mono-phasic solution of phenol and guanidine isothiocyanate.
The sample was harvested using trypsin once the cells had reached the exponential
phase of growth as viewed down a microscope. The RPMI media containing 10%
FCS and 1% glutamine was poured off, and 3mls of trypsin was pipetted into the
flask to cover the cells. The trypsin was then poured off, and a further 5mls of
trypsin was added to the flask, and left in the incubator at 37ºC, 5% CO2 for 5
minutes. After 5 minutes the trypsin was pipetted off and added to 5mls of RPMI
media containing 10% FCS and 1% glutamine in a 10ml conical tube, and spun in a
centrifuge at 270g for 5 minutes. The supernatant was poured off. 10mls of RPMI
media containing 10% FCS and 1% glutmaine was added to the sample, and
pipetted up and down to resuspend the cell pellet.
The cells were counted (see section 2.2b). 4x106 cells were used for total RNA
extraction, and the appropriate volume of RPMI media containing 10% FCS and 1%
glutamine, and the cells was pipetted into a 20ml conical shaped tube. The sample
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was spun in a centrifuge at 249g for 5 minutes, and the supernatant poured off. 1ml
of TRIzol was added to the sample on dry ice, and the sample left overnight at -
80C.
0.2ml of chlorofom-phenol solution (Sigma, Pool, Dorset,UK) was added, the caps
secured and the tube shaken vigorously by hand for 15 seconds. The sample was
then incubated at room temperature for 2-3 minutes before being centrifuged at
15,000g for 15 minutes at 2-8C. Following this, the mixture separates into a lower
red, phenol-chloroform phase, an interphase, and a colourless upper aqueous phase.
RNA remains exclusively in the aqueous phase.
The aqueous phase was carefully pippetted into a fresh eppendorf (capacity1.5ml),
and 0.5ml of isopropyl alcohol (VXR International, Leicester, UK) was added and
left at room temperature for 10 minutes to precipitate the RNA. The sample was
then centrifuged at 15,000g for 10 minutes at 2-8C. The RNA was often seen as a
gel-like pellet at the bottom of the tube. The supernatant was removed by pipetting
and 1ml of 75% ethanol was added and centrifuged at 7,500g for 5 minutes, at 2-
8C, to wash the sample. The supernatant was carefully removed, taking care not to
dislodge the RNA pellet, and the sample was air-dried. The pellet was re-suspended
in 40l of RNase-free water.
2.7.1.2 Isolation of total RNA from ovarian solid tumour tissue from patients
The sample was removed from liquid nitrogen and placed on dry ice. 1 ml of TRIzol
was pipetted into the eppendorf, and the tissue homogeniser was used for several
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minutes to break up the tissue. The sample was then left at -80C overnight. The
tissue homogeniser was cleaned meticulously between samples. This was done by
using the homogeniser in a beaker of 100% ethanol, followed by a beaker of DEPC
water, followed by spraying it with a solution to decontaminate the homogeniser
from RNAases. The protocol for extraction of total RNA using TRIzol was then
followed (see section 2.7.1).
2.7.2 Preparation of microarray sample
See section 2.6.2
2.7.3 Processing the microarray sample
See section 2.6.3
2.8 Real-time polymerase chain reaction (PCR)
Real time PCR was done using a selection of primers of genes that were
significantly up or down regulated to confirm the microarray results obtained. The
genes chosen were Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene
(used as a control), and excision repair cross-complementation group 1 (ERCC1)
gene. Only cDNA from the paired samples were used for this experiment, which
included patient 17 asc.tu, pt 17B asc.tu, pt 33 asc.tu, pt 33B asc.tu, pt 41 asc.tu, and
pt 41B asc.tu..
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cDNA was made using the protocol previously described for microarrays (see
section 2.6b(i)). Only 6l of the 12l sample of cDNA was used for microarrays,
and the remaining 6l sample was diluted with 73.97l DEPC water to produce a
concentration of cDNA of 0.0625g/l.
First experiments were done to assess the relative efficiencies of the primers used.
The relative primer efficiencies (comparing each primer to GAPDH – the control
primer) had to be less than 0.1 to ensure that one primer was not binding more
efficiently than the other, which would bias the results.
Serial dilutions of 1:2, 1:5, 1:10, 1:20, 1:50, and 1:100 of the cDNA were made
using DEPC water. A mastermix containing 250l of Taqman universal PCR
mastermix (Applied biosystems, Warrington, UK), 25l of the appropriate
primer/probe mix (Applied biosystems, Warrington, UK), and 222.5l of DEPC
water, was made and 17.5l was added to each of the 21 wells (which does not
include the wells containing only water) on the 96 well PCR detection plate
(ABgene, Surrey, UK). 2.5l of the appropriate concentration of cDNA was added
to each well. This was repeated for each primer/probe set that was being
investigated, so on one 96 well PCR detection plate 2 genes (and their respective
primers) were investigated for 1 of the patient samples. Different plates were used
for all of the 6 different samples of patient cDNA.
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The wells were checked to make sure all of the reagents were at the bottom, and a
PCR seal (Applied biosystems, Warrington, UK) was placed over the top of the
plate before being put into an ABI prism 7000 (Applied biosystems, Warrington,
UK). Initially the machine heated the plate to 50C for 2 minutes, and then 95C for
10 minutes before 40 cycles were performed as follows:
95C for 15 seconds
60C for 1 minute
Once the relative primer efficiencies were shown to be less than 0.1, the main
experiment to determine differences in gene expression was then set up in triplicate.
The RNA concentration of each patient sample that had been diluted by 50% was
used (serial dilution ½). For each patient sample 2.5µl of this ½ concentration of
RNA was added to each of three wells on the 96 well plate, followed by 17.5µl of
mastermix (see above for making the mastermix). The same cycling conditions as
the standard curve experiment were used (see above). This meant there were a total
of 18 wells used – three for each patient 17, patient 17B, patient 33, patient 33B,
patient 41, patient 41B.
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3. RESULTS
3.1 Introduction
A2780 and A2780cisR human ovarian cancer cell lines were used to establish
cisplatin cytotoxicity using the SRB assay. These same cell lines were used to
measure the peak of ICL formation and repair after exposure to cisplatin to identify
differences that could be further investigated in the clinical setting.
Human ovarian cancer cells were obtained from patients before and after
chemotherapy and the peak of ICL formation and repair were measured after
exposure to cisplatin and melphalan ex vivo to establish any differences which may
relate to clinically acquired resistance. Microarray technology was used to determine
if these differences could be explained at the gene level.
3.2 Human ovarian cancer cell lines treated in vitro with cisplatin
3.2.1 Measurement of cisplatin cytotoxicity in paired cisplatin sensitive (A2780)
and resistant (A2780cisR) human ovarian cancer cell lines
The A2780 and A2780cisR cell lines are a paired cell line produced from human
ovarian cancer cells, and were used as an in vitro model. The A2780 cisplatin
resistant (A2780cisR) cell line used in these experiments was produced by chronic
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exposure of the parent cisplatin-sensitive A2780 cell line to increasing
concentrations of cisplatin (Behrens et al., 1987). The resulting cell line was
originally called 2780CP8 where CP8 refers to this cell line’s growth in medium
containing 8M cisplatin (Behrens et al., 1987). Once the A2780cisR cell line had
been produced it was stable, and therefore remained resistant to cisplatin without the
need for continually growing it in the drug.
A2780cisR resistance to cisplatin chemotherapy was demonstrated using the
Sulphur-Rhodamine Blue (SRB) assay. The IC50 is the concentration of the drug that
inhibits growth by 50%. SRB assays to determine the cisplatin IC50 for the A2780
and A2780cisR cell lines following 1 hour exposure to cisplatin were performed
(figure 12).
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Figure 12: Inhibition of growth of A2780 and A2780cisR cell lines after treatment
with cisplatin, as measured by the SRB assay (A2780 n=2, A2780cisR n=3, standard
error bars are shown)
The cisplatin IC50 for A2780 cell line was 1.6M, and for the A2780cisR cell line
was 9.9M, which resulted in a 6.2-fold difference between their sensitivities to
cisplatin.
3.2.2 Measurement of ICL formation and repair in human ovarian cancer cell
lines treated with cisplatin using the comet assay
The single cell gel electrophoresis (comet) assay has enabled the study of strand
breaks and DNA interstrand crosslinking in clinical material due to the low number
of cells needed from patients, its sensitivity (compared with techniques such as
alkaline elution), and the reproducibility of results (Hartley et al., 1999). It has
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become an important tool in the investigation of ICL formation and repair in the
clinical setting.
The comet assay was originally developed to measure strand breaks, and has been
adapted to measure interstrand crosslinking (Hartley et al., 1999). Cells are
irradiated to produce a fixed level of random single strand breaks (which will
include some double strand breaks if two single strand breaks occur at the same
point). The shortening of the comet tails in the crosslinking drug treated and then
irradiated sample, compared to the irradiated control is a measure of the level of
ICLs present (Hartley et al., 1999). Shortening of the comet tails is due to the
decrease in electrophoretic mobility caused by the presence of interstrand crosslinks
within the DNA.
The figures below represent the DNA of individual cells, and are typical examples
of the images that are produced by the comet assay. The percent decrease in tail
moment is a measure of the amount of interstrand crosslink formation present in the
cells at a given time, and is calculated using the formula shown in methods section
2.3d(viii). Figures 13(a)-13(d) are typical images from A2780 cells of the four
components used in the formula.
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(a) (b)
(c) (d)
Figure 13: (a): non-irradiated non-drug treated cells, (b): irradiated non-drug treated cells, (c): non-
irradiated drug-treated cells, (d): irradiated drug-treated cells
In Figure 13(a), the cells have almost no comet tails. This is because their DNA is
not damaged and is of high molecular weight and therefore has low electrophoretic
mobility. This sample is a control to establish the amount of background DNA
damage present within these cells, before any drug is added. In this sample there is
very little background DNA damage.
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In figure 13(b) the cells have very large comet tails. This results from the controlled
dose of irradiation introducing a fixed number of random DNA strand breaks. As the
DNA is broken into smaller fragments its electrophoretic mobility increases
resulting in large comet tails. The amount of DNA damage in this sample is a
baseline to which other irradiated drug-treated samples are compared.
In Figure 13(c), the cells have almost no comet tails after drug treatment with
cisplatin. This is because cisplatin does not produce strand breaks and therefore the
DNA has a high molecular weight, and low electrophoretic mobility, similar to
figure 13(a). This sample is a control to show very few single or double strand
breaks are produced by cisplatin, and therefore it is the irradiation alone that
produces fixed levels of strand break DNA damage.
The cells in Figure 13(d) have received the same amount of irradiation as those in
figure 13(b), but they have smaller comet tails due to the presence of ICLs produced
by the drug. The interstrand crosslinks that are present in this sample decreases the
electrophoretic mobility in the gel due to the increased size of the DNA fragments,
compared to fragments produced by irradiation alone. This difference (percent
decrease in tail moment) is a measure of the amount of DNA interstrand crosslinks
present in this sample.
In figure 14, media containing different concentrations of cisplatin were incubated
with the cells for 1 hour and then removed. The cells were incubated for a further 9
hours in drug-free media. 9 hours was chosen because it has previously been shown
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to be the peak of ICL formation in these cells (Wynne et al., 2007). As can be seen
from figure 14, the relationship between concentrations of cisplatin and the percent
decrease in tail moment is hyperbolic. Above 100µM the amount of ICL formation
present plateaus as the concentration of cisplatin increases.
Figure 14: Relationship between the percent decrease in tail moment and
concentration of cisplatin (data used from three individual experiments, standard
error bars are shown)
In figure 14, 100M cisplatin produces approximately 50% decrease in tail moment
in both A2780 and A2780cisR cell lines, and this concentration of cisplatin was
used to investigate formation and repair of ICLs in the A2780 and A2780cisR cell
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lines. Students paired t-test was used to see if there was any statistical difference
between the % decrease in tail moment of A2780 and A2780cisR cells when treated
with 100µM cisplatin. Statistical significance was achieved if p≤0.05. This test was
used as these cell lines are paired, and only differ in their resistance to cisplatin.
Their results do not significantly differ (p< 0.40). However, it is noted that 100µM
cisplatin is a far higher concentration that the cells are exposed to, than in the
clinical setting. The dose of carboplatin that the patients are exposed to decreases
over time, but a concentration of between 5 to 7mg/ml min -1 which is the area under
the concentration curve (AUC) gives a maximal response rate (Duffull et al., 1997),
which is in the order of 10 fold lower than in these experiments. 100M cisplatin
was also used to investigate formation and repair of ICLs in clinical samples taken
from newly diagnosed and treated patients. As 100μM cisplatin produces
approximately 50% of interstrand crosslink formation, this concentration was
arbitarly chosen as it provided a level from which formation and repair could be
measured over time. Therefore small changes in either ICL formation or repair could
be detected.
In figure 15, 100μM cisplatin was incubated with A2780 and A2780cisR human
ovarian cancer cell lines for 1 hour and then removed. The cells were then incubated
in drug-free media for 0, 3, 6, 9, 24, 30 and 48 hours, and then harvested, and the
level of ICL formation present at each time point was measured using the comet
assay.
Page 124
Figure 15: Time course over 48 hours to show the relationship between the percent
decrease in tail moment in A2780 and A2780cisR cell lines when incubated in vitro
with 100M cisplatin for 1 hour (data used from three individual experiments,
standard error bars are shown).
The percent decrease in tail moment after treatment with 100M cisplatin at 9 hours
for the A2780 and A2780cisR cell lines are similar at 70%6 and 73%10
respectively (figure 15). Using students paired t-test there is no significant difference
in the peak of crosslinking (p<0.40). This is the maximum decrease in tail moment
over a 48-hour period, corresponding to the peak of ICL formation.
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The levels of crosslinks remain at a high level over a 48 hour period in the A2780
cell line. In contrast there is a rapid decrease in the % decrease in tail moment by 24
hours in the A2780cisR cell line as a result of repair (unhooking) of the crosslinks.
At 24 hours there is a significant difference of the %decrease in tail moment
between the A2780 and A2780cisR (p<0.025, using students paired t-test). This
significant difference in % decrease in tail moment continues at 48hours (p<0.05,
using students paired t-test). This repair of ICLs is likely to be an important
mechanism in the resistance to cisplatin seen in the A2780cisR cell line when
compared to the parent A2780 cell line.
3.2.3 Discussion
The results from the SRB assay found the A2780cisR human cancer cell line had a
6.2-fold increase in resistance to cisplatin compared to the A2780 human cancer cell
line. Behrens et al (1987) found that the A2780cisR (or 2780CP8) resistant cell line
was 7.3-fold resistant to cisplatin compared to the A2780 cell line (Behrens et al.,
1987). Another group found this A2780cisR cell line was 7.7-fold resistant to
cisplatin (Schmidt et al., 1993). Therefore, the results obtained are of a similar
magnitude to those found in the literature.
As the concentration of cisplatin increases, so too does the formation of ICLs, in a
hyperbolic relationship up to 100μM cisplatin, demonstrating similar amounts of
ICLs are present in both A2780 and A2780cisR human ovarian cancer cell lines.
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This is supported by Masuda H et al (1990) who showed that binding of platinum to
DNA as measured by flameless atomic absorption spectrophotometry, of either
A2780 or A2780cisR cell line was a linear function of concentration ranging from
20-80M cisplatin (Masuda et al., 1990). This implies that similar concentrations of
cisplatin interact within the DNA of these cells to produce ICLs, suggesting that
mechanisms upstream of DNA damage such as increased efflux, or reduced influx
of cisplatin, or drug detoxifying mechanisms are not different between the two cell
lines. However, in contrast, Schmidt et al (1993) have shown decreased
accumulation of cisplatin in the A2780cisR cell line as measured by atomic
absorption spectrometry, resulting in less formation of platinum-DNA adducts,
including ICLs, compared to the parent cell line, which they suggested contributes to
cisplatin resistance (Schmidt et al., 1993).
Importantly, other cells such as lymphocytes show similar properties when treated
with other crosslinking agents. Hartley et al (1999) demonstrated a linear
relationship between decrease in tail moment as measured by the comet assay and
the level of ICL formation in lymphocytes treated ex vivo with increasing
concentrations of chlorambucil (Hartley et al., 1999).
The increase in repair of ICLs found in the A2780cisR cell line as compared to the
A2780 cell line is supported by Masuda H et al (1990). They suggested that the
mechanism of resistance in the A2780cisR (or A2780/CP8) cell line was due to their
increased ability to remove platinum-DNA adducts (mostly intrastrand crosslinks
were measured), and not to a difference in initial binding of cisplatin, as measured
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by flameless absorption atomic spectophotometry (Masuda et al., 1990). There is
further evidence using a 3H-thymidine incorporation assay that showed a two-fold
increase in the repair ability of the A2780cisR cell line (Masuda et al., 1988).
Further studies have also showed increase in repair of the A2780cisR cell line as a
mechanism of cisplatin resistance (Scmidt et al., 1993) (Zhen et al., 1992).
Parker et al. 1991, and Masuda et al. 1990 found the A2780/CP8 cell line to have
similar levels of DNA damage, including ICL formation when treated with 100µM
cisplatin compared to the parental A2780 cell line. Masuda et al. also found the
A2780/CP8 resistant cell line to be two-fold more efficient at repairing DNA
damage, including ICLs and intrastrand crosslinks, compared to the parent A2780
cell line (Masuda et al., 1990). This shows that these resistant cell lines behave very
similarly to the ones used in the experiments, and supports the data from our
experiments.
3.3 Clinical ovarian cancer tissue treated ex vivo with cisplatin
3.3.1 Obtaining ovarian cancer cells from patient samples
A total of 48 patients were included in this study, who were all suspected to have
epithelial ovarian cancer. Informed consent was obtained from all of them. From six
of these patients a sample was collected before they received any chemotherapy, and
also, after they had received platinum-based chemotherapy. These are the six
‘paired’ patients. Three of the 48 patients did not have ovarian cancer when the
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histopathology was examined, and so were excluded from the study. There were cell
culture problems with a further five patients, which meant they were not included in
the study as experiments were unable to be carried out. Overall cells from 40
patients with epithelial ovarian cancer were analysed in the study, including the six
paired patient samples. Patients who had not yet received chemotherapy and are
newly diagnosed are called ‘pre-chemotherapy’ patients, and those that had received
platinum-based chemotherapy are called ‘post-chemotherapy’ patients.
3.3.2 Patient characteristics
Table 1 and 2 show the individual patient characteristics in both newly diagnosed
(pre-chemotherapy) and treated (post-chemotherapy) patient groups. The average
age in the pre-chemotherapy group is 66  11, and in the post-chemotherapy group
is 66  10.
The Platinum-free interval (PFI) is the time taken from when the patient had their
last dose of chemotherapy (before the sample was taken), until they had evidence of
disease relapse (around the time the sample was taken), such as a doubling of their
Ca-125, or evidence on CT scan. Therefore, only post-chemotherapy patients have a
PFI. The PFI is used to guide future chemotherapy treatment, as it describes the
likelihood of responding to future platinum-based chemotherapy. A PFI of 6 months
or less suggests the patient is clinically resistant to platinum, and their next
chemotherapy should be changed to second-line chemotherapy. A PFI of 7 months
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or more suggests the patient may still respond to platinum based chemotherapy, and
therefore their next course of chemotherapy should include platinum.
The progression-free survival (PFS) is the time from the patients first dose of
chemotherapy (usually around the time the sample was taken) until the patient
clinically relapses. Doubling of Ca-125 levels from the upper limit of normal has
been shown to predict progression (Rustin et al., 2001). Persistently elevated levels,
or doubling of Ca-125 from its nadir level has now also been shown to accurately
define progression (Rustin et al., 2001) with a false positive rate of less than 2%
(Rustin et al., 2003). Clinical relapse is also defined as evidence of disease on CT
scan (Rustin et al., 2003).
Interval debulking surgery (IDS) patients are in the post-chemotherapy group of
patients as they have already received three doses of chemotherapy. They then
undergo an operation to remove as much of the tumour as possible. However, these
patients will not have received a full course of platinum-based chemotherapy as
three doses are half the six doses required for a full course.
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Patient
number
Age Treatment FIGO
stage
PFS Outcome Sample and hitological type
1 63 Carboplatin/
paclitaxel
4 11 Ca125 36 to 67, with
symptoms
ascites/solid tumour,
serous papillary adenocarcinoma
2 68 Carboplatin/
paclitaxel
2c >13 NED(no evidence of
disease)
solid tumour,
endometrioid adenocarcinoma
3 91 none Not
known
No treatment given ascites/solid tumour,
endometrioid adenocarcinoma
4 72 Carboplatin/
paclitaxel
3c >10 NED solid tumour,
serous papillary adenocarcinoma
5 65 Carboplatin/
paclitaxel
3c >4 NED solid tumour,
peritoneal serous adenocarcinoma
8 74 Carboplatin/
paclitaxel
3c 10 Doubled Ca125 ascites/solid tumour,
serous papillary adenocarcinoma
10 51 Carboplatin/
paclitaxel
3c >8 NED ascites/solid tumour,
serous papillary adenocarcinoma
12 63 Carboplatin/
paclitaxel
3c 7 Doubled Ca125 ascites/solid tumour,
serous papillary adenocarcinoma
15 50 Carboplatin/
paclitaxel
2c >4 NED solid tumour,
serous papillary adenocarcinoma
16 63 Carboplatin/
paclitaxel
3c >4 NED solid tumour,
not known
17 54 Carboplatin/
paclitaxel
3c 0 Progressive disease on
chemo
Ascites,
serous papillary adenocarcinoma
18 62 Carboplatin 1c >6 NED ascites/solid tumour,
serous papillary adenocarcinoma
19 45 Carboplatin/
paclitaxel
3a >8 NED solid tumour
22 77 Carboplatin 2b >6 NED solid tumour
24 62 Carboplatin 2b >7 NED solid tumour
26 73 Carboplatin/
paclitaxel
3c >7 NED Ascites,
serous papillary adenocarcinoma
27 70 Carboplatin/
paclitaxel
3c 9 Doubled Ca125, R
inguinal lump
Ascites,
serous papillary adenocarcinoma
29 61 Carboplatin 1a >4 NED solid tumour
30 54 None (too
unwell)
3c N/A Died Aug 05 ascites
32 64 Carboplatin/
paclitaxel
3 3 Doubled Ca125,CT-
abdo disease
ascites
33 58 Carboplatin/
paclitaxel
4 0 Disease progression on
chemo
ascites
34 63 Carboplatin/
paclitaxel
3c 5 CT-progressive
disease, symptoms
ascites
36 87 Carboplatin 3c >6 NED solid tumour
38 80 Carboplatin 3c >6 NED ascites
39 76 Carboplatin 3c >4 NED ascites/solid tumour
40 78 None (too
unwell)
3c N/A Died ascites
41 77 Carboplatin
(intraperitoneal)
3c 0 Disease progression on
chemo
ascites
43 66 Carboplatin/paclit
axel
4 >3 NED ascites
45 56 Info not available 3c Info not available ascites
46 66 Carboplatin/paclit
axel
3c >4 NED ascites
48 63 Carboplatin 3c 19 NED ascites
NED is no evidence of disease, PFS Progression free survival
Table 1: Newly diagnosed patient characteristics
Patient
number
Age Treatment FIGO
stage
category PFI PFS outcome Sample and histological type
1B 63 Carboplatin/paclitaxel 4 IDS N/A 11 Ca125 36 to 67, with symptoms solid tumour,
serous papillary adenocarcinoma
27B 70 Carboplatin/paclitaxel 3c IDS N/A 9 Doubled Ca125, R inguinal lump Ascites,
serous papillary adenocarcinoma
28 53 Etoposide 4 IDS N/A 11 Doubled Ca125, CT-lymph node solid tumour,
serous papillary adenocarcinoma
37 69 Cisplatin/etoposide 3c IDS N/A 0 Disease progression, died jan 06 Ascites/solid tumour,
Clear cell carcinoma
38B 80 Carboplatin 3c IDS N/A >6 NED ascites
44 82 Carboplatin 3c IDS N/A >8 NED solid tumour
6 69 Carboplatin 4 <6months 0 0 Died, unable to assess Ascites,
serous papillary adenocarcinoma
7 66 None 3c <6months 3 0 Died, unable to assess Ascites,
serous papillary adenocarcinoma
17B 54 None 3c <6months 0 0 Disease progression Ascites,
serous papillary adenocarcinoma
21 49 Carboplatin/paclitaxel 3c <6months 4 0 Died Ascites,
Clear cell carcinoma
33B 58 Cisplatin/etoposide 4 <6months 0 >6 Responding to treatment ascites
35 63 Carboplatin 4 <6months 4 0 Doubled Ca125, symptoms. Died Dec 05 ascites
41B 77 none 3c <6months 0 N/A Unwell with severe COPD ascites
47 68 Gemcitabine/
Carboplatin
3c >6months 16 >6 NED ascites
NED is no evidence of disease
PFI Platinum free interval
PFS progression free survival
Table 2: Post-chemotherapy patient characteristics
Ovarian tumour cells were obtained from ascites by separating them from the
mesothelial cells using cell culture techniques (see methods section 2.4c(i)). The
samples were observed under the microscope (see figure 16), and stained to confirm
presence of specific cell types.
Figure 16: Phase contrast images taken down a microscope of primary culture of
ovarian tumour cells isolated from ascites (Wynne, 2006).
Figure 16 illustrates the morphology characteristic of ovarian tumour cells. They are
more rounded, tend to cluster together, and have abnormal nuclei. This is in contrast
to mesothelial cells (figure 17).
Page 126
Page 133
Figure 17: Phase contrast images taken down a microscope of primary culture of
mesothelial cells isolated from ascites (Wynne, 2006).
Figure 17 illustrates the morphology characteristic of mesothelial cells. They are
more spindle-shaped compared to ovarian tumour cells. Once the sample had been
separated into mesothelial cells and ovarian tumour cells, the samples were stained
to confirm the percentage of mesothelial and ovarian tumour cells.
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Figure 18: Ovarian tumour cells from ascites stained using CK7 from a typical
patient sample
Cytokeratin 7 (CK7) stains epithelial cells, and therefore stains ovarian tumour cells
as they are of epithelial origin. CK7 does not stain mesothelial cells (Plaza et al.,
2004). In the tumour cell sample shown in figure 18, there is almost 95% positive
staining for CK7, indicating the presence of epithelial cells. This is representative of
all the separated tumour cell samples that were stained.
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Figure 19: Ovarian tumour cells from ascites stained with CK5 from a typical
patient sample
Cytokeratin 5 (CK5) stains mesothelial cells (Plaza et al., 2004), and not epithelial
cells. In figure 19, the same tumour cell sample as in figure 18 was used. There is
almost no staining present, as there are very few mesothelial cells present. Figure 19
and figure 18 confirms the presence of approximately 95% epithelial cells present in
this sample. As ascites is mainly a mixture of ovarian tumour cells and mesothelial
cells, the epithelial cells confirmed in this sample are ovarian tumour cells.
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Figure 20: Mesothelial cells from ascites stained with CK5 from a typical patient
sample.
Figure 20 shows the staining with CK5 of a typical mesothelial cell sample isolated
from ascites. There is positive staining for mesothelial cells using the CK5 antibody
marker, confirming the presence of mesothelial cells in this sample.
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Figure 21: Mesothelial cells stained with CK7 from a typical patient sample.
Figure 21 shows the same sample as figure 20, but stained with CK7. There is no
staining, which means there are no epithelial cells present. These two figures
confirm the presence of approximately 80% mesothelial cells in this sample. Only
samples with >80% ovarian tumour cells or mesothelial cells were used in further
experiments. The majority of ovarian tumour cell samples stained >95% positive
with the CK7 marker. Other techniques such as fluorescent active cell sorting
(FACS) or magnetic bead sorting could have been used to further purify the cells,
but because the vast majority of cells were 95% pure, it was deemed an unnecessary
expense.
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Solid tumour cell samples obtained from patients with ovarian cancer were also
stained to confirm the presence of ovarian cancer cells. They were stained with CK7
and were all shown to be strongly positive (>95% ovarian cancer cells).
3.3.3 Measurement of ICL formation and repair in ovarian cancer cells
obtained from patient ascites and solid tumour when treated with cisplatin
ICL formation and repair were measured in ovarian cancer cells obtained from
patients. 100M cisplatin was used as this has been shown to produce a significant
level of ICL formation in the A2780 and A2780cisR cell lines.
Figure 22 shows an individual crosslink response curve for patient 37. This patient
had not received any chemotherapy before a sample was taken. The peak of ICL
formation at 9 hours is maintained over 48 hours in these cells. No repair or
unhooking of ICLs has occurred in this patient. It is thought that the inability to
repair platinum ICLs confers sensitivity to the drug and a clinical response.
However, this patient had progressive disease and died soon after diagnosis.
Histopathology showed clear cell ovarian carcinoma which is known to be a very
aggressive form of the disease. This may have contributed to the progressive nature
of her disease despite chemotherapy.
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Figure 22: Time course over 48 hours illustrating ICL formation and persistence in
ovarian cancer cells isolated from ascites in patient number 37 before chemotherapy.
There were limited cells obtained from some patient samples, and so only two time
points were chosen to measure ICL formation and repair. These were 9 hours, as this
is the peak of ICL formation (as already demonstrated), and 24 hours.
In a number of patients it was possible to repeat the comet assay two or three times
depending on the amount of cells obtained. Patient numbers 1, 1B, 3, 4 and 8 had
duplicate comet assay results, patient numbers 2, 5, 6 and 10 had triplicate comet
assay results, and the other patients had one result from the comet assay. Where
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duplicate or triplicate samples were processed successfully, error bars are present on
the relevant figures.
Some of the values of percent repair at 24 hours are ‘negative’. This means that the
percent decrease in tail moment, and therefore the level of crosslinks, increased from
9 hours to 24 hours. All the patient data for the peak of ICL formation at 9 hours are
shown in figure 23.
Figure 23: Peak of ICL formation in patients before and after chemotherapy (some standard error bars are shown on this figure for
the patients that had duplicate or triplicate results)
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Figure 24: Peak of ICL formation in pre and post-chemotherapy samples. Horizontal
line shows mean of each group. Dots show distribution of results.
Figures 23 and 24 both show data for the peak of ICL formation in pre- and post-
chemotherapy samples. The results are clearly similar for the two groups of patients.
There is no statistically significant difference between the two groups, using
students paired t-test (p<0.75), and this is especially noticeable in the scatter plot of
figure 24 which shows the distribution of the data clustered together. Figure 23
illustrates the results obtained for each patient. Students paired t-test was used as the
two groups of patients are paired as some samples are taken before chemotherapy,
and others are taken after chemotherapy. Statistical significance was achieved if
p≤0.05.
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In total there are 34 pre-chemotherapy (newly diagnosed) patient samples, and 14
post-chemotherapy (treated) patient samples. Overall, the level of ICL formation as
measured by the % decrease in tail moment ranged from 41-80 (see figure 24). The
mean level of crosslinking in all samples was 60% ±10, while it was 61% 9 in the
pre-chemotherapy group of patients (newly diagnosed), and 58% 10 in the post-
chemotherapy patients (treated patients). There was no significant difference in
these values using students paired t-test (p<0.40). This suggests that similar amounts
of cisplatin interact with the DNA of both groups of patient cells, to cause similar
amounts of ICL formation within the DNA. These results also suggest that upstream
mechanisms such as drug efflux, and detoxification mechanisms are not contributing
to reducing the levels of cisplatin entering and reaching the DNA of these cells.
In five patients it was possible to obtain mesothelial and ovarian cancer cells from
ascites in pre- and post-chemotherapy patients. The peak of ICL formation was
measured in these two cell populations to determine if their cellular metabolism of
cisplatin was similar. These cells were treated with 100M cisplatin for 1 hour, and
then the drug was removed. The cells were left for 9 hours and the level of ICL
formation at 9 hours was measured using the comet assay (figure 25).
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Figure 25: Percent decrease in tail moment at 9 hours in ascites and mesothelial cells
from the same patient before and after chemotherapy.
Figure 25 shows similar levels of ICL formation in both tumour (i.e ovarian cancer),
and non-tumour (i.e mesothelial) cells. The average level of ICL formation as
measured by percent decrease in tail moment at 9 hours in the mesothelial cells from
pre-chemotherapy patients was 5811, and for the corresponding ovarian cancer
cells was 6111 (figure 25). There was no significant difference in these values
using students paired t-test (p<0.40). The percent decrease in tail moment at 9 hours
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in the mesothelial cells from one post-chemotherapy patient was 56, and for the
corresponding ovarian tumour cells it was 60.
Ovarian cancer cells obtained from ascites and solid tumour samples were
investigated to determine if these cells had similar levels of ICL formation at 9
hours, or if ovarian tumour cells obtained from different tissues behaved differently.
Figure 26: percent decrease in tail moment at 9 hours in ascites and solid tumour
patient samples taken before and after chemotherapy.
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In eight patients it was possible to obtain both ascites and solid tumour samples.
Figure 26 shows similar levels of ICL formation in both ascites and solid tumour
samples taken from the same patient, suggesting these cell types do not differ
significantly in their cellular uptake or metabolism of cisplatin which has enabled
similar levels of DNA damage to occur. The level of ICL formation as measured by
the average % decrease in tail moment at 9 hours was 5910and 6516 for ascites
and solid tumour cells, respectively, taken before chemotherapy. There was no
significant difference in these values using students paired t-test (p<0.40) The one
patient sample collected after chemotherapy showed comparable levels of percent
decrease in tail moment at 9 hours for ascites (59), and solid tumour (62). Patient 13
has benign ovarian disease, and was included to illustrate the similarity of ICL
formation present after treatment with cisplatin, in mesothelial cells and benign
ovarian cells before receiving any chemotherapy in the clinical setting.
Levels of ICL formation were measured at 9 hours and 24 hours after the samples
were incubated ex vivo with 100M cisplatin, and then the percent repair at 24 hours
calculated. The percent repair (at 24 hours) is the difference between the peak of
ICL formation at 9 hours and 24 hours. The data are shown in figure 27 for the
individual patients and figure 28 as a scatter plot to show the distribution of the data.
Figure 27: Percent repair at 24 hours in patients before and after chemotherapy (standard error bars are shown on the patient samples
that have been done in duplicate or triplicate).
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Figure 28: Percent repair in patient samples taken before and after chemotherapy.
Horizontal lines indicate the mean of each group.
From figures 27 and 28, there appears to be a much more heterogeneous response between
the patient samples, with values for repair at 24 hours ranging from no repair to almost
100% repair. Some patients demonstrated ‘negative’ repair, in which the levels of ICLs
present actually increased between 9 and 24 hours. There is a clear difference between the
patient groups. In the pre-chemotherapy patient group, the average percent repair after 24
hours was 4%19, but it was 45%43 in the post-chemotherapy group (figure 28). This
was statistically significant using students paired t-test (p<0.001). In the pre-chemotherapy
patient population only four patients had >20% ICL repair, while the remaining 30 patients
had <20% repair. In contrast only four patients had <20% ICL repair in the post-
chemotherapy group, while 1 patient had 28% repair, and the remaining nine patients had
>50% repair.
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In six patients a sample was collected before the patient had received any chemotherapy,
and again after the same patient had received platinum-based chemotherapy. Each sample
was incubated with 100M cisplatin for 1 hour, and then analysed after 9 hours and 24
hours. The levels of ICL formation and repair were measured using the comet assay (figure
29).
Figure 29: percent repair at 24 hours in six patients treated with cisplatin before and after
they had received platinum-based chemotherapy. B denotes the sample taken after
chemotherapy.
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Although similar levels of ICL formation are present in the two patient populations, the
percent repair after 24 hours was very different. The ovarian tumour cells taken before
chemotherapy show very little unhooking of crosslinks ranging from -8% to 26%, but in contrast
the ovarian tumour cells taken after chemotherapy show extensive unhooking with % repair
ranging from 28% - 95%. Average % ICL repair in the pre-chemotherapy patient samples
was low at 7%13 but was much higher at 70%23 in the post-chemotherapy samples
from the same patient, respectively (figure 29). This was statistically significant using
students paired t-test (p<0.002). Patients 1B, 27B, and 38B all had samples taken at
interval debulking surgery (IDS), which means they had only had 3 doses of carboplatin
before the sample was taken. These data clearly demonstrate that increase in ICL repair at
24 hours plays a role in resistance to platinum chemotherapy after as little as three doses of
carboplatin. What is also clear is that nearly all patients who are treated with platinum
chemotherapy will show some level of repair of ICLs, but not all of them will relapse.
Therefore not all ICL repair will be clinically relevant.
In six patients it was possible to obtain mesothelial and ovarian cancer cells from ascites in
pre- and post-chemotherapy patients. The repair of ICLs was measured in these two cell
populations to determine if their response to treatment with cisplatin were similar.
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Figure 30: Percent repair (or unhooking) of ICLs in ovarian cancer cells and mesothelial
cells before and after chemotherapy
In the ovarian cancer and mesothelial cells obtained from patients before chemotherapy,
there does not appear to be any difference in the levels of ICL repair at 24 hours, as they all
have <10% repair. There was no significant difference in these values using students paired
t-test (p<0.40). This suggests that these cells have similar metabolic pathways when
incubated with cisplatin ex vivo, and that the ovarian cancer cells have not yet acquired the
resistance mechanism of ICL repair
.
In the post-chemotherapy patient there is an obvious difference between the percent repair
(at 24 hours) of ICLs in the ovarian cancer cells and the lack of repair at 24 hours in the
mesothelial cells (72 and -14%, repectively). Although these data are from only one treated
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patient, it does seem that the ovarian cancer cells obtained from the ascites of patient 6
have acquired this mechanism of increased ICL repair. The mesothelial cells are also
obtained from ascites, but do not seem to have acquired this same mechanism of resistance,
suggesting that this acquired resistance is unique to the cancer cells. Cancer cells are
genetically unstable, and are therefore more likely to acquire mutations within the DNA.
However, the time interval is much too short for this to occur. A more likely mechanism is
that ovarian cancer cells that repair ICLs have been selected out by treatment with
carboplatin.
3.3.4 Discussion
The similarity in levels of ICL formation at 9 hours between pre-chemotherapy, and post-
chemotherapy patients resembles the results from the A2780 platinum sensitive and A2780
cisplatin resistant human ovarian cancer cell lines (figure 15). Data from ICL formation
and repair in clinical ovarian cancer samples has not been published before now.
The initial levels of ICL formation in ovarian cancer cells obtained before and after
chemotherapy are very similar (figure 23). Many studies have shown that the level of
platinum-DNA adducts correlates with patient response to platinum-based chemotherapy
(Altaha et al., 2004), which implies that drug influx and efflux mechanisms that influence
the level of drug available to reach the DNA play an important role in response to platinum
chemotherapy.
The clinical response of patients to platinum chemotherapy was investigated to see if data
from the level of ICL formation at 9 hours obtained from the laboratory could be used to
predict which patients would not respond to platinum-based chemotherapy.
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Patient 17, 33, and 41 had intrinsic (or primary) platinum resistance as their disease
actually progressed whilst on carboplatin chemotherapy. As the levels of ICL formation in
these patients are similar to the average for the newly diagnosed patients, it seems that drug
influx/efflux or other upstream mechanisms such as detoxification do not play an important
role in inherent (or primary) platinum resistance in these patients. This is also true for the
other patients that developed acquired resistance to platinum chemotherapy (patients 37, 6,
7, 17B, 21, 33B, 35, 41B) as they have similar levels of ICL formation at 9 hours. Since
ICLs are critical cytotoxic lesions, similar levels of cell death within these cancer cells
might be expected to occur. The similar level of ICL formation is also striking in the six
paired patient samples taken before and after each patient had received platinum
chemotherapy. From these data it seems that the level of ICL formation at 9 hours in
ovarian cancer cells obtained from newly diagnosed patients (pre-chemotherapy), and
treated patients (post-chemotherapy) cannot be used to predict their response to platinum
based chemotherapy.
There are a number of patients that have very different values of percent repair at 24 hours
compared to the mean. In the pre-chemotherapy group, patient 19, 33, 40, and 46 have
percent repairs at 24 hours of 25%, 26%, 29%, and 57%, respectively. This is in
comparison to the mean for this pre-chemotherapy group of 4%. The clinical data for some
of these patients was compared to see if the data for repair of ICLs can be supported with
clinical evidence of resistance.
Looking at their clinical data patient 33 has a PFS of 0, and patient 40 was not given any
chemotherapy, as she was not fit enough, therefore PFS cannot be calculated (she died
soon after diagnosis). A PFS of 0 means that not only is patient 33 clinically resistant, but
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this patient actually progressed whilst on carboplatin chemotherapy. Progression whilst on
chemotherapy is very significant and is strong clinical evidence of an intrinsic resistance
mechanism within the tumour cells. This intrinsic quality may be due to the higher than
average levels of ICL repair. However, resistance is multi-factorial and it is always
difficult to assign clinical outcome to only one resistance mechanism.
Clinical details of newly diagnosed patients, was compared to the levels of ICL repair to
see if there are any correlations. Patient 17 and 41 have a PFS of 0, patient 32 has a PFS of
3, and patient 35 has a PFS of 5. This means these patients had disease recurrences soon
after starting platinum chemotherapy. For further support of the theory that high levels of
ICL repair correlate with inherent clinical resistance to carboplatin chemotherapy, we
would expect these patients to have high levels of ICL repair. Patient 17 had 13% repair,
patient 32 had 3% repair, patient 34 had -13% repair and patient 41 had 4.7% repair, so
overall these patients had low levels of ICL repair. There is little correlation with clinical
outcome and levels of ICL repair. This does not support the theory that high levels of ICL
repair are a major mechanism of inherent clinical resistance to platinum chemotherapy.
However, ICL repair could still play a role in acquired resistance to platinum.
The other newly diagnosed patients that have not previously been discussed have low
levels of ICL repair suggesting platinum sensitivity, which seems to be consistent with
their PFS. As can be seen from table 1, most patients do not have a specific number for
PFS. This is because these patients have not yet had a recurrence of their disease, and so
the exact PFS cannot be calculated. Most of the patients with no exact PFS have only 1 or
2 months more before they are considered to be platinum sensitive, and is this is such a
short time interval, it is unlikely they will relapse within this time. However, it must be
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pointed out that there are 6 patients with a PFS of >3, or >4, and so they have 5-6 months
in which to relapse to be considered platinum resistant. So this means no firm conclusions
can be drawn from these 6 patients. However, overall it seems as though there is a good
correlation between low levels of ICL repair and sensitivity to platinum based
chemotherapy in newly diagnosed patients with ovarian cancer.
Another important practical aspect of deciding which patient is put into either platinum
sensitive or resistant groups, is the timing of particular blood tests and scans e.g. if a
patient has been free of recurrent disease for 6 months since starting chemotherapy
(PFS>6), and they are reviewed in clinic in a further 3 months at which time recurrence is
detected, their PFS is 9. This means they are in the platinum sensitive group (only just), but
their disease recurrence may have been apparent before this if the patient came to the clinic
sooner and reported symptoms, and/or blood tests had been done sooner, which would
have put them into the platinum resistant group.
It may be that if a newly diagnosed patient has high levels of ICL repair (above 20%) this
could be used to predict inherent resistance to carboplatin chemotherapy. However there
would still be a few patients that would not be identified as platinum resistant using this
method. Measuring ICL repair could be used in conjunction with other methods currently
being developed to determine outcome to platinum chemotherapy e.g. microarray
profiling. If outcome to platinum chemotherapy can be pre-determined, it would prevent
unnecessary treatment and serious side effects for some patients.
In the post-chemotherapy group patient 35, 37, 44, and 47 have low percent repairs at 24
hours of -4%, 6%, -28%, and -35% respectively. This is in comparison to the mean for this
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group of 45%. The clinical data for these patients will now be compared to see if there are
any correlations. Patient 44 has a PFS >8 which means that this patient has no evidence of
disease recurrence at this time, and is therefore likely to fit into the platinum sensitive
group. This is consistent with this patients’ low levels of ICL repair. Patient 47 has a PFI
of 16 months, and a PFS >6 months which means that this patient is in the platinum
sensitive group (their PFI is 16 and therefore >6 months). This is also consistent with low
levels of ICL repair in the ovarian cancer cells.
Of the remaining ten treated patients, the majority of them have a high level of repair
which is consistent with their PFI of <6, as they are clinically resistant to platinum
chemotherapy. There are four patients (1B, 27B, 28, 38B), who all have high PFS, which
correlates with clinical sensitivity to platinum chemotherapy, but have all got high levels of
ICL repair. However, on closer inspection, two of these patients (patients 27B and 28)
have levels of ICL repair less than 50%. This could mean that the cut-off for the prediction
of resistance to platinum chemotherapy could be an ICL repair level above 50% at 24
hours.
Overall what is striking is the marked difference in ICL repair in the six paired patient
samples taken before and after chemotherapy (figure 29). Initially all six patients have very
little capacity for repair of ICLs, but after undergoing chemotherapy the cells were able to
repair ICLs. Some of these samples (patients 1, 27, and 38) taken after chemotherapy were
after as little as three doses as they were taken at interval debulking surgery. One possible
explanation is that these tumour cells aquired this ability within a short time, but a more
plausible explanation is that platinm-based chemotherapy killed the sensitive cells, and so
those that were left behind were resistant. When ovarian cancer cells were taken at interval
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debulking surgery these resistant populations of cells were taken and shown to be resistant
at the cellular level by repair of ICLs. There are probably other mechanisms present within
these cells that also confer resistance as resistance is likely to be multifactorial.
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3.4 Human ovarian cancer cell lines treated in vitro with melphalan
3.4.1 Measurement of ICL formation and repair in paired human ovarian cancer cell
lines treated with melphalan using the comet assay
Having established the formation and repair of ICLs produced by cisplatin chemotherapy
in resistant patients with ovarian cancer, other crosslinking agents were investigated for
cross-resistance, to see if increased repair of ICLs was relevant to other crosslinking
agents, such as melphalan. The A2780 and A2780cisR paired human ovarian cancer cell
line was used initially as the in vitro model.
A2780cisR resistance to melphalan chemotherapy was demonstrated using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. The IC50 is the
concentration of the drug that causes 50% cell death. MTT assays to determine the
cisplatin IC50 for the A2780 and A2780cisR cell lines following 1 hour exposure to
melphalan were performed (figure 30a).
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Figure 30a: Percentage cell survival of A2780 and A2780cisR cell lines after treatment
with melphalan, as measured by the MTT assay (A2780 n=2, A2780cisR n=3, standard
deviation bars are shown) (unpublished data H.Lowe 2006).
The melphalan IC50 for A2780 cell line was 26M, and for the A2780cisR cell line was
100M, which resulted in a 4-fold difference between their sensitivities to melphalan.
Melphalan is another chemotherapy agent that causes formation of ICLs. There is very
little known about the formation and repair of melphalan induced crosslinks in ovarian
cancer cells obtained from patients.
A2780 and A2780cisR ovarian cancer cells were incubated with melphalan for 1 hour
(similar to cisplatin), and the cells analysed after varying amounts of time to establish the
peak of ICL formation. The peak of ICL formation was found to be at 16 hours post
melphalan incubation. Therefore the time points used in this experiment were 16 hours,
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and 40 hours which is 24 hours after the peak of ICL formation to investigate the level of
ICL repair.
The concentration of melphalan that gave 50% decrease in tail moment at the peak of ICL
formation was also investigated. Too high a concentration would kill the cells, and too low
a concentration of melphalan would result in not enough ICL formatio to enable
measurement. The optimum concentration of melphalan was found to be 50µM.
Figure 31: A time course over 40 hours to show the change in percent decrease in tail
moment over time in A2780 and A2780cisR cell lines after treatment with melphalan (n=3,
standard error bars are shown)
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The level of ICL formation as measured by the percent decrease in tail moment at 16 hours
for the A2780 and A2780cisR cell lines are similar at 40%1 and 46%0, respectively
(figure 31). There was no significant difference in these values using students paired t-test
(p<0.40). The peak of ICL formation is very similar in both cell lines, suggesting similar
amounts of melphalan reaches the DNA in both cell lines, to produce similar levels of
DNA damage in the form of ICLs.
After 24 hours the percent decrease in tail moment in the A2780cisR cell line decreases to
10%18, while the A2780 cell line maintains a level of 42%7. This was not significantly
different using students paired t-test p<0.10, because significance is usually taken if
p<0.05. The lack of statistical significance was probably because the sample size was too
small. This illustrates the persistence of ICLs in the A2780 cell line, and the unhooking (or
repair) of ICLs in the A2780cisR cell line over 40 hours.
3.5 Clinical ovarian cancer tissue treated ex vivo with melphalan
3.5.1 Measurement of ICL formation and repair in ovarian cancer cells obtained
from patient ascites and solid tumour when treated with melphalan ex vivo.
As the peak of ICL formation was confirmed to be 16 hours in A2780 and A2780cisR cell
lines, this time point was used in the clinical samples. ICL formation and repair were
measured in clinical samples at 16 hours and 40 hours following a 1 hour treatment of
50µM of melphalan.
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Figure 32: Percent decrease in tail moment at 16 hours in pre- and post-chemotherapy
patients treated ex vivo with 50M melphalan.
In 12 pre-chemotherapy patients the average percent decrease in tail moment at 16 hours
was 49% 12, and for 7 post-chemotherapy patients was 45% 8 (figure 32 and figure 33).
These values are statistically similar, using students paired t-test (p<0.65), which suggests
there is no difference in the level of ICL formation at 16 hours in these two groups of cells.
Page 163
Pre-chemo Post-chemo
20
40
60
80
49 44
N=12 N=7
%
de
cr
ea
se
in
ta
il
m
om
en
t
Figure 33: Percent decrease in tail moment at 16 hours in pre- and post-chemotherapy
patients treated ex vivo with 50M melphalan. Horizontal bars indicate mean of each
group.
In the pre-chemotherapy patient group, samples ranged from 30-64% decrease in tail
moment, with the majority between 44-64% decrease in tail moment. The post
chemotherapy group of patients had a similarly narrow range of results between 38-58%
decrease in tail moment (figure 33). There was no significant difference in these values
using students paired t-test (p<0.40). The similar levels of ICL formation present in both
these patient groups illustrates that similar amounts of melphalan reaches the DNA of the
cells to produce similar levels of ICLs.
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After the peak of ICL formation had been established, the percent repair was measured at
40 hours (figure 34 and 35).
Figure 34: Percent repair at 40 hours in pre- and post-chemotherapy patients treated with
melphalan.
Figure 34 and 35 show the percent repair at 40 hours in both patient populations. In
general, both pre- and post-chemotherapy patients have low levels of melphalan ICL
repair. The mean was 4% 28 and 3% 26 for the pre- and post-chemotherapy patients
respectively, which is very similar. There was no significant difference in these values
using students paired t-test (p<0.40)
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Figure 35: percent repair at 40 hours in pre- and post-chemotherapy patients treated with
melphalan. Horizontal lines indicate mean of each group.
In some pre-chemotherapy patients the number of ICLs present actually increased at 40
hours, which is why the percent repair figure is negative. This occurred in twelve patient
samples, both before and after chemotherapy. Overall both groups of patients show very
little repair of the ICLs at 40 hours. There are, however exceptions to this in both groups,
which can be seen from the distribution in figure 35. Patient 39, and 45, who are from the
pre-chemotherapy group, repair 60% and 33% of the ICLs that are present, respectively,
whilst the mean for this group is -4%. Patients 27B and 47 from the post-chemotherapy
group, repair 22% and 54% of their ICLs respectively, whilst the mean for this group is
3%.
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Interestingly, patients 39 and 45 have high levels of melphalan ICL repair – 60% and 33%,
respectively (figure 34), but they have very low levels of cisplatin ICL repair – 4% and
6%, respectively (figure 27). This supports the theory that differect mechanisms of ICL
repair exist.
There are two patients in which, a sample was obtained before and after they had received
platinum-based chemotherapy from the data set in fugure 23 and 24. These patients are
numbers 38 (and 38B) and 41 (and 41B). Their percent decrease in tail moment at 16 hours
is 55% and 64% for patients 38 and 41, respectively, and their percent repair at 40 hours is
-16% and 4%, respectively. Both these samples from pateints post-chemotherapy show
very little repair of the ICLs after 40 hours.
Melphalan is not currently given to patients with ovarian cancer. As melphalan and
cisplatin both cause ICLs (which is their main cytotoxic lesion), it was hypothesised that
patients that are clinically sensitive to platinum chemotherapy (and therefore do not repair
cisplatin induced ICLs), would also be clinically sensitive to melphalan if the drug was
given to them, and therefore not repair the ICLs induced by melphalan. It is also
hypothesised that the reverse would also be true, i.e. those patients that are clinically
resistant to platinum chemotherapy, would also be clinically resistant to melphalan, and
therefore repair ICLs induced by either cisplatin or melphalan. However, our data suggest
that this hypothesis is wrong (figure 34 and 35).
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Figure 36: Percent repair in post-chemotherapy patients after treatment ex vivo with either
cisplatin or melphalan
Post-chemotherapy patient ascites samples have been treated ex vivo with either 100M
cisplatin, or 50M melphalan, and the percent repair has been measured at 24 hours for
cisplatin, and 40 hours for melphalan (figure 36). There are high levels of repair in the cells
treated ex vivo with cisplatin ranging from 28% to 77% repair with a mean of 55%±25.
However, ICL repair in the same cells after treatment ex vivo with melphalan is much
lower (mean 2 18). This is statistically significant using students paired t-test (p<0.05).
This means that not only is the ICL repair mechanism different in cells treated ex vivo with
cisplatin or melphalan, but that these cells may be sensitive to melphalan chemotherapy.
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This has implications for the clinical setting and suggests that melphalan could be used to
treat these patients.
3.5.2 Discussion
The results from the MTT assay found the A2780cisR human cancer cell line had a 4-fold
increase in resistance to melphalan compared to the A2780 human cancer cell line (figure
30a). This demonstrates that there is cross resistance of the A2780cisR cell line to
melphalan as well as cisplatin.
In figure 31 the A2780 and A2780cisR cell lines have a very similar percent decrease in
tail moment at 16 hours after incubation with melphalan, indicating they have similar
levels of ICL formation. However at 40 hours (24 hours after the peak of ICL formation),
the A2780 cell lines show little evidence of repair, while the A2780cisR cell lines repair
(unhook) the ICLs, indicating resistance to melphalan. This has not been shown before.
Roy et al (2000) used A2780 and A2780 (100) human ovarian cancer cells that were
selected by exposure to high levels of the nitrogen mustard chlorambucil. They
demonstrated a 5 to 10-fold increase in resistance to nitrogen mustards with A2780(100)
compared to A2780 ovarian cancer cell lines. However Roy et al showed that there was no
difference in the level of DNA repair proteins found in these cells, but instead, the
increased resistance of the A2780(100) cell line was due to the 4 to 8-fold increase of anti-
apoptotic proteins such as Bcl-XL and Mcl-1 (Roy et al., 2000). This mechanism of
resistance appears to be different to the increase in ICL repair which was demonstrated in
the A2780cisR cell line in figure 31. However, the cell lines that were used in their
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experiments were different as the resistant lines had been selected using chlorambucil
instead of cisplatin.
The results found in the A2780 and A2780cisR cell lines after incubation with melphalan,
are very similar to that obtained when the same cell lines were incubated with cisplatin. It
appears the A2780cisR cell line repairs the crosslinks produced by both cisplatin and
melphalan, suggesting there is cross-resistance between the two drugs. However, resistant
mechanisms to melphalan in vitro can differ from cisplatin e.g drug transport, drug efflux,
or detoxification mechanisms using glutathione (Ozols et al., 1992).
Ovarian cancer cells obtained before and after chemotherapy, and then incubated with
melphalan show similar levels of ICL formation (figure 32). This implies that cellular
metabolism of melphalan, influx/efflux, and other ‘upstream’ mechanisms do not play
important roles in the potential resistance to melphalan in the clinical setting. This suggests
that the same concentration of melphalan interacts with the DNA as the same levels of ICL
formation are produced. It also shows that melphalan, like cisplatin, can cause ICL
formation in these cells.
Overall, newly diagnosed, and treated patients show very little repair of melphalan induced
ICLs (figure 34). This implies that these cells are not resistant to melphalan through an
increase in ICL repair. The levels of ICLs that are produced by melphalan appear to be
maintained in the cells over 40 hours, and as these are the main cytotoxic lesions, it follows
that these cells should be sensitive to melphalan. These data also imply that most of the
ovarian cancer cells obtained from newly diagnosed patients are not intrinsically resistant
to melphalan chemotherapy.
Page 170
Ovarian cancer cells from post-chemotherapy patients had very different levels of ICL
repair following melphalan or cisplatin exposure. Those cells incubated ex vivo with
melphalan demonstrated very little repair, while those incubated ex vivo with cisplatin had
high levels of repair. This suggests that ovarian cancer cells obtained from post-
chemotherapy patients should be resistant to cisplatin, but sensitive to melphalan
chemotherapy, which could have implications in clinical practice.
There are a few patients that do not fit the overall trend of low levels of ICL repair after
treatment ex vivo with melphalan, as they actually show high levels of ICL repair at 40
hours. These are newly diagnosed patients 39 and 45, and treated patients 27B and 47.
Patients 27B and 47 both have high levels of melphalan induced ICL repair, but have low
levels of repair of cisplatin-induced ICLs (compared to their treated patient group) which
supports the possibility of two distinct mechanisms to repair (unhook) cisplatin and
melphalan induced ICLs. As for patient 39, patient 45 can repair ICLs induced by
melphalan, but not ICLs induced by cisplatin. Both these patients again support the
hypothesis that the repair (or unhooking) of ICLs differs depending on the drug that caused
their formation. However there are lots of other possible resistance mechanisms, and the
comet assay just looks at one aspect, which is repair of ICLs. So it is still possible these
patients could be resistant to melphalan, but via a different mechanism(s). These
mechanisms (if they exist) are unlikely to include drug influx/efflux or other drug
detoxification mechanisms because there are the same levels of ICLs present at 16 hours in
newly diagnosed and treated patients, suggesting that the same concentration of melphalan
encounters the DNA to produce ICLs.
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There are also conflicting reports of patients’ response to melphalan in the clinical trial
setting. There have been two trials, one by Magagnoli et al., (2004), and the other by
Hasan et al., (2003) that have given melphalan to platinum resistant patients with
advanced disease (FIGO stages III-IV). Magagnoli et al., (2004) gave double intermediate-
dose melphalan (100mg/m2) supported by autologous stem cells in 14 patients with
refractory ovarian cancer and poor performance status, and Hasan et al., (2003) gave 10mg
of oral melphalan once a day for 5 days every 6 weeks for 6 cycles in patients with
platinum-resistant relapsed ovarian cancer. These studies report conflicting data. The
regimen by Magagnoli et al., (2004) was well tolerated, and converted one patient from
partial remission (PR) to complete remission (CR). Another four patients had disease
stabilisation, while nine patients with progressive disease (PD) showed a partial response.
Interestingly all patients had a marked improvement in their performance status. The
retrospective study by Hasan et al (2003) showed melphalan was well tolerated, but there
were no responses in these 22 patients. Melphalan had no impact on progression-free
survival or overall survival.
In the analysis undertaken by Hasan et al (2003), it is unclear why nearly all of the patients
did not continue the treatment. This may have a major impact on the poor responses that
were seen. Also, each trial had a different dosage regimen of melphalan, which could have
a major impact on patient response. It appears from the trial by Magagnoli et al (2004),
that high dose melphalan could be used in the clinical setting once it has undergone further
evaluation. This is supported by data in figure 36 in which clinically platinum resistant
patients that repair their ICLs after treatment ex vivo with cisplatin, do not appear to repair
the ICLs caused by treating ovarian cancer cells from the same patient with ex vivo
melphalan.
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3.6 Gene expression Studies
3.6.1 Comparison of gene expression between newly diagnosed and treated patients,
and between A2780 and A2780cisR human ovarian cancer cell lines, using
microarrays
It has been demonstrated that most ovarian cancer cells obtained from post-chemotherapy
patients repaired cisplatin-induced ICLs, more efficiently than the ovarian cancer cells
from pre-chemotherapy patients. The gene expression profiles for each patient population
were investigated to determine if specific differences in gene expression could account for
this difference in their phenotypes. It is also evident that A2780cisR cells repair cisplatin-
induced ICLs which may play an important role in their resistance to platinum
chemotherapy, whereas A2780 cells do not repair cisplatin-induced ICLs. Gene expression
profiles were also investigated in the A2780 and A2780cisR paired human ovarian cancer
cell line to determine if differences in gene expression could account for their difference in
ICL repair.
The Microarray technology used oligonucleotide arrays to analyse 30,000 genes (from the
human genome) from a single sample, and was used to compare gene expression between
pre- and post-chemotherapy patients. A single microarray chip contains thousands of
single-stranded oligonucleotide sequences that are complementary to target sequences,
which are bound onto a glass support about the size of a microscope slide. Fluorescent
dyes were used to label the mRNAs from the cell sample to be analysed, and hybridised
with the oligonucleotide array. The array was then washed to remove any non-specific
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hybrids. A laser then excites the attached fluorescent dyes to produce light which is
detected by a (confocal) scanner which generates a digital image. The digital image is
further processed by specialized software to transform the image of each spot to a
numerical reading. This process is performed, first, finding the specific location and shape
of each spot, followed by the integration (summation) of intensities inside the defined spot,
and, finally, estimating the surrounding background noise. Background noise generally is
subtracted from the integrated signal. This final reading is an integer value assumed to be
proportional to the concentration of the target sequence in the sample to which the probe in
the spot is directed (Trevino et al., 2007). A statistical test is used to assess each gene to
determine whether the expression is statistically different between the two groups of
samples.
The microarray data was analysed by Stephen Henderson at the Wolfson Institute for
biomedical research, University College London using the following protocol:
Data analysis was carried out using the R statistical environment and programming
language (Venables et al., 2002) and packages from the Bioconductor open source
bioinformatics project (Gentleman et al., 2004). The affymetrix package and specifically
the 'rma' algorithm for pre-processing (background correction), normalisation and
calculation of expression values were used (Irizarry et al., 2003). To determine differential
expression between groups of genes in pre-chemotherapy and post-chemotherapy patient
samples, the ‘limma’ package was used. This method is a simple extension of standard
linear models that uses a moderated estimate of the standard deviation modeled on the
overall mean-variance characteristics of the data (Smyth et al., 2004). In essence a
moderated t-test for paired data was used.
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The first step to produce a sample for microarray analysis is to extract good quality total
RNA from ovarian cancer cells from patient samples. It was very difficult to establish an
effective protocol to extract good quality total RNA in the clinical setting. It was found
that ovarian solid tumour tissue needed to be frozen in liquid nitrogen within 5 minutes of
being removed from the patient otherwise all the RNA would degrade and become
unusable. This meant that a flask of liquid nitrogen was taken into the theatre at the start of
the operation, in readiness for the surgeon to remove the ovarian tissue. However, this
meant that patients 1, 1B, and 2 had no usable total RNA extracted from the solid tumour
samples, as it was unknown at this stage how important it was to freeze the samples in
liquid nitrogen within 5 minutes. It was easier to extract total RNA from ovarian cancer
cells from ascites, as it was less likely the RNA would degrade, because the cells were
cultured and grown in the laboratory.
Altogether 17 patients had good quality total RNA extracted from samples as determined
by gel electrophoresis (figure 37), and by analysis of nucleic acid content using the
nanodrop machine where only samples with a ratio of 1.8-2.05 were used. Of these 17
patient samples, 4 patients had paired samples (taken before and after chemotherapy), and
1 patient had both ascites and solid tumour microarray samples.
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Pt 33 pt 37 pt 41
Figure 37: A typical gel produced after gel electrophoresis on total RNA extracted from 3
patients. All these samples are extracted from ascites.
Microarray experiments were conducted using patients numbered 21, 24, 25, and 26 but
the quality of these results were very poor, because the fragmented cRNA had degraded.
Therefore these results are not included. In total there are 12 samples from patients before
chemotherapy, 6 from patients after chemotherapy. Of these samples 4 patients had a
sample taken before and after chemotherapy (paired samples).
Heat map 1 (figure 38) shows the difference in gene expression in pre- and post-
chemotherapy samples taken from the same patient, in 4 patients. The gene expression in
samples from post-chemotherapy patients, are used as a baseline to which gene expression
from pre-chemotherapy patients are compared. This subset of patients is shown separately,
Page 176
as within this group of patients are statistically significant different levels of gene
expression. The red colour denotes an increase in gene expression and blue denotes a
decrease in gene expression. White means there is not a decrease or an increase in gene
expression. The letter B indicates a post-chemotherapy sample, and 1 or 2 denotes repeated
microarray experiment using the same sample, but processed independently. Figure 39 and
40 show the names of the differentially expressed genes found, and the statistical analysis.
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Figure 38: Heat map 1 shows the difference in gene expression in 4 paired patient ascites
samples. Gene abbreviations are shown down the right hand side, and patient sample
numbers are across the top (asc. is ascites, pt is patient)
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Genes upregulated in post-chemotherapy samples:
symbol Gene name M
value
A value t value p value
TRAF3IP1 TNF receptor-associated
factor 3 interacting protein
1
-0.3219 3.7635 -4.0572 0.0017491
PTAR1 Protein prenyltransferase
alpha subunit repeat
containing 1
-0.4798 3.4530 -4.2153 0.0013298
AT4G28910 N/A -0.9991 3.6493 -4.4545 0.0008833
STK38L Serine/threonine kinase like -1.0745 6.6846 -4.6433 0.0006430
NDUFS5 NADH dehydrogenase
(ubiquinone) Fe-S protein 5
-0.4683 11.0169 -3.9615 0.0020678
DNAJB4 DnaJ (heat shock protein 4)
homolog, subfamily B,
member 4
-1.0322 6.4489 -4.8552 0.0004529
SGEF Src homology 3 domain-
containing guanine
nucleotide exchange factor
-0.8252 3.903 -5.966 0.0000798
GSPT1 G1 to S phase transition 1 -0.5990 3.0582 -4.3073 0.0011351
CDK6 Cyclin dependent kinase 6 -0.7719 8.3511 -4.7224 0.0005636
MRPS22 Mitochondrial ribosomal
protein s22
-0.5480 4.8587 -3.8699 0.0024293
PGK1 Phosphoglycerate kinase -0.6810 3.4497 -4.4319 0.0009180
LOC440900 N/A -0.4331 3.4623 -4.3742 0.0010126
SCAMP1 Secretory carrier membrane
protein 1
-0.5792 6.6094 -4.7199 0.0005661
LOC492311 N/A -1.0677 4.7226 -4.1283 0.0015457
ARHGAP5 Rho GTPase activating
protein 5
-0.9813 4.521 -5.976 0.0000787
TRIM62 Tripartite motif-containing
62
0.4888 5.5970 -4.2370 0.0012810
GUCY1B3 Guanylate cyclase 1,
soluble, beta 3
-0.3951 3.2064 -4.3878 0.0009893
KPNB1 Karyopherin (importin)
beta 1
-0.5415 7.7464 -4.3336 0.0010853
MICAL3 Microtubule associated
monoxygenase, calponin
and LIM domain containing
3
-0.4041 3.8238 -4.0189 0.0018701
Figure 39: Statistical analysis of the genes shown in heat map 1 (figure 38), that are
upregulated in post-chemotherapy samples. M is the log difference between the two
groups. A is the average expression. A t value an estimation of a coefficient, the t-statistic
for that coefficient is the ratio of the coefficient to its standard error. That can be tested
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against a t distribution to determine how probable it is that the true value of the coefficient
is really zero.
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Genes down-regulated in post-chemotherapy samples:
symbol Gene name M
value
A value t value p value
ILKAP Integrin –linked kinase-
associated serine-threonine
phosphatase 2C
0.2912 2.7734 3.9893 0.0019694
TMEM5 Transmembrane protein 5 0.8255 9.1113 4.3747 0.0010118
LACTB2 Lactamase beta 2 0.9287 7.2117 4.0665 0.0017212
SSU72 RNA polymerase II CTD
phosphatase homolog
(yeast)
0.4407 4.4793 3.8891 0.0023485
SAP30 Sin-3-associated
polypeptide, 30kDa
1.1544 6.9173 4.2875 0.0011745
CTBP2 C-terminal binding protein
2
0.4470 9.4976 4.4742 0.0008544
PLSCR1 Phospholipid scramblase 1 0.6761 8.1481 4.6702 0.0006149
RNF135 Ring finger protein 135 0.6891 7.9558 3.9057 0.0022807
RPS6KA5 Ribosomal protein s6
kinase
0.5550 3.7897 3.9339 0.0021704
RP11 Retinitis pigmentosa 11 0.5101 6.8815 5.161 0.0002758
C17orf76 Chromosome 17 open
reading frame 45
0.5128 3.7123 3.8603 0.0024709
RPL4 Mitogen-activated protein
kinase 13/ ribosomal
protein 4
0.8080 9.127 5.638 0.0001308
TOMM22 Translocase of outer
mitochondrial membrane
22 homolog (yeast)
0.6196 6.3192 3.9544 0.0020937
KIAA1026 Kazrin 0.6559 7.7342 3.9396 0.0021490
CDV3 CDV3 homolog (mouse) 0.8663 9.2605 4.1380 0.0015200
UBE3C Ubiquitin protein ligase
E3C
0.2892 2.6860 4.0613 0.0017368
Figure 40: Statistical analysis of the genes shown in heat map 1 (figure 38), that are
downregulated in post-chemotherapy samples. M is the log difference between the two
groups. A is the average expression. T-value is an estimation of a coefficient, the t-statistic
for that coefficient is the ratio of the coefficient to its standard error. That can be tested
against a t distribution to determine how probable it is that the true value of the coefficient
is really zero.
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Heat map 1 is divided into two with the top half indicating genes that are overexpressed in
post-chemotherapy samples, and the bottom half indicates genes that are underexpressed in
post-chemotherapy samples.
Genes that are most upregulated in the post-chemotherapy samples (i.e show a more
negative M value in figure 39, and show a darker red colur in the heat map) include
STK38L (Serine/threonine kinase like), DNAJB4 (DnaJ (heat shock protein 4) homolog,
subfamily B, member 4), SGEF (Src homology 3 domain-containing guanine nucleotide
exchange factor), CDK6 (cyclin-dependent kinase 6), and ARHGAP5 (Rho GTPase
activating protein 5). The probe sites for these genes are blue/white for low expression in
the pre-chemotherapy samples and red for over expression in the post chemotherapy
samples (the darker the colours, the greater the difference in gene expression). The colours
alternate from blue/white to red as the heat map is read from left to right as the pre-
chemotherapy sample is next to its corresponding post-chemotherapy sample taken from
the same patient. These genes are clearly consistently expressed at a higher level in the
post-chemotherapy samples as the colours on the heatmap demonstrate.
Genes that are most down regulated in post-chemotherapy samples (i.e show a more +ve M
value in figure 40, and a darker blue colour on the heatmap) include LACTB2 (Lactamase
beta 2), SAP30 (Sin-3-associated polypeptide, 30kDa), and RNF135 (Ring finger protein
135). The probe sites for these genes are red/white for high expression in the pre-
chemotherapy samples, and blue for low expression in the post-chemotherapy samples.
These genes are clearly consistently expressed at a lower level in the post-chemotherapy
samples as the colours on the heatmap demonstrate. However, it should be noted that
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patient 33 ascites tumour (pt 33 asc.tu), and its corresponding post-chemotherapy sample
(pt 33 asc.tu b) have overall lighter colours on heatmap 1. This means the genes are not as
highly or lowly expressed compared to other patient samples e,g patient 41. However, the
results still fit into the overall pattern of gene expression.
Comparing gene expression levels between all pre- and post-chemotherapy patient samples
yielded results that were not statistically significant, and could have occurred by chance.
Instead, the panel of differentially expressed genes that were identified in the paired patient
data set were looked at, to see if the same genes were up- or down regulated in these
samples also. The gene expression profiles in ovarian cancer cells from post-chemotherapy
patients were used as a baseline (samples; pt 06 asc. tu., pt 37 asc. tu., pt 33B asc. tu, pt
17B asc. tu., pt 27B asc.tu, pt 41B asc. tu.) to which the gene expression of pre-
chemotherapy patients, were compared (figure 41). The red colour denotes an increase in
gene expression and blue denotes a decrease in gene expression. White means there is not a
decrease or an increase in gene expression.
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Figure 41: heat map 2 shows the gene expression profiles of cell lines, and all patient samples. Gene
abbreviations are shown down the right hand side, and patient sample numbers are across the top (asc.tu is a
sample from ascites, s.tu is a sample from solid tumour)
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Heat map 2 (figure 41) shows the difference in gene expression in 14 patient samples.
There are 6 patients that have post-chemotherapy samples, and they are numbers 6 and 37,
as well as patients 17, 27, 33, and 41 that have paired samples (taken before and after
chemotherapy). All the others are pre-chemotherapy samples (patient numbers 1, 3, 4, 10,
12, 16, 18 as well as patients 17, 27, 33 and 41 that have paired samples taken before and
after chemotherapy). Most these samples are from ascites, but patient 3, 4, 12, and 16 are
all from pre-chemotherapy solid ovarian tumour.
In heatmap 2 there are only 2 post-chemotherapy samples (patient 6 ascites tumour, and
patient 37 ascites tumour), apart from the paired patient samples. This makes it difficult to
make comparisons between the two groups of samples. Also some of the samples contain
solid tumour as well as ascites, which can have an impact on the levels of gene expression
because variations occur between tissue types.
The top part of heatmap 2 from gene SSU72 down to TRIM62 demonstrate lower gene
expression levels of these genes in the post-chemotherapy paired patient samples (on the
left hand side). This is demonstrated by the darker blue colour in these probe sites. It would
be expected, therefore that pre-chemotherapy patient samples would have slightly higher
levels of these genes expressed. The right hand side contain mainly pre-chemotherapy
samples, and these probe sites are mainly red indicating that genes SSU72 to TRIM62 are
indeed expressed at a higher level in these samples.
The bottom part of heatmap 2 from gene CDK6 downwards demonstrate higher gene
expression levels of these genes in the post-chemotherapy paired patient samples (on the
left hand side). This is demonstrated by the darker red colour in these probe sites. It would
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be expected, therefore that pre-chemotherapy patient samples would have slightly lower
levels of expression of these genes. This is demonstrated by the mainly blue colours of the
pre-chemotherapy sample probe sites on the right hand side.
The two post-chemotherapy samples (pt 6 asc.tu, and pt 37 asc.tu) that are within the pre-
chemotherapy samples on the right hand side do not appear to stand out according to their
levels of gene expression. Patient 37 overall has very low levels of gene expression, and
only a few genes from the gene expression profile of patient 6 appear to fit the pattern.
These include genes GUCY1B3, and KIAA1026 which are down regulated, and gene
MRPS22 (Mitochondrial ribosomal protein s22) which is up-regulated in the post-
chemotherapy patient 6 sample, and appears to fit with the pattern. However, although the
trend of gene expression seems consistent in these data set compared to the paired patient
data set, the results are not statistically significant.
3.6.2 Relative levels of gene expression in ovarian cancer cells from newly diagnosed
and treated patients using real-time polymerase chain reaction
ERCC1 and GAPDH (internal control) were investigated using real time PCR. ERCC1 was
used because this gene is known to be involved in repair of cisplatin damage and in ICL
repair. An increase in ERCC1 gene expression in post chemotherapy patients could
therefore contribute to their increase in ICL repair. The primers for ERCC1 had already
been optimised, but further experiments were carried out to ensure the primers had very
similar relative binding efficiencies compared to the internal control primer (GAPDH).
This meant that both primers bound their respective sequences of DNA at the same rate.
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Therefore if differences in gene expression were detected, it would not be due to a higer
efficiciency of one primer set.
The experiment was set up according to the template for the standard curve (see method).
This meant that RT-PCR with each primer set was performed on serial dilutions of cDNA.
Once the experiment was complete, the cycle threshold (Ct) values were arbitrarily set by
hand in the region of exponential flouresence on the amplification plot (for both GAPDH
and ERCC1), and the results were analysed at this given Ct value. The Ct values for the
primer (ERCC1) being investigated had to be the same as GAPDH to make it a direct
comparison. Flouresence values for GAPDH and ERCC1 were read at the given Ct value
and the results subtracted from one another. Results were then plotted and the slope of the
figure was calculated to give the relative primer efficiencies over a given cDNA starting
amount.
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Figure 42: shows the relative efficiency for ERCC1 primer compared to GAPDH.
The relative primer efficiency for ERCC1 compared to GAPDH is 0.0316, which is the
slope of the line in figure 42. This means this primer is optimised as the relative efficiency
is less than 0.1.
The Ct value for ERCC1 and GAPDH was 0.597. The experiment was then set up in
triplicate using the same cycling conditions as the standard curve experiment. The same Ct
value was used to analyse the data. The fluorescence of GAPDH was taken away from the
ERCC1 value and the results averaged for each patient sample.
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Figure 43: Relative gene expression levels of ERCC1 in pre- and post-chemotherapy
patient samples, using the pre-chemotherapy samples normalised to 1.
As can be seen from figure 43 there is an increase in ERCC1 gene expression in the post-
chemotherapy samples. The average increase is 14.4% +/-0.8%. This apparent difference
in gene expression may contribute to the increase in ICL repair seen in the post-
chemotherapy patient samples. Results obtained from microarray samples also showed a
small increase in ERCC1 expression in post-chemotherapy samples, but this was not
statistically significant, using students paired t-test (p<0.40).
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3.6.3 Discussion
The samples used to investigate gene expression using microarray analysis were taken
straight from the patient and either processed immediately (such as solid tumour samples),
or cultured in the lab (such as ovarian cancer cells extracted from ascites). The gene
expression levels measured are basal levels. The discussion relates to the different basal
levels of gene expression found between the two groups. In the comet assay, the data are
derived following cisplatin treatment. No attempt to measure changes in gene expression
following cisplatin treatment was made in this study.
Interestingly, none of the differentially expressed genes identified included apoptotic
regulators, ATP binding cassette transporters, metallothionein, and DNA repair
components, which have all been implicated in cisplatin resistance in cell model systems.
This was similar to a study by Hartmann et al (2002) where microarray analysis was
performed on solid ovarian cancers obtained from patients to predict early relapse after
treatment with carboplatin-paclitaxel. In a different study Hartmann et al showed genes
involved in inhibiting BRCA1, and other genes involved in activating nuclear factor κB 
were up-regulated (Hartmann et al., 2005). But there were other genes identified in our
experiments that were up or down regulated in pre-chemotherapy patients when compared
to post-chemotherapy patients.
Genes that are most upregulated in the post-chemotherapy samples (i.e show a –ve M
value) include unknown genes such as LOC492311, and AT4G28910. Other genes highly
upregulated in post-chemotherapy samples encode proteins involved in cell-cycling such as
ARHGAP5 (Rho GTPase activating protein 5), CDK6 (cyclin-dependent kinase 6), and
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GSTP1 (G1 to S phase transition 1). GUCY1B3 (Guanylate cyclase 1, soluble, beta 3) is
involved in cell signalling, and is also upregulated.
Rho GTPase activating protein 5 is part of the family of Rho GAPs (Rho GTPases
activating protein) that are key protein regulators of the various and numerous small
GTPases. Rho GAPs mediate a variety of receptor-transduced signals, and appear to play
an essential role in growth factor dependent GTPase regulation (Bernards et al., 2005).
Rho GAPs are also involved in cell-cycle progression (Settleman et al., 1992), but there
are no known link to DNA repair, and it is unclear whether its role in cell-cycle
progression could have an effect on resistance to chemotherapy as shown in cells from
post-chemotherapy patients.
CDK4/6 on binding to cyclin D begins the phosphorylation of retinoblastoma protein
(pRb) complexed to E2F/DP (transcription factor E2F with dimerisation partner).
Following pRb phosphorylation, cyclin E activates CDK2 (cyclin-dependent kinase 2) to
effect further phosphorylation of pRb, thereby enabling the cells to cross the G1 restriction
point (Sridhar et al., 2006). CDK6 is important in promoting cell gowth and division, and
therefore has oncogenic properties. Its upregulation in post-chemotherapy samples
indicates it may have a role in the cells resistance to chemotherapy by overcoming the cell
cycle checkpoints, and by promoting cell growth and division. This is a different
mechanism of resistnace to the increase in ICL repair seen in these cells. However, cellular
chemotherapy resistance is likely to be multifactorial.
Guanylyl cyclases are a family of enzymes that catalyze the conversion of GTP to cGMP.
Accumulation of cGMP regulates complex signaling cascades through immediate
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downstream effectors, including cGMP-dependent protein kinases, cGMP-regulated
phosphodiesterases, and cyclic nucleotide-gated ion channels (Lucas et al., 2000).
Guanylyl cyclases are regulated by peptide hormones, bacterial toxins, and free radicals, as
well as intracellular molecules, such as calcium and adenine nucleotides. It is unclear why
Guanylate cyclase 1 is upregulated in post-chemotherapy samples, and what relevance this
has to increase in ICL repair shown in these cells. However their involvement in diverse
signalling pathways could play a role in cellular communication of yet unknown relevance.
Genes that are most down-regulated in post-chemotherapy samples (i.e show a +ve value)
include ring finger protein 135, and SAP30 (Sin-3-associated polypeptide, 30kDa). SAP30
interacts with parts of the Sin3A corepressor complex which recruits histone deacetylases
and in many cases represses transcription (Viiri et al., 2006). The down-regulation of this
gene repressor could potentially result in the over-expression of other genes, such as those
involved in promoting chemotherapy resistance.
The protein encoded by Ring finger protein 135 (RNF 135) contains a RING finger domain
that is known to be involved in protein-protein, and protein-DNA interactions. This gene is
located in a chromosomal region known to be frequently deleted in patients with
neurofibromatosis (Douglas et al., 2007). It is thought that mutations within RNF135 can
promote human growth, as well as give rise to dysmorphic features, and learning disability
which is characteristic of this syndrome (Douglas et al., 2007). It is unclear what
involvement in the promotion of growth this protein has, and future developements are
awaited.
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This type of microarray analysis is used to determine levels of gene expression, by
measurement of mRNA levels. However post-transcriptional and post-translational
modifications of mRNA and proteins are not accounted for and therefore different
techniques need to be used to investigate these modifications. These modifications can
have a profound impact on the functions of the cell, as a small increase in gene expression
may have a greatly amplified affect caused by post-transcriptional and post-translational
modifications. The reverse is also true that a large increase in gene expression may have
only limited affects on the cell due to these modifications to mRNA and proteins. This
could contribute to why there are no clear differences in DNA repair gene expression in the
post-chemotherapy patients. It is therefore appropriate to investigate differences in gene
expression at the protein level.
It is also unclear what impact treatment of patient samples with cisplatin ex vivo would
have on the relative levels of gene expression in pre and post-chemotherapy patients. This
may have had a profound impact on the results obtained from microarray analysis, and will
be the subject of future research.
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4. DISCUSSION
The results presented demonstrate that ICL repair may play an important role in the
resistance of both the A2780cisR cell lines and in 14 treated patients to cisplatin
chemotherapy. Interestingly this was demonstrated in both primary ovarian solid tumour,
and ovarian cancer cells obtained from ascites, suggesting they have similar cellular
pathways that process cisplatin and its adducts.
However, it should be noted that measurement of % decrease in tail moment is really a
measurement of ‘unhooking’ of one arm of the ICL that releases the linkage of the two
DNA strands. Unhooking is the first step in the repair of ICLs, and is also thought to be the
rate limiting step of this complex process (McHugh et al., 2001). The comet assay
measures unhooking, but does not provide information on the completion of repair and the
resulting restoration of integrity of both DNA strands of the double helix.
Although ovarian cancer cells from treated patients (post-chemotherapy) are not
necessarily the same as resistant patients, they behave similarly to the A2780cisR ovarian
cancer cells as they both repair ICLs after treatment with cisplatin. However, this does not
appear to be true when the cells are treated with melphalan, another crosslinking agent.
The A2780cisR cell line appears to repair the crosslinks produced by melphalan, but the
post-chemotherapy patients do not appear to repair the ICLs after exposure to melphalan ex
vivo. This means caution should be used when examining the responses of this cell line as
it may not correspond completely to the clinical situation. However, cell lines are still a
valuable tool, because obtaining good quality ovarian cancer cells from patients is both
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time consuming and difficult, and cell lines may help to guide experimentation in the
clinical setting.
4.1 Cisplatin-induced ICL repair in human ovarian cancer cell lines
A possible mechanism of enhanced ability to repair ICLs by the A2780cisR cell line
involves ERCC1 (excision repair cross-complementation group 1), part of the nucleotide
excision repair (NER) pathway (Yan et al., 2006) which is one of the major repair
pathways and also part of the mechanism of repair of ICLs. ERCC1-XPF plays a role in
DNA damage recognition and makes the initial cut in the DNA strand 5’ (Sancar et al.,
1996), which is termed unhooking of the ICL, and is thought to be the rate limiting step
(Mu et al., 1995). In support of this, cells defective in ERCC1 are very sensitive to ICL
agents, such as nitrogen mustards (De Silva et al., 2000), and cisplatin (De Silva et al.,
2002). It is thought that NER, as well as homologous rembination (HR) are involved in the
repair of cisplatin ICLs, although the role of ERCC1 is thought to be mainly unhooking of
ICLs and not part of the recombinational components of cross-link repair (De Silva et al.,
2000).
The importance of ERCC1 is demonstrated by Li et al who demonstrated a six-fold
increase in the mRNA levels of ERCC1 in A2780/CP70 cells after treatment with cisplatin.
The A2780cisR cell lines that were used in our experiments were A2780/CP8, and
therefore are different to the A2780/CP70 cell lines mentioned here. The A280/CP70 cell
lines were made resistant to cisplatin by exposure to higher concentrations of cisplatin.
However, there are still similarities in their behaviour. In in vitro studies, over-expression
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of ERCC1 is associated with a platinum-resistant phenotype in ovarian cancer cells (Parker
et al., 1991). Cisplatin hypersensitive, repair deficient cells have 30- to 50-fold lower
levels of ERCC1 compared to inherently resistant cells (Lee et al., 1993). Furthermore,
Interleukin (IL)-1α has been shown to increase cisplatin cytotoxicity in vitro in the
A2780/CP70 cell line by reduction of ERCC1 mRNA levels (Li et al., 1998). This has led
to a reduction in repair of ICLs, and further supports the role of ERCC1 in resistance of
A2780/CP70 cells to cisplatin (Li et al., 1998). XPA (xeroderma pigmentosum A) is also
important in NER and down-regulation of gene expression by antisense RNA transfection
can reduce DNA repair, and therefore reduce resistance of tumour cells to cisplatin (Wu et
al., 2003).
The MCAS cell line and the A2780/CP70 cell line are equally resistant to cisplatin,
although the MCAS cell line differs by an ERCC1 polymorphism at codon 118, which
markedly reduces induction of ERCC1 mRNA levels compared to A2780/CP70 cells (Yu
et al., 2000). The A2780/CP70 cell line repaired 50% more cisplatin-DNA adducts present
compared to the MCAS cell line, although these cells have less cisplatin-DNA adduct
formation present due to their increased cytosolic inactivation of the drug (Yu et al., 2000).
This mechanism may be a compensatory cellular response to the decreased ability to repair
the ICLs (Yu et al., 2000). Antisense ERCC1 RNA was used to sensitize the resistant
OVCAR10 human ovarian cancer cells to cisplatin in an ovarian cancer xenograft model
(Selvakumaran et al., 2003). These results suggest the importance of ERCC1 in cisplatin-
DNA adduct repair in A2780 cell lines as well as other human ovarian cancer cell lines.
ERCC1 appears to be regulated by genes such as AP-1 (activator protein 1) and MZF1
(myeloid zinc finger gene 1) (Li et al., 1998) located approx 410bp upstream from the
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ERCC1 gene (Yan et al., 2006). AP-1 is bound by c-fos and c-jun transcription factors,
which have a 4-fold increase in mRNA levels, and a 14-fold increase in c-jun
phosphorylation, in response to a 1-hour incubation with cisplatin in A2780/CP70 cells (Li
et al., 1998). This corresponds to increased binding of the AP-1 site (Li et al., 1998).
MZF1 encodes a transcription factor that functions as a transcription repressor of ERCC1,
as well as a repressor of the promoter of ERCC1 (AP-1) (Yan et al., 2006). Studies have
shown that cisplatin reverses this repression of ERCC1 by MZF1 in A2780/CP70 cells,
which could explain the mechanism of cisplatin resistance in these cells (Yan et al., 2006).
Inhibition of DNA repair by reduction of ERCC1 mRNA levels could potentially be used
in the clinical setting to combat resistance to cisplatin, if a suitable inhibitor was found.
Lactacystin is a selective inhibitor of the proteasome that can inhibit the ubiquitin pathway,
and was used at concentrations that do not appear harmful, to increase cisplatin
cytotoxicity in three resistant human ovarian carcinoma cell lines via inhibition of ERCC1
transcription (Li et al., 2001). Lactacystin also significantly enhanced DNA platination (Li
et al., 2001).
Ets-1 is a transcription factor which has been found to be important in resistance of a
human ovarian cancer cell line called C13 to cisplatin (Bergoglio et al., 2001). Ets-1 was
up-regulated in cisplatin-resistant C13 cells as compared with the sensitive 2008 cell line
and over-expression of this protein in 2008 cells led to a seven fold increase in resistance
(Wilson et al., 2004). There is also evidence that Ets-1 transcriptionally activates genes
whose products are well described in cisplatin resistance such as DNA repair enzymes
(Wilson et al., 2004). The association of Ets-1 to cisplatin resistance may have therapeutic
significance, but this remains to be established.
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Other possible mechanisms to up-regulate NER in mammalian cells have been found.
Wang et al have shown that selective post-translational modification of histones on
platinated nucleosomes may provide a general strategy for recruiting NER factors more
efficiently and thus help to overcome the nucleosome barrier to excision repair (Wang et
al., 2003). This may lead to cellular resistance to platinum compounds. The comet assay
measures unhooking of interstrand crosslinks, and it is clear from the results (figure 15)
that there is increased repair in the A2780 cisplatin resistant cell line, which could partly be
due to histone modifications.
It has also been shown that binding of the MMR complex to DNA adducts appears to
increase the cytotoxicity of cisplatin in tumour cells (Papouli et al., 2004). This may occur
by activating downstream signalling pathways that lead to apoptosis or by causing ‘futile
cycling’ during translesion synthesis past DNA adducts of cisplatin (Vaisman et al., 1998).
Both hMSH2 and MutS proteins (Fourrier et al., 2003), as components of the MMR
complex have been shown to bind to cisplatin adducts. Defects in MMR in human kidney
cells may result in resistance or tolerance of cancer cells to cisplatin (Papouli et al., 2004).
This may contribute to the resistance found in the A2780cisR cell line to cisplatin.
P53 is a tumour suppressor involved in DNA repair, cell cycle, and apoptosis, and its levels
increase upon exposure to genotoxic compounds due to several post-transcriptional
mechanisms (Brabec et al., 2005). Interestingly, cisplatin-induced stabilisation of p53
protein in A2780 cell line (platinum sensitive) is markedly less pronounced then in the
A2780cisR cell line (Yazlovitskava et al., 2001). This is consistent with the observation
that inactivation of wild-type p53 function in A2780 cells by transfection with HPV-16 E6
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(a protein that binds p53 and targets it for degradation) increases cisplatin sensitivity and
decreases cisplatin-DNA adduct repair (Pestell et al., 2000).
There is clearly evidence that A2780cisR resistance to platinum based chemotherapy is
characterised by up-regulation of DNA repair mechanisms, and increase in ICL unhooking
in cell lines. The literature suggests this could include up-regulation of ERCC1. Little is
known about the occurrence of this in the clinical setting. The comet assay has not been
used before to measure ICL unhooking in ovarian cancer cells direct from patients. This
was investigated to determine if increased ICL repair was involved in the development of
platinum resistance in the clinical setting.
4.2 Cisplatin-induced ICL repair in ovarian cancer cells obtained from patient
samples
There is evidence that there is a difference in the levels of DNA repair in cells obtained
from patients at different ages. This was clearly demonstrated in a study by Rudd et al
(1995) where peripheral blood mononuclear cells were taken from patients of varying age.
It was found that peripheral blood mononuclear cells from older patients treated with
cisplatin, had markedly reduced levels of ICL repair as measured by alkaline elution,
compared to peripheral blood mononuclear cells obtained from younger patients (Rudd et
al., 1995). This is also thought to be true in other cell types. In this study there were no
significant differences in the ages of newly diagnosed and treated patients (mean age
newly diagnosed patients 66 +/- 11, and mean age treated patients 66 +/- 10). This means
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that this variable should have equal affect on each patient group, and therefore should not
bias the results.
In figure 27 (results chapter) there is a clear increase in ICL repair in ovarian cancer cells
from patients after they have received platinum chemotherapy. This suggests that the
increase in ICL repair is not likely to be intrinsic to these ovarian cancer cells, but they
acquire this mechanis. It could also be that by treating these cells with chemotherapy, the
cells that survive are selected for for their ability to repair DNA. It is possible that this
increase in ICL repair is mediated by an increase in the levels of ERCC1, which is an
important protein involved in the rate limiting step of the ICL repair process. AP-1 is an
important transcription factor of ERCC1, and can induce the levels of ERCC1 mRNA and
protein expression in A2780 human ovarian cancer cell lines when they are incubated in
vitro with cisplatin (Li et al., 1998). There is some evidence, that cisplatin can induce
expression of proto-oncogenes c-fos/c-jun and activate c-Jun NH2 –terminal Kinase /
stress-activated protein kinase (JNK/SAPK – a subfamily of the MAP kinases involved in
the Ras pathway) in ovarian cancer cells and other tumour cells (Liu et al., 1996).
JNK/SAPK phosphorylates transcription factor c-jun protein which greatly increases the
transcriptional activity of AP-1, and AP-1 related genes (Derijard et al., 1994). These
observations of induction of ERCC1 expression have been seen in cancer cell lines, rather
than in clinical samples obtained from patients. However, it is still possible that cisplatin
can induce ERCC1 protein expression, through activation of the transcription factor AP-1,
that accounts for the acquired mechanism of increased ICL repair in these patients.
To support this theory, high levels of ERCC1 mRNA and protein in patient samples have
been associated with clinical resistance to platinum chemotherapy (Altaha et al., 2004).
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Furthermore, drugs that decrease expression of ERCC1 cause the reversal of platinum
resistance when given to cancer cell lines in vitro prior to platinum-based chemotherapy
(Altaha et al., 2004). Also, in patients with completely resected non-small-cell lung
cancers that are ERCC1 negative benefit from adjuvant cisplatin chemotherapy, whereas
those that are ERCC1 positive do not benefit (Olaussen et al., 2006). Interestingly, cells
defective in ERCC1 are much more sensitive to cisplatin than cells defective in other
components of the NER pathway (e.g XPB, XPD, XPG mutants), even though all these
cells are equally defective in the unhooking step of ICL repair (De Silva et al., 2002). This
suggests that ERCC1 is involved in other repair processes as well as NER that are
important in ICL repair such as homologous recombination. In support of this, XRCC2 and
XRCC3 mutants are extremely sensitive to cisplatin and, as these proteins are involved in
HR, this suggests that HR is necessary for the repair of cisplatin adducts (Caldecott et al.,
1991). It has also been shown in human tissues from patients with ovarian cancer, a
possible molecular basis for co-ordinate mRNA expression of genes involved in NER,
suggesting that NER is important in human cancers (Zhong et al., 2000).
Results from qPCR indicate that there is a small up-regulation of basal ERCC1 mRNA
levels in the post-chemotherapy samples from patients 17B, 33B, and 41B, as compared to
their pre-chemotherapy samples (figure 43). However, these results are not statistically
significant. This is probably because there are only three samples, and so further
experiments should be undertaken. An increase in ERCC1 mRNA levels may be more
following cisplatin treatment. This was not studied, but could be in the future.
These results are supported by microarray analysis, as the trend is towards a small
upregulation of ERCC1 in post-chemotherapy patients (results not shown). However, these
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results are not statistically significant either. This could be because there has to be a large
fold increase in gene expression to be able to be detected using microarray analysis. As
was previously discussed, only small increases in mRNA may be necessary to have an
effect due to post-transcriptional, and post-translational modifications. Results from both
microarray analysis, and qPCR are supported by the literature as discussed above.
Other methods to validate qRT-PCR and microarray experiments at the protein level could
have been used, such as western blots that use fluoresecent antibodies to measure protein
levels. Other types of functional assays, other than those used, could also have been
employed, as well as candidate-based approaches to identify genes involved in
chemotherapy resistance.
4.3 Melphalan-induced ICL repair in A2780 and A2780cisR human ovarian cancer
cell lines, and patient samples
It is also apparent that treated patients resistant to cisplatin chemotherapy, repair cisplatin-
induced ICLs, but do not appear to repair melphalan-induced ICLs. Interestingly, in the
A2780, and A2780cisR paired human ovarian cancer cell line the resistant cells repair both
cisplatin-induced ICLs and melphalan-induced ICLs, which is in contrast to the clinical
samples. This suggests that the ovarian cancer cells obtained from treated patients behave
differently to the A2780cisR ovarian cancer cell line model, and if so, the cell line would
be of limited use to study melphalan induced ICL repair in vitro.
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The difference between melphalan-induced ICL repair and cisplatin-induced ICL repair in
treated patients with ovarian cancer suggests the possibility that melphalan could be used
to treat these patients. Also these results suggest that melphalan-induced ICLs and
cisplatin-induced ICLs are repaired differently. Previous clinical trials using melphalan to
treat platinum-resistant patients with ovarian cancer as already discussed have been very
small, and therefore larger trials are needed.
Interestingly, Spanswick et al demonstrated that multiple myeloma patients that were
clinically resistant to melphalan chemotherapy had between 42-100% ICL repair, even
though they had similar levels of ICL formation at the peak of crosslinking compared to
melphalan-sensitive patients with multiple myeloma who did not repair the ICLs
(Spanswick et al., 2000). Work carried out in our laboratory suggests that patients with
multiple myeloma that are resistant to melphalan chemotherapy may be sensitive to
cisplatin chemotherapy. Lymphocytes from patients with multiple myeloma demonstrated
low levels of cisplatin-induced ICL repair compared to high levels of melphalan-induced
ICL repair (unpublished data H. Lowe). Not only does this suggest that cisplatin
chemotherapy could be used to treat these patients, but also is more evidence that
melphalan-induced ICLs and cisplatin-induced ICLs are repaired differently.
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4.4 Comparison of gene expression between A2780 and A2780cisR human ovarian
cancer cell lines, and between newly diagnosed and treated patients using
microarrays
The gene expression profiles obtained from patients before and after chemotherapy did not
show any statistical difference in expression of known genes involved in DNA repair, even
though there was a clear phenotypical difference between these cells. However there were
other genes involved in cell cycle and cell signalling that showed up- or down-regulation in
ovarian cancer cells from post-chemotherapy patient samples, but the significance, and
their involvement in DNA repair is as yet unknown. Cells used to extract total RNA for use
in microarray experiments were not treated ex vivo with cisplatin or melphalan, although
cells used in the comet assay were treated ex vivo with these drugs. It may be that treatment
ex vivo with either cisplatin or melphalan is necessary to induce differential changes of
gene expression within these cells. In support of this, it has been shown that there is an
increase in c-fos and c-jun transcription factors that bind Ap-1 (a gene that regulates
ERCC1) in A2780/CP70 cells after a 1 hour exposure to cisplatin (Li et al., 1998),
although it is unclear if the same changes are seen in ovarian cancer cells obtained from
clinical samples.
Microarray is a relatively new and powerful technique, but does have limitations that may
have influenced the difficulties of obtaining statistically significant results for differences
in gene expression of DNA repair genes between pre- and post-chemotherapy patients.
According to the Goldie-Coldman hypothesis, acquired chemotherapy resistance is driven
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by clonal selection of cells that have acquired a genetic mutation that has conferred an
advantage (Goldie et al., 1979). This means that in primary tumours only a small
percentage of cells will possess a chemo resistant phenotype with the associated molecular
change, resulting in a ‘dilution’ of any changes in gene expression in this population
(Goldie et al., 1979). This may mean that there are other genes associated with
chemotherapy resistance (e.g DNA repair genes) that are not apparent from this kind of
microarray analysis.
Within solid tumours there are blood vessels and connective tissue as well as ovarian
cancer cells. This mixture of cells influences the gene expression profiles for each patient
sample, and also adds to the dilution of any changes in gene expression. To minimise this
problem, all samples were stained with antibodies to assess the percentage of ovarian
cancer cells present, and only those with >80% of ovarian cancer cells present were used.
The ‘dilution’ effect can be problematic because microarray experiments accurately detect
differences in gene expression of 2 fold or more. This means that subtle differences in gene
expression will not be detected. This was evident in the RT-PCR experiments which
showed an increase in ERCC1 gene expression levels by 15% in ovarian cancer cells
obtained from patients that had received platinum-based chemotherapy. However,
differences in ERCC1 gene expression levels were not detected using microarray
techniques on all samples of ovarian cancer cells from the same patient. Some patients did
show a small increase in ERCC1 expression in post-chemotherapy samples using
microarray analysis. Analysis of microarrays may also add to this dilutional affect. The
primary expression data are in the form of logarithmic intensity ratios. Secondary data such
as average gene expression levels of genes within a group, are derived by calculating the
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geometric rather than the arithmetic means of logarithmic intensity ratios, resulting in
smaller values, and smaller apparent differences (Jazaeri et al., 2005).
It is important to point out that the microarray technology used only determines levels of
mRNA of specific genes, but does not provide any information about the post-translational
and post-trancriptional modifications of mRNA. These modifications may have dramatic
effects on the overall function of the proteins that are produced by these genes. Many
genes involved in chemotherapy resistance have been identified through microarray
analysis, and as is often the case there is no genetic overlap between results obtained from
different research groups. Differences in gene expression signatures between two groups of
investigators may be due to the end point of interest (eg, chemoresistance v natural history
such as tumour growth rate and metastatic potential), the algorithms used to define gene
expression thresholds, the bioinformatics used to define expression clusters, as well as
more subtle differences between the patient populations under study. Many different gene
expression signatures may be identified over the next few years, each containing different
genes, but each converging on an equally powerful and valid prognostic end point
(Spentzos et al., 2005).
4.5 Clinical Relevance and Future Work
It may be possible to use the comet assay to predict which patients will respond to
platinum based chemotherapy. This may be used along with microarray technology, that
use gene profiling to try and predict a patient’s response to chemotherapy. These
techniques should be evaluated in a clinical trial, because if they are successful, it would
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prevent patients suffering from side effects of chemotherapy drugs with very little benefit
in terms of disease response.
The comet assay may also be used to determine which patients may respond to melphalan
chemotherapy. Although as the two clinical trials already discussed from Magagnoli et al
(2004) and Hasan et al (2003) demonstrate, more clinical trials need to be done in this area
to establish whether melphalan chemotherapy is effective (Magnoli et al., 2004), (Hassan
et al., 2003), and also to clarify the dosing regimen. The clinical trial by Maganoli et al
(2004) and data obtained from our experiments support the possibilty of melphalan usage
in some patients with clinically platinum resistant ovarian cancer (Maganoli et al., 2004).
With the emergence of microarray technology, it is hoped that, along with other
techniques, it can be used to tailor chemotherapy to each patient. Although this has wide
cost implications, it has the potential to improve patient response, maintain disease
stabilisation, and perhaps improve the cure rates for ovarian cancer.
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APPENDIX 1 – Study protocol
Department Of Oncology
The Middlesex Hospital
Mortimer Street
London, W1T 3AA
Telephone: 020 7387 9300
STUDY PROTOCOL
Version: 2
October 7th 2004
Ref no: 04/Q0505/77
TITLE : The Mechanism of Resistance to Chemotherapy Drugs in Ovarian Cancer
Aims:
It is thought that patients who are resistant to chemotherapy agents (particularly platinum-based),
repair the DNA interstrand crosslinking that is caused by these agents.
The objective of the study is to look at the gene expression in the chemotherapy resistant cells that
repair their DNA, and the chemotherapy sensitive cells, to see if there are any differences in gene
expression.
This will be done by splitting patients into two groups based on clinical findings. The amount of
DNA interstrand crosslinking will be looked at in each patient, to confirm or refute their resistance
to chemotherapy. Then gene expression will be measured.
Selection of patients
Patients with ovarian cancer are included in the study, there are no exclusions. Patients will be
approached in clinics, and on wards. They will be given study information sheets and told about the
study. They will be given time to think about whether or not they want to be included. Written
signed consent will be taken from the patients wanting to participate. Their samples will be held up
to 5 years if they have given consent specifically for this, and then destroyed. If they have not
consented for storage for 5 years, the samples will be destroyed after this study.
1. Collection of tumour, and mesothelial cells
Tumour and mesothelial cells will be separated from ascitic, or pleural effusion samples, received
from patients at the time of drainage, or operation. Separation will involve splitting them by
trypsinisation. Mesothelial cells attach and detach from the flasks quicker than tumour cells.
Therefore timing of removing cells still suspended in media is essential.
Gross phenotypical differences between the two cell types exist, which will make it easy to visibly
gauge the level of contamination between the two cell types. Immunocytochemistry will be
performed to confirm the predominance of each cell type.
UCL Hospitals is an NHS Trust incorporating the Eastman Dental Hospital, Elizabeth Garrett
Anderson & Obstetric Hospital, The Heart Hospital, Hospital for Tropical Diseases, The
Middlesex Hospital, National Hospital for Neurology & Neurosurgery, The Royal London
Homoeopathic Hospital and University College Hospital.
2. Collection of solid tumour cells
Primary tumour tissue will be finely chopped in sterile conditions, and suspended in media.
3. Collection of blood samples
Lymphocytes will be isolated from patients’ blood as a source of germ line DNA.
4. Ovarian cell lines
Ovarian Cell lines will also be used in this study.
5. Experiments involving Ovarian cell lines
Initially these cell lines will be used to ascertain the cisplatin IC50. This is the dose of
cisplatin that will cause 50% of the cells to die. The ovarian cell lines will be incubated
with cisplatin for 1 hour, and the cells incubated in media for 6 days following this. The
SRB (sulphorhodamine B) assay will be used in this experiment
Different doses of cisplatin will be incubated for 1 hour in these cell lines. The amount of
DNA interstrand crosslinking present in the two cell lines will be investigated using the
Comet Assay.
The IC50 dose will be used in a timed drug response experiment. The two Ovarian cell
lines will be incubated with cisplatin for 1 hour, and the level of DNA interstrand
crosslinking measured (using the Comet Assay) at different times e.g 0,6,9,24,30,48,72
hours.
DNA microarrays will be used on these cell lines to investigate the up-regulation, or down-
regulation of genes involved in DNA repair mechanisms.
6. Experiments involving Tumour, Mesothelial, and solid Tumour cells
The timed drug response experiment using cisplatin, and possibly other chemotherapeutic
agents will be repeated in these cells.
DNA microarrays will also be repeated in the same cells.
UCL Hospitals is an NHS Trust incorporating the Eastman Dental Hospital, Elizabeth Garrett
Anderson & Obstetric Hospital, The Heart Hospital, Hospital for Tropical Diseases, The
Middlesex Hospital, National Hospital for Neurology & Neurosurgery, The Royal London
Homoeopathic Hospital and University College Hospital.
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Department Of Oncology
The Middlesex Hospital
Mortimer Street
London, W1T 3AA
Telephone: 020 7387 9300
PATIENT INFORMATION SHEET
Version: 2
October 7th 2004
Project I.D: 04/Q0505/77
Study Title : Mechanism of Resistance to Chemotherapy Drugs in Ovarian Cancer
Invitation Paragraph
You are being invited to take part in a research study. Before you decide it is important for you to
understand why the research is being done and what it will involve. Please take time to read the
following information carefully and discuss it with others if you wish. Ask us if there is anything
that is not clear or if you would like more information. Take time to decide whether or not you
wish to take part.
What is the purpose of the study?
Some patients with Ovarian Cancer become resistant to some forms of chemotherapy.
Chemotherapy drugs cause damage to the tumour cell which kills it. It is thought that the tumour
cells acquire mechanisms to repair this damage, thus making them resistant. The purpose of this
study is to investigate the tumour cell repair mechanisms involved in this process. This will involve
looking at expression of different proteins and genes involved in these repair mechanisms, within
the cells.
It is hoped that this research will help the design and development of newer drugs for treating
Ovarian Cancer. Patients involvement will only be brief, as all we require are small samples of
tissue taken at the same time as any necessary procedures.
Why have I been Chosen?
All patients with ovarian cancer are eligible for this study. We will be treating samples of patients
tissue, which have been removed, with chemotherapy agents and monitoring them. This means it
does not matter if you have had chemotherapy or not.
Do I have to take part?
It is up to you to decide whether or not to take part. If you do decide to take part you will be given
this information sheet to keep and be asked to sign a consent form. If you decide to take part you
are still free to withdraw at any time and without giving a reason. A decision to withdraw at any
time, or a decision not to take part, will not affect your future medical care.
UCL Hospitals is an NHS Trust incorporating the Eastman Dental Hospital, Elizabeth Garrett
Anderson & Obstetric Hospital, The Heart Hospital, Hospital for Tropical Diseases, The
Middlesex Hospital, National Hospital for Neurology & Neurosurgery, The Royal London
Homoeopathic Hospital and University College Hospital.
What will happen to me if I take part?
As part of your treatment for ovarian cancer, you may undergo surgery, or other procedures such as
draining some fluid from your abdomen or chest. At this time, samples of tumour or fluid will be
taken as part of your treatment. They will be examined, and then thrown away. You are invited to
allow these samples to be used in this study. They will still be examined in the proper way. No
extra tissue or fluid will be taken from these procedures.
During your treatment you will have several blood tests to monitor your general condition. We
would like 20mls of your blood (1 tube) which would normally be taken at the same time as your
other blood tests.
This means that you are only in the study for less than one day, while we collect the samples during
your procedures.
If you were to return for additional procedures, then we would also collect tissue or fluid samples
from these, unless you wanted to withdraw your participation from the study.
Tissue samples taken may be retained for future research. We will hold your samples for a
maximum of 5 years, and then they will be destroyed. Your name and personal details will be
separate from your samples. Any new research will be reviewed and passed by a research ethics
committee before the research starts. However, we will not contact you in the future to obtain
consent.
Some insurance companies ask whether you have had gene studies to see if you suffer from a
hereditary disease. This research does not involve looking at genes which cause ovarian cancer, we
are investigating genes which could become involved in treating ovarian cancer. There will be no
link between your DNA and your name or your notes.
Please note that volunteers give up their legal title to their samples when they sign the consent
form.
What do I have to do?
No extra procedures are needed for this study apart from a single blood test.
What are known risks of the study or the side effects of any treatment received?
There are no added risks or side effects if you take part in this study. There are also no
disadvantages.
What are the possible benefits of taking part?
The study will not affect your treatment directly. However, if the study is successful it may lead to
further studies to develop new treatments for cancer that could benefit patients in the future.
Will my taking part in the study be kept confidential?
Access to your medical records is necessary to find out details about your treatment and your
general condition. Personal details including initials of first and last name, date of birth and
hospital number will be taken and stored securely on a computer at UCL. Only the local
investigator will have access to this information. However, sometimes, representatives from the
ethics board at UCLH may be allowed to see your records to check on the study. These details will
be kept for a limited period of time and then destroyed.
Your GP will not be informed of your participation because it will not affect your treatment in any
way. It will also not affect your participation in any other studies, should you wish to join.
UCL Hospitals is an NHS Trust incorporating the Eastman Dental Hospital, Elizabeth Garrett
Anderson & Obstetric Hospital, The Heart Hospital, Hospital for Tropical Diseases, The
Middlesex Hospital, National Hospital for Neurology & Neurosurgery, The Royal London
Homoeopathic Hospital and University College Hospital.
Your clinical record will be kept separate from the laboratory result. No individual identities will
be used in any reports or publications resulting from the study.
All data will be used and stored according to the Data Protection Act.
What will happen to the results of the research study?
Your clinical record will be kept separate from the laboratory result. No individual identities will
be used in any reports or publications resulting from the study.
The results are likely to be published in approximately 2 years. Any patients wanting to obtain a
copy of the results can write to us at the above address.
Who is organising and funding the research?
The trustees of the Elizabeth Garrett Anderson Hospital are funding the research, as well as Cancer
research UK, and the department of Oncology, UCL.
Who has reviewed the study?
All proposals for research using human subjects are reviewed by an ethics committee before they
can proceed. This proposal was reviewed by the joint UCL/UCLH Committees on the ethics of
human research.
Contact for further information
If you have any questions after reading this information, please ask Dr Claire Newton (0207 679
9319), Dr Jonathan Ledermann (020 7679 8040), or the Gynaecological Cancer Research Nurse,
Elga Atkins (020 7387 9300 x3133) for further information.
Thank you for taking time to read this information and for considering participation in this research
study. You will be given a copy of this information to keep, and a copy of the consent form if you
decide to join this study.
UCL Hospitals is an NHS Trust incorporating the Eastman Dental Hospital, Elizabeth Garrett
Anderson & Obstetric Hospital, The Heart Hospital, Hospital for Tropical Diseases, The
Middlesex Hospital, National Hospital for Neurology & Neurosurgery, The Royal London
Homoeopathic Hospital and University College Hospital.
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APPENDIX 3 – Patient consent form
Department Of Oncology
The Middlesex Hospital
Mortimer Street
London, W1T 3AA
Telephone: 020 7387 9300
UCLH project number: 04/Q0505/77
Form version and date: version 2, 7th October
Patient identification number for this study:
Name of principal investigator: Dr. Ledermann
CONSENT FORM
TITLE : The Mechanism of Resistance to Chemotherapy Drugs in Ovarian Cancer
Please initial box
1. I confirm that I have read and understood the information sheet
dated 7th October, version 2 for the above study and have had the 
opportunity to ask questions
2. I confirm that I have had sufficient time to consider whether or 
not I want to be included in the study
3. I understand that my participation is voluntary and that I am free
to withdraw at any time, without giving a reason, without my 
medical care or legal rights being affected
4. I understand that sections of any of my medical notes may be
looked at by responsible individuals from UCLH or from regulatory 
authorities where it is relevant to my taking part in research. I give
permission for these individuals to have access to my records
5. I agree to take part in the above study 
1 form for patient
1 to be kept as part of study documentation
1 to be kept with hospital notes page 1 of 3
UCL Hospitals is an NHS Trust incorporating the Eastman Dental Hospital, Elizabeth Garrett
Anderson & Obstetric Hospital, The Heart Hospital, Hospital for Tropical Diseases, The
Middlesex Hospital, National Hospital for Neurology & Neurosurgery, The Royal London
Homoeopathic Hospital and University College Hospital.
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UCLH project number: 04/Q0505/77
Form version and date: version 2, 7thOctober
Patient identification number for this study:
Name of principal investigator: Dr. Ledermann
CONSENT FORM
TITLE : The Mechanism of Resistance to Chemotherapy Drugs in Ovarian Cancer
___________________________ ____________________
______________________
Name of patient Date Signature
___________________________ ____________________
_____________________
Name of Person taking consent Date Signature
Part B: initial
box
I agree to my samples retained for up to 5 years, and then destroyed. I
understand that my consent will not be sought if they are used for future
research. I understand that any future research must be approved by the
UCL/UCLH ethics committee on human research. 
___________________________ ____________________
______________________
Name of patient Date Signature
Page 2 of 3
UCL Hospitals is an NHS Trust incorporating the Eastman Dental Hospital, Elizabeth Garrett
Anderson & Obstetric Hospital, The Heart Hospital, Hospital for Tropical Diseases, The
Middlesex Hospital, National Hospital for Neurology & Neurosurgery, The Royal London
Homoeopathic Hospital and University College Hospital.
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___________________________ ____________________
_____________________
Name of Person taking consent Date Signature
Researcher (to be contacted if any problems): Dr Claire Newton, tel. 020 7679 9319
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Anderson & Obstetric Hospital, The Heart Hospital, Hospital for Tropical Diseases, The
Middlesex Hospital, National Hospital for Neurology & Neurosurgery, The Royal London
Homoeopathic Hospital and University College Hospital.
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Appendix 4 - NAMES AND ADDRESSES OF SUPPLIERS
ABgene
ABgene house
Blenheim road
Epsom
Surrey
KT19 9AP
Applied Biosystems
Lingley House
120 Birchwood Boulevard
Warrington
WA3 7QH
Affymetrix
Voyager Mercury Park
Wycombe Lane
Woburn Green
High Wycombe
Bucks
HP10OHH
Autogen Bioclear
Holly Ditch Farm
Mile Elm
Calne
Wiltshire
SN11OPY
Eppendorf AG
22331 Hamburg
Germany
Invitrogen Life technology
3 Fountain Drive
Paisley
PA49RF
Kendro Laboratory Products
Stortford Hall Park
Bishop’s Stortford
Hertfordshire
CM235GZ
MWG Biotech
90 Longacre
Covent Garden
London
WC2E9RZ
Nunc
Kamstupvej 90
PO BOX 280
Denmark
Shandon
93-96 Chadwick Road
Astmoor
Runcorn
Cheshire
WA71PR
Sigma
Fancy Road
Poole
Dorset
BH177NH
Thermoelectron Corporation
Unit 5
The Ringway centre
Eddison Roaad
Basingstoke
Hampshire
R6216YH
Vision Biosystems
Balliol Business Park West
Benton Lane
Newcastle-upon-tyne
NE128EW
VWR International
Hunter Boulevard
Lutterworth
Leicester
LE174XN
